I4T-MC-JVDF(b) Clinical Protocol  
 
An Open -Label, Multicenter, Phase [ADDRESS_953540] Cancer  
 [STUDY_ID_REMOVED]  Approval Date: 11- Feb-2016 
 
 
I4T-MC-JVDF(b)Clinical Protocol Page 1
LY3009806Protocol I4T-MC-JVDF(b)
An Open-Label, Multicenter, Phase [ADDRESS_953541] Cancer
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copi[INVESTIGATOR_702341] (LY3009806 )or pembrolizumab (MK3475) , unless such persons are bound 
by a confidentiality agreement with Eli Lilly and Company or its subsidiaries.  This 
document and its associated attachments are subject to United State s Freedom of 
Information Act Exemption 4.
Ram ucirumab (LY3009806) and Pembrolizumab (MK3475)
This is a n open -label , multicenter, Phase 1 study of ramucirumab plus pembrolizumab :  
Phase 1a (dose -limiting toxicity) and Phase 1b (safety and pr eliminary effica cy) will include 
patients with locally advanced and unresectable or metastatic gastric or gastroesophageal 
junction adenocarcinoma, non -small cell lung cancer, or transitional cell carcinoma of the 
urothelium.
Eli Lilly and Company
Indianapolis, Indiana US A [ZIP_CODE]
Protocol Electronically Signed and Approved by [CONTACT_229490] 30 April 2015.
Amendm ent (a) Electronically Signed and Approved by [CONTACT_454848] 02 June 2015.
Amendm ent (b) Electronically Signed and Approved by [CONTACT_81098].
Approval Date: 11-Feb-2016 GMT
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953542] Cancer
Section Page
1.Synopsis............................................................................................................................. 9
2.Introduction ...................................................................................................................... 11
3. Objectives and Endpo ints.................................................................................................. 20
4.Study Design..................................................................................................................... 21
4.1.Overview of Study  Design........................................................................................... 21
4.1.1. Phase 1a: Dose -Limiting Toxicity Observation.................................................... 22
4.1.2. Phase 1b:  Expansio n........................................................................................... 23
4.1.3. Study Period and Continued Access Definit ions................................................... 23
4.2.Rationale for Study  Design........................................................................................... 25
4.2.1. Dose Selection for Ramucirumab ......................................................................... 25
[IP_ADDRESS]. Rationale for Sel ection of Ramucirumab Dose Schedule 
1 (8mg/kg every  3weeks on Day  1 and Day  8 in Patients 
with Gastric-GEJ Cancer and BTC) ................................................................ 25
[IP_ADDRESS]. Rationale for Sel ection of Dose Schedule 2 (10m g/kg 
every 3 weeks) ................................................................................................ 26
4.2.2. Dose Selection for Pembro lizumab....................................................................... 27
4.3.Benefit/Risk Assessment .............................................................................................. 28
4.4.End of Study /Trial Definition....................................................................................... 28
5.Study Population............................................................................................................... 29
5.1.Inclusion Criteria.......................................................................................................... 29
5.2.Exclusion Criteria........................................................................................................ 33
5.3.Rescreening .................................................................................................................. 37
6.Treatment .......................................................................................................................... 38
6.1.Treatments Administered ............................................................................................. 38
6.1.1. Selection and Timing o f Doses............................................................................. 38
[IP_ADDRESS]. Phase 1a: Dose -Limiting Toxicity Observation............................................... 39
[IP_ADDRESS].1. Definition of Dose-Limiting Toxicit ies..................................................... 39
6.1.2. Investigator Responsibilit ies................................................................................. 40
I4T-MC-JVDF(b)Clinical Protocol Page 3
LY30098066.2.Treatment Assignment .................................................................................................41
6.3.Blinding....................................................................................................................... 41
6.4.Packaging and Labeling ............................................................................................... 41
6.5.Preparation/Handling/Storage ....................................................................................... [ADDRESS_953543] ments, Delays, and 
Discontinuati on.................................................................................................... 41
6.6.2. Pembrolizumab Dose Delays and Discont inuation................................................ 47
6.6.3. Dose Delays for Reasons Not Related to Study  Treatment.................................... 52
6.7.Treatment Compliance .................................................................................................52
6.8.Lifestyle and/or Dietary Requirements ......................................................................... 52
6.8.1. Diet...................................................................................................................... 52
6.8.2. Contraception ....................................................................................................... 52
6.9.Concomitant Therapy ................................................................................................... 53
6.9.1. Supportive Care ................................................................................................... 54
[IP_ADDRESS]. Infusion-Related Reactions -Ramucirumab and 
Pembrolizumab ............................................................................................... 54
[IP_ADDRESS].1. Infusion-Related Reactions -Ramucirumab ................................................ 54
[IP_ADDRESS].2. Infusion-Related Reactions -Pembrolizumab.............................................. 55
[IP_ADDRESS]. Supportive Care for Ramucirumab .................................................................. 55
[IP_ADDRESS].1. Supportive Care by  [CONTACT_702368] ............................... 55
[IP_ADDRESS].1.1. Hypertension....................................................................................... 55
[IP_ADDRESS].1.2. Proteinuria .......................................................................................... 55
[IP_ADDRESS].1.3. Thromboembo lic Events ..................................................................... 55
[IP_ADDRESS].1.4. Bleeding/Hem orrhage......................................................................... 56
[IP_ADDRESS].1.5. Gastrointestinal Perforation .................................................................56
[IP_ADDRESS].1.6. Reversible Posterior Leukoencephalopathy  
Syndrome............................................................................................ 56
[IP_ADDRESS].1.7. Congestive Heart Failure ..................................................................... 57
[IP_ADDRESS].1.8. Fistula Formation................................................................................ 57
[IP_ADDRESS].1.9. Surgery and Impaired Wound Healing ................................................ 57
[IP_ADDRESS].1.10. Liver Failure and Other Significant Liver Injury .................................57
[IP_ADDRESS].2. Supportive Care Agents for Ramucirumab-
Guidelines................................................................................................ 57
[IP_ADDRESS].2.1. Antiemetic Agents.............................................................................. 58
[IP_ADDRESS].2.2. Analgesic Agents ................................................................................ 58
[IP_ADDRESS].2.3. Appetite Stimulants ............................................................................. 58
[IP_ADDRESS].2.4. Granulocyte -Colony Stimulating Factors ............................................. 58
[IP_ADDRESS].2.5. Erythroid Growth Factors .................................................................... 58
I4T-MC-JVDF(b)Clinical Protocol Page 4
LY30098066.[IP_ADDRESS].6. Other Supportive Care Agents ............................................................. 58
[IP_ADDRESS]. Supportive Care for Pembro lizumab............................................................... 58
[IP_ADDRESS].1. Pneumonitis -Pembrolizumab .................................................................. 59
[IP_ADDRESS].2. Diarrhea/Co litis -Pembrolizumab ............................................................. 59
[IP_ADDRESS].3. Type 1 Diabetes Mellitus or Hy perglycemia -
Pembrolizumab ......................................................................................... 59
[IP_ADDRESS].4. Hypophysitis -Pembrolizumab.................................................................59
[IP_ADDRESS].5. Hyperthyroidism or Hypothyroidism -
Pembrolizumab ......................................................................................... 60
[IP_ADDRESS].6. Hepatic Events -Pembrolizumab .............................................................. 60
[IP_ADDRESS].7. Renal Failure or Nephrit is -Pembrolizumab ............................................. [ADDRESS_953544] to Follow -Up..................................................................... 63
8.Study Assessments and Procedures ................................................................................... 64
8.1.Efficacy........................................................................................................................ 64
8.1.1. Efficacy Assessments at Baseline and during Study 
Treatment ............................................................................................................. 64
[IP_ADDRESS]. Baseline Tumor Imaging ................................................................................ 64
[IP_ADDRESS]. Tumor Imaging During Study  Treatment........................................................ 64
[IP_ADDRESS]. Immune-Related RECIST (irRECIST) ............................................................ 65
8.1.2. Efficacy Assessments during Postdiscontinuat ion Follow-Up............................... 67
8.1.3. Efficacy Measures ................................................................................................ 67
8.1.4. Appropriateness of Measurements ........................................................................ 68
8.2.Safety........................................................................................................................... 68
8.2.1. Adverse Events .................................................................................................... 69
[IP_ADDRESS]. Reporting Ramucirumab Adverse Events of Special 
Interest and Pembrolizumab Events of Clinical Interest .................................. 70
[IP_ADDRESS].1. Infusion-Related Reactions -Ramucirumab and 
Pembrolizumab ......................................................................................... 70
[IP_ADDRESS].2. Adverse Events of Special Interest -Ramucirumab .................................... 70
[IP_ADDRESS].3. Events of Clinical Intere st-Pembrolizumab.............................................. 71
[IP_ADDRESS]. Serious Adverse Events .................................................................................. 71
[IP_ADDRESS]. Pregnancy ....................................................................................................... 72
[IP_ADDRESS]. Suspected Unexpected Serious Adverse React ions.......................................... 72
8.2.2. Other Safet y Measures ......................................................................................... 73
I4T-MC-JVDF(b)Clinical Protocol Page 5
LY30098068.2.2.1. Electrocardiograms ......................................................................................... 73
[IP_ADDRESS]. Echocardi ogram or Multiple-Gated Acquisit ion Scan..................................... [ADDRESS_953545] ical Considerat ions................................................................................ 78
9.3.Patient Characteri stics.................................................................................................. 79
9.3.1. Concomitant Therapy ........................................................................................... 79
[IP_ADDRESS]. Postdiscontinuati on Therapy ........................................................................... 80
9.3.2. Treatment Compliance ......................................................................................... 80
9.4.Efficacy Analysis: Phase 1b ......................................................................................... 80
9.5.Safety Analyses............................................................................................................ 80
9.6.Pharmacokinet ic/Pharmacodynamic Analyses .............................................................. 80
9.7.Other Analysis ............................................................................................................. 81
9.7.1. I mmunogenicity................................................................................................... 81
9.7.2. Biomarker Analysis .............................................................................................. 81
9.8.Interim Analyses .......................................................................................................... 81
10.Regulatory and Ethical Considerat ions, Including the Informed 
Consent Process ................................................................................................................ 82
10.1.Informed Consent ......................................................................................................... 82
10.2.Ethical Review ............................................................................................................. 82
10.3.Regulatory  Considerat ions........................................................................................... 82
10.4.Investigator Informat ion............................................................................................... 83
10.5.Protocol Signatures...................................................................................................... 83
10.6.Final Report Signature .................................................................................................. 83
10.7.Complaint Handling ..................................................................................................... 83
10.8.Data Qualit y Assurance ................................................................................................ 83
10.8.1. Data Capture System ............................................................................................ 84
10.9.Study and Site Closure.................................................................................................84
10.9.1. Discontinuati on of Study Sites............................................................................. 84
10.9.2. Discontinuati on of the Study ................................................................................ 84
11.References ........................................................................................................................ 85
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953546] of Tables
Table Page
TableJVDF.1. Ramucirumab and Pembrolizumab Data Summary: Gastric -GEJ, 
NSCLC, and Urothel ial Indicat ionsa....................................................... 15
TableJVDF.2. Phase 1 Treatment Regimens/Dosing Schedule ....................................... [ADDRESS_953547] Radio logic Evidence of 
Progressive Disease ................................................................................ 66
TableJVDF.7. Adverse Event and Serious Adverse Event Reporting Guidelines ...........69
TableJVDF.8. Summary  of Statistical Power for Overall Response Rates for 
NSCLC 2 -4L, Bladder 2-4L, BTC 2 -3L, and Gastric 2-3L ...................... 78
TableJVDF.9. Summary  of Statistical Power for Overall Response Rates for 
NSCLC 1L and Gastric 1L ..................................................................... 78
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953548] of Figures
Figure Page
FigureJVDF.1. Illustration of study design...................................................................... 22
FigureJVDF.2. Study period and continued access diagram. ........................................... 24
FigureJVDF.3. Predicted C min,ss following different dose regimens. ................................ 26
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953549] Criteria 1.1 ..................................................... 107
Attachment 7. Protocol JVDF Restricted and Prohi bited Conco mitant Therapy ...........114
Attachment 8. Protocol JVDF Abbreviat ions and Definit ions...................................... 116
Attachment 9. Protocol JVDF Amendment(b)
Summary  An Open -Label, Mult icenter, Phase [ADDRESS_953550] Cancer ......................................................................................... 122
I4T-MC-JVDF(b)Clinical Protocol Page 9
LY30098061.Synopsis
Title of Study: An Open-Label, Multicenter, Phase 1 Study of Ramucirumab plus Pembrolizumab in Patients with 
Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma ;
Non-Small Cell Lung Cancer ;Transitional Cell Carcinoma of th e Urothelium ;or Biliary Tract Cancer
Summary of Study Design:
Study I4T-MC-JVDFis an open-label, multicenter Phase 1 studyto evaluate the safety and efficacy of ramucirumab 
in combination with pembrolizumab.  Phase 1a ( dose-limiting toxicity [DLT]) and Expansion Phase 1b (s afety and 
preliminary  efficacy) will include patients with locally advanced and unresectable or metastatic gastricor 
gastroesophageal junction adenocarcinoma ;non-small cell lung cancer (NSCLC) ;transitional cell carcinoma of the 
urothelium (urothelial cancer) ;or biliary tract cancer (BTC) .  If sufficient tolerability and preliminary efficacy are 
demonstrated in Phase 1, the protocol will be amended to further evaluate efficacy and safety , and re-submitted 
accordingly.
Objective(s)/Endpoints
Objectives Endpoints
Phase 1a 
and 1bPrimary: To assess the safety and tolerability of 
2dosing regimens of ramucirumab plus 
pembrolizumabDose-limiting toxicities, observed during a
21-day treatment cycle
Safety (include but are not limited to):
TEAEs, SAEs, deaths, laboratory 
abnormalities, vital signs, and physical exams
Secondary:
To characterize the PK of ramucirumab when co-
administered with pembrolizumabPK: 
Cminand approximate C maxof ramucirumab 
in serum
Phase 1b Secondary:
To assess the preliminary efficacy of ramucirumab 
plus pemb rolizumabEfficacy:
ORR (RECIST 1.[ADDRESS_953551])
DCR, DOR, TTR, PFS ,and OS
Abbreviations: Cmax= maximum concentration; C min= minimum concentration; DCR = disease control rate; 
DOR= duration of response; irRECIST= immune -related RECIST; ORR =objective response rate; OS =overall 
survival; PFS =progression-free survival; PK =pharmacokinetics; RECIST =Response Evaluation Criteria In 
Solid Tumors; SAEs =serious adverse e vents; TEAEs =treatment -emergent adverse events; TTR = time to 
response.
I4T-MC-JVDF(b)Clinical Protocol Page 10
LY3009806Treatment Arms and Duration:
DLT Phase 1a
Patients will be treated for up to 21 days (1 cycle); patients without a DLT may continue in Expansion 
Phase 1b.
Dosing Schedules
Schedule 1:ramucirumab 8 mg/kg on Day 1 and Day 8 and pembrolizumab 200 mg (fixed dose) on 
Day 1, in 3 patients with gastric -gastroesophageal ( GEJ)canceror biliary tract cancer (BTC)
Schedule 2:ramucirumab 10mg/kg and pembrolizumab 200 mg (fixed dose) on Day 1, in 3 patients 
with either gastric -GEJ, NSCLC, or urothelial cancer
Number of patients: up to 12 DLT -evaluable patients (up to 6 enrolled in each dosing schedule)
Expansion P hase 1b
Duration: Continues until approximately [ADDRESS_953552] patient received study treatment.  
Individual patients may continue treatment for up to 35 cycles(approximately 2 years), until confirmed 
progressive disease or discontinuation for any other reason.
Treatment Cohorts
Schedule 1Dose:  
oGastric-GEJ(2nd- 3rdLine) Cohort A (15 patients) ,
oBTC (2nd-3rdLine) Cohort A 1(25 patients) , and 
oGastric-GEJ (1stLine) Cohort A 2(25 patients).  
Schedule 2Dose: 
oGastric-GEJ(2nd- 3rdLine)Cohort B (15 patients), 
oNSCLC (2nd-4thLine) Cohort C (25 patients), 
oUrothelial (2nd - 4thLine) Cohort D (25 patients) , and
oNSCLC (1stLine) Cohort E (25 patients) .
Number of patients: approximately 155 patients
Statistical Analysis:   
For the Phase 1a, a 3+3 design will be used to assess the safety of ramucirumab in combination with 
pembrolizumab .  Additional patients will be enrolled in a dosing schedule to achieve the minimum of 3 evaluable 
patients, if dropouts or dose interruptions or reductions occur that result in a patient being non -evaluable for DLTs.  
Data will be reviewed by[CONTACT_702369] (3 patients) .
The final analysis of safety and preliminary efficacy will occur approximately [ADDRESS_953553] completed approximately 
24 weeks of study treatment , or discontinued for any reason . Safety and preliminary efficacy will be analyzed 
separately for each cohort .  
Descriptive statistics will be derived where appropriate.   The rate of DLTs will be summarized by [CONTACT_9084]; dose 
exposure and density for each study drug will be calculated for each cohort.
I4T-MC-JVDF(b)Clinical Protocol Page 11
LY30098062.Introduction
Ramucirumab (Cy ramza™), a hum an immunogl obulin, subclass 1 anti -vascular endothelial 
growth factor (VEGF) Receptor 2monoclonal antibody, has obtained marketing authorizat ion in 
the [LOCATION_002] (US), European Unio n (EU),and Japan for the treatment of advanced gastric or 
gastroesophageal junct ion (gastric-GEJ) adenocarcino ma as monotherapy  (Study I4T-IE-JVBD 
[REGARD]) or in combination wit h paclitaxel (Study I4T-IE-JVBE [RAINBOW ]), with disease 
progression on or after prior fluoropyrimidine -and/or plat inum-containing chemotherapy.  
Ramucirumabis also approved in the US and EU for the treatment of advanced non -small cell 
lung cancer (NSCLC) in co mbination with docetaxel  (Study I4T-MC-JVBA [REVEL]), with 
disease progressi on on or after pri or platinum-based chemotherapy .Patients with epi[INVESTIGATOR_702342] d have 
disease progressi on on approved therapy  for these aberrat ions prior to receiving ramucirumab.  
Ramucirumab is also approved in the US and EU for the treatment of metastatic colorectal 
cancer(CRC)in combinat ion with FOLFIRI ( irinotecan, 5 -fluorouracil, and fo linic acid; Study 
I4T-MC-JVBB [RAISE]) with disease progression on or after therapy  with bevacizumab, 
oxaliplatin, and a fluoropyrimidine.
In a well-controlled, randomized urothelial Phase 2 StudyI4Y-IE-JCDC(JCDC), the addition of 
ramucirumab to the standard docetaxel regimen provided a significant improvement in 
progression -free survival ( PFS)compared with the control  therapy.  The magnitude of 
improvement in PFS and investigator -assessed resp onse versus the st andard single -agent 
docetaxel regimen represents a meaningful therapeutic benefit.
In addition,the toxicity profile of ramucirumab has been manageable given as a monotherapy  or 
in combination.  REGARD, a single -agent, placebo-controlled,Phase 3 gastric cancer study , 
25patients (10.5%) receiving ramucirumab discontinued study  treatment due to adverse events
(AEs).  The most comm on adverse drug reactions reported in ≥10% of ram ucirumab -treated 
patients were abdominal pain, diarrhea, and h ypertensio n.  Clinically relevant reactions 
(including Grade ≥3) associated with antiangiogenic therapy  observed in ramucirumab -treated 
patients across clinical trials were proteinuria, infusion -related reacti ons, and gastrointestinal 
(GI) perforations.
Pembrolizumab [Keytruda (US)], a humanized monoclonal ant ibody against the programmed 
death receptor -1 (PD-1) protein, has been developed by [CONTACT_44873] & Co for the treatment of cancer. 
Pembrolizumab is approved for treatment of melanoma in several countries; in the US and EU i t 
is approved for the treatment of advanced (unresectable or metastatic) melano ma in adults. 
Pembrolizumab has also been approved for treatment of NSCLC in several countries; in the US 
it is indicated for the treatment of pat ients with metastatic NSCLC whose tumors express PD -L1 
as determined by  [CONTACT_13247]-approved test and who have disease progression on or after plat inum-
containing chemotherapy .Patients with NSCLC and epi[INVESTIGATOR_3506] ( EGFR)
or anaplastic lymphoma (ALK)genomic tumor aberrations should also have disease progression 
on FDA-approved therapy  for these aberrat ions prior to receiving pembro lizumab.
I4T-MC-JVDF(b)Clinical Protocol Page 12
LY3009806There are mult iple Phase 3 programs ongo ing, including but not limited to NSCLC (KEYNOTE 
024, 042), squamous cell hea d and neck squamous cell carcino ma (KEYNOTE 040), and 
urothelial cancer (KEYNOTE 045).  Results from studies of pembro lizumab used as a 
monotherapy  in advanced NSCLC, gastric -GEJ cancer ,and in urothelial cancer have shown 
preliminary ant itumor activit y with a manageable safet y profile.  Single -agent efficacyin each of 
these tumor types ranged from  22%to 24% object ive response rates in PD -L1-positive patients
(TableJVDF.1).  Additional efficacy and safet y information is shown in the table below.
The toxicity profile of pembrolizumab has been manageable ,with <10% of pati ents stoppi[INVESTIGATOR_702343].  The m ost comm on adverse react ions (≥20%) seen with 
pembrolizumab were fatigue, cough, nausea, pruritus, rash, decreased appetite, constipat ion, 
arthralgia, and diarrhea. Similar side effect profiles were seen in pat ients with tumor types other 
than melanoma. Although lesscommon, immune -mediated adverse react ions, including 
pneumonitis, colitis, hepatitis, hypophysit is, renal failure, immune -mediated nephrit is, 
hypothyroidism, and hyperthyroi dism, need to be carefully monitored when treating wit h these 
types of agents (Keytruda US packageinsert[USPI]).
TableJVDF.1presents a high level summary o f the ramucirumab and pembrolizumab safet y and 
efficacy data for the 3patient populations that are being explored in this study, gastric -GEJ, 
NSCLC,and urothelial cancer.
More informat ion about the clinical data, including known and expected benefits, risks ,and 
reasonably  anticipated AEs of monotherapy  with either pembro lizumab or ramucirumab ,may be 
found in the respect ive Invest igator’s Brochures (IBs).
Immune Checkpoint Blockers Targeting PD -1/PD-L1
The PD-[ADDRESS_953554] mAbs, such 
as PD-1 antibodies nivolumaband pembro lizumab and PD-L1 antibody MEDI4736.   In 
nivolumab and MEDI4736 trials, response rate ranged fro m 14% to 22% in NSCLC, head and 
neck canc er, and renal cell carcino ma in unselected patient populat ions (both PD -L1-positive and 
PD-L1-negative patients)(Brahmer et al. 2014a, 2014b; Fury et al 2014; Motzer et al . 2014).
Recent publicat ions suggest m ultiple factors that predi ct outcom es of patients treated with 
immune checkpo int inhibitors.  Most notably is the evidence that higher expressio n levels of 
PD-L1 on the tumor -infiltrating immune cells is associated with better clinical outcomes 
(Herbstet al. 2014).  In pembro lizumab trials, response rate increased approximately  2-fold in 
PD-L1 “strong positive” patients ,ranging fro m 39% to 50%, in NSCLC and head and neck 
cancer(Garon et al 2014, Chow et al 2014 )In addition, tumor cells develop adapt ive immune 
resistance through up -regulation of PD-L1 expressio n (Termeet al. 2012).  As the 
immuno-oncology field is gaining further knowledge on the bio markers to predict ant itumor 
I4T-MC-JVDF(b)Clinical Protocol Page 13
LY3009806response, including bio marker assay consensus of expressio n level and validation, both 
PD-L1-positiveand PD-L1-negativepatients will be enrolled in this trial based on the 
ramucirumab and other PD -1 and PD-L1 blockers’ clinical act ivity in unselected patient 
population.  The Spons or plansto utilize the current PD -L1 assay, under development with 
[COMPANY_006],to explore whether PD-L1 expressio n further improves the outcome of patients when 
treating with a combinat ion regimen o f immune checkpoint inhibitor pembro lizumab and 
VEGFReceptor 2 inhibitor ramucirumab.
FurtherRationale for the Study
The antitumor activity with manageable safety  has been demo nstrated by  [CONTACT_702370] 3 tumor ty pes (gastric-GEJ, NSCLC ,and urothelial cancer) as described 
above, and the synergist ic preclinical activit y with the combination o f ramucirumab and 
pembrolizumab described below, laid the foundat ion for invest igating whether the combinat ion 
therapy might further enhance the efficacy of these age nts.
Preclinical Activity of the Combination
A synergist ic antitumor effect when blocking VEGF Receptor 2 and PD- 1 simultaneously was 
demonstrated in preclinical murine colon cancer model (Yasuda et al. 2013).  Dual blockade of 
both PD-1 and VEGF Receptor 2 inhibited tum or growth significant ly compared to each mAb 
treatment, individually.  There were no overt toxicities in treated mice.  Treatment with 
anti-PD-1 mAb and ant i-VEGF Receptor 2 mAb induced a significant increase in the expressio n 
of several potent pro-inflammatory cytokines and mediators.  There was also a constant tendency 
of increase in CD4+and CD8+T-cell infiltration in tumor tissues treated with the combinat ion.
Preclinical data also demonstrated that vascular- normalizing doses of ant i-VEGF Receptor [ADDRESS_953555]  from immunosuppressio n.  With 
T-cell activation induced by a who le cancer cell vaccine therapy, vascular -normalizing doses of 
anti-VEGF Receptor 2 antibody  enhanced ant icancer efficacy in a CD8+T-cell–dependent 
manner in both immune -tolerant and immunogenic murine breast cancer models (Huang et al. 
2012).
Cellular and Molecular Rationale of the Combination 
Voron et al. recent ly demonstrated that VEGF -A enhances simultaneous expressio n of several 
inhibitory  receptors, including PD -1, Tim-3, CTLA-4 and LAG3, on CD8+ T cells.  Anti -VEGF-
R2 antibody, not anti-VEGF-R1 antibody, can revert the expressio n of these inhibitory  molecules 
that are invo lved in CD8+ T cell exhaust ion (Voron et al . 2015).  Thus, combining ant i-VEGF-
R2 antibody with anti-PD-1 antibody  potentially alleviates effector CD8+ T cells from 
exhaustion in a synergist ic way.  
This combinat ion may also effect ively target the two “parallel lives” as described by [CONTACT_702371]: immunosuppressio n and angiogenesis (Motz and 
Coukos 2011) .  Multiple immunosuppressive cells recruited tothe tumor microenvironment 
directly promote angiogenesis by [CONTACT_702372] -A and other factors.   Tumor endothelium 
generated by  [CONTACT_702373], but also prevents T cell 
I4T-MC-JVDF(b)Clinical Protocol Page 14
LY3009806infiltration through VEGF (derived fro m tumor)/VEGFR (expressed on endothelium) pathway
(Motz and Coukos 2013) .  
In addition, as summarized by [CONTACT_702374] , antiangiogenic mo lecules appear to have several 
advantages to combine with other immunotherapy  agents: (1) they only restore regulatory T-cell 
proportion to a phy siological level, avoiding autoimmune -mediated side effects; (2) they  do not 
deplete activated T -cells; (3) they  inhibit other immunosuppressive pathways such as myelo id-
derived suppressor cells (MDSC); and (4) they have potenti al antitumor effect on thei r own 
(Terme et al.2012).
Clinical Safetyof the Combination
A recent study  combining MPDL3280A (anti -PD-L1) with bevacizumab (ant i-VEGF-A) in 
patients with metastatic CRCdemonstrated combining PD1/PD -L1 pathway  blocker with 
antiangiogenic agent was well tolerated with no unexpected toxicit ies (Bendell et al . 2015).  
Most commo n AEs>20% in patients treated with MPDL3280A  and bevacizumab were fatigue, 
diarrhea, nausea, py rexia, vomi ting, headache, and cough. Hodi et al. also demonstrated 
combining bevacizumab and ipi[INVESTIGATOR_125] ( cytotoxic T-lymphocy te-associated antigen-4 
[CTLA-4]blocker) can be safely  administered in melanom a patients.  The study  findings 
provided a basis for further invest igating future combinat ions of antiangiogenesis agents and 
immune checkpo int blockade (Hodi et al. 2014).
The manageable safet y profile, clinical efficacy of these 2agents individually , and the 
synergistic preclinical ant itumor activit y demonstrated, provi de evidence supporti ng the rati onale 
for clinically  testing whether the simultaneous blockade of PD -1 and VEGF Receptor2enhances 
single-agent activity while maintaining an acceptable safet y profile.
I4T-MC-JVDF(b) Clinical Protocol Page 15
LY3009806TableJVDF.1. Ramucirumab and Pemb rolizumab Data Summary : Gastric-GEJ, NSCLC, and Urothelial Indicationsa
Indication Study 
TreatmentN Efficacy Safety Reference
Gastric-GEJRam 238 ORR: 3%
Median PFS: 2.1months
Median OS: 5.2 monthsAdverse reactions occurring at a rate of ≥10% and in ≥2% more in 
ramucirumab than in placebogroup:hypertension (16% [all grade s]; 
8% [Grade 3-4]) and diarrhea (14% [all grade s];1% [Grade 3-4])Cyramza US Package 
Insert, April 2015
Ram + 
Paclitaxel330 ORR:  28%
Median PFS:  4.4 months
Median OS: 9.6 monthsAdverse reactions occurr ingat a rate of ≥30% and in ≥2% more in 
ramucirumab + paclitaxel than in the paclitaxel control group: 
fatigue/asthenia (57% [all grades]; 12% [ Grade ≥3]), neutropenia 
(54% [all grades]; 41% [G rade ≥3]), diarrhea (32% [all grades]; 4% 
[Grade ≥3]), and epi[INVESTIGATOR_3940] (31% [all grades]), 0 % [Grade ≥3]).Cyramza US Package 
Insert, April2015
Pembro 39, 
PD-L1+ onlyORR: 22%
6-mo PFS rate:   24%
6-mo OS rate: 69%Grade 3-5 drug -related AEs occurred in 4 patients, peripheral 
sensory neuropathy, fatigue, decreased appetite, hypoxia, and 
pneumonitis (n=1 each).Muro et al . 2015
(ASCO GI 
Symposium)
NSCLC Ram+ 
Docetaxel628 ORR:22.9%
Median PFS: 4.5 months
Median OS: 10.5monthsAdverse reactions occurred at a rate ≥30% and ≥2% more in the 
ramucirumab + docetaxel than in the docetaxel control group: 
fatigue/asthenia (55% [all grades]; 14% [ Grade 3-4]), neutropenia 
(55% [all grades]; 49% [G rade 3-4]), and stomatitis/mucosal 
inflammation (37 % [all grades]), 7 % [Grade3-4]).Cyramza US Package 
Insert, April2015
Pembro 495 ORR: 19.4% overall; 18% 
previously treated, 24.8% 
treatment naïve, 45.2% in 
PD-L1 strong + ( ≥50%), 
16.5% in PD -L1+ (1-49%), 
10.7% in PD -L1-(<1%)Most common AEs were fatigue, pruritus, and decreased appetite.  
Grade 3-5 drug -related AEoccurred in 47patients (9.5%), most 
commonly dyspnea (n=19, 3.8%) and pneumonitis (n= 9, 1.8%).Garon et al . 2015
I4T-MC-JVDF(b) Clinical Protocol Page 16
LY3009806Ramucirumab and Pembrolizumab Data Summary: Gastric -GEJ, NSCLC, and Urothelial Indications (concluded)
Indication Study 
TreatmentN Efficacy Safety Reference
Urothelial Ram+
Docetaxel46 ORR: 19.6%,
median PFS: 5.1 months
DCR: 67.4%Most common AEswere fatigue (80.4%), decreased appetite 
(54.3%), nausea (54.3%), and neuropathy (50.0%). Grade ≥3 AEs, 
febrile neutropenia (19.6%), pneumonia (13%), and hypertension 
(4.3%) were higher with Doc + Ram.Petrylak et al. 2015
(ASCO GU 
Symposium)
Pembro 33, PD-L1+ 
onlyORR: 24%
Median PFS:   8.6 weeks
Median OS: 9.3 months 
(6-monthOS rate: 58%)Most common AE swerefatigue (n=6), peripheral edema (n=4), and 
nausea (n=3); Grade 3 -4 drug-related AEs were reported for 
4patients (12%), with only rash seen in >1 patient (n=2) .O’Donnell et al.2015
(ASCO G U
Symposium)
Abbreviations:  AE = adverse event; ASCO = American Society of Clinical Oncology; DCR = disease control rate; Doc = docetaxel ; GEJ = gastroesophageal; 
GI=gastrointestinal; GU = genitourinary; N = number of patients; NSCLC = non -small cell lung cancer; OR R = objective response rate; OS = overall 
survival; PD -L1 = programmed death ligand 1; Pembro = pembrolizumab; PFS = progression -free survival; Ram = ramucirumab; US = [LOCATION_002].
aPreliminary efficacy and safety data for BTC (2nd-3rdLine), NSCLC (1stLine) and Gastric/GEJ (1stLine) are described below this table.
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953556] Line 
NSCLC
1). Biliary Tract Cancer :
Vascular endothelial growth factor (VEGF), one of the main proangiogenic factors, is 
overexpressed in approximately  50% to 60% of cholangiocarcino ma (CCC) (Yoshikawa, et al .
2008).  Bencke rt et al. also showed VEGF was secreted by [CONTACT_337346][INVESTIGATOR_1663], andVEGFR1 
and VEGFR2 were exclusively expressed on tumor endothelial cells in CCC (Benckert et al . 
2003).  In gallbladder carcino mas, an increased VEGF secretion was significant ly associated 
with increased angiogenesis ( Giatromanolaki et al. 2003).  I ncreased microvascular densit y 
(MVD) was alsoobserved in CCC (Benckert et al. 2003; Tang et al. 2006).  High MVD 
(increased angiogenesis) is associated with poor survival in BTC ( Giatromanolaki et al. 2003; 
Möbius et al. 2007) .  The above observations provided ra tionale for targeting angiogenesis 
pathway in developi[INVESTIGATOR_702344] .
Anti-angiogenic agents have been invest igated in BTC wi th comparable efficacy  as standard 
chemotherapy , including bevacizumab in co mbination with gemcitabine and oxaliplat in, 
bevacizumab in co mbination with erlotinib, sorafenib, and sunitinib(Bengalaet al.2010; Lubner 
et al.2010; Zhu et al . 2010; Yi et al. 2012; Lee et al. 2013).  In a more recent study ,cediranib, a 
pan-VEGF receptor ty rosine kinase inhi bitor, in combinat ion with gemcitabine/cisplat in,
demonstrated an improved efficacy  outcome in response rate (44% for 
cediranib/gemcitabine/cisplatin vs. 19% for placebo/gemcitabine/cisplatin) and 10% 
improvement in 6 -month PFS survival and 1 -year overall survival (71% vs. 61%; 58% vs. 48%, 
respectively )(Valle et al . 2015).  However, early discontinuat ion was observed due to the 
toxicity of the cediranib/chemotherapy  combinati on. As a result, the early efficacy signal in this 
study did not translate into sustained ant i-tumor activity.Thus, a well -tolerated ant i-VEGFR 
therapy in combination with standard chemotherapy  or other tar geted therapy should be 
investigated further to enhance the efficacy  outcome in BTC.   
Pembrolizumab has demonstrated preliminary efficacy in CRC and non -CRC patientswith 
mismatch -repair (MMR)-deficiency in their tumors (Le et al. 2015). Patients with MMR -
deficient non -CRC had similar efficacy  outcomes as MMR -deficient CRC.  MMR-deficiencyis 
present in 2 % to 20% of BTC s and other non -CRC GI cancers (Le et al. 2016).Recent data 
update confirmed the preliminary  efficacy demonstrated previ ously in MMR –deficient non -CRC 
patients (n=10): objective response rate ( ORR)is 50%, disease control rate ( DCR)is 70%, and 
overall survival ( OS)is 21 months (Le et al. 2016).  
This study  will investigate the combinat ion therapy in previously treatednon-selected BTC 
patients with regard to MMR status based on sever al considerat ions: 1) ramucirumab targets
angiogenesis that is commo nly observed in BTCs; 2) percentage of BTC patients whose tumors 
haveMMR deficiency  may below (for example, occurrence of MMR deficiency  in ampullary  
carcinoma appears less than in CRC [Agaram 2010] ); 3) the hy pothesis that the combination 
targetsthe two processes, angiogenesis and immu nosuppressio n, simultaneously  in the tum or 
microenviron ment, may generate synergist ic anti-tumor activity.  
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953557] been well 
tolerated.  Despi[INVESTIGATOR_702345], no targeted agent has been appro ved in this setting, and there rem ains 
a high unmet need for new treatment options .
2). First Line Gastric -GEJ:
Advanced gastric/GEJ cancer patients treated with current standard first -line chemotherapy have 
a median OS between 9 and 11 months ( Cunningham et al. 2008; Pasini et al. 2011 ).  OS is 
further extended (13. 8months vs.11.1 months) when adding trastuzumab to chemotherapy , 
capecitabine and cisplat in,for patients with HER2overexpressio n/amplificat ion, which accounts 
foronly approximately  20% of gastric patients ( Bang et al. 2010; Lordick 2011).  
Targeted therapi[INVESTIGATOR_702346], but have yet to demonstrate significant improvement in OS .  AVAGAST trial 
indicated that ad ding bevacizumab to chemotherapy , fluoropy rimindine and cisplat in, increased 
OS as com parison wi th chemotherapy alone (12.1 m onths vs. 10.1 m onths), but failed to 
demonstrate statistical significance (p=.1002) (Ohtsu et al. 2011) .  Regional differences in the 
efficacy outcome were observed between North America/Latin America versusAsia, in which a 
survival benefit was observed with addit ion of bevaci zumabin North America and Latin 
America, but not in Asia.   Besides a preliminary efficacy signal with addit ion of bevacizumab , 
the combination therapy did not substant ially alter the safet y profile of the chemotherapy 
backbone.   Ramucirumab was also investigated in combinat ion with mFOLFOX -[ADDRESS_953558] 
line setting for advanced adenocarcino ma of the esophagus , GEJ,or stomach (I4T -MC-JVBT 
CSR).  Al though median PFS was similar between the ramucirumab + mFOLFOX- 6 armversus 
the mFOLFOX -6alonearm, the PFS rate at 3 months and DCR were improved in the 
ramucirumab+ mFOLFOX- 6 arm.  In addition, median PFS wa s improved in patientswith 
primary tumor location in gastri c/GEJ/cardia (8.7 mo nths vs.7.1 months, HR=0.77).  Al though 
the safety profile for ramucirumab in this study  was consistent with the know nsafety profile of
ramucirumab, a higher discont inuation rate was observed in the ramucirumab+mFOLFOX -6 
arm than in the mFOLFOX -6 alone arm. A different chemotherapy  backbone, capeci tabine and 
cisplatin, is being ut ilized to combine with ramucirumabin a Phase 3 study  for metastatic 
gastric/GEJ cancers in the f irst line setting (I4T -MC-JVCU, RAINFALL).
Pembrolizumab is also being investigated in first line setting for gastric/GEJ cancers as 
monotherapy  and combination therapy with chemotherapy for advanced gastric/GEC cancers, 
KEYNOTE 059 (Phase 2 study ) and KEYNOTE 062 (Phase 3 study).  Cisplatin and [ADDRESS_953559] and RAINBOW, pembrolizumab preliminary  data shown in 
gastric-GEJ cancer patients ( KEYNOTE 012), and preliminary data combining ant i-angiogenic 
agents with backbone chemotherapy, exploration of ramucirumab pl us pembrolizumab
combination is warranted in the first lin e setting.  Simultaneously targeting angiogenesis and 
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953560] line therapy  that does not 
contain a chemotherapy  backbone for gastric/GEJ pati ents.
3).First Line NSCLC:
Inhibition of the angiogenesis pathway in combination with chemotherapy  has been established
as a treatment option for NSCLC in the first line setting.  Bevacizumab in co mbination with 
paclitaxel and carboplatin obtained marketing authorizat ion for non-squamous NSCLC as front 
line therapy  (Sandler et al.2006).  Preliminary  efficacy was also dem onstrated combining 
bevacizumab with erlotinib in Japanese pat ients with EGFR mutation -positive NSCLC as first 
line therapy  in JO25567 study  (Kato et al . 2014; Seto et al. 2014).  A Phase [ADDRESS_953561] line setting (Study I4T -MC-JVCY, RELAY).
Immune checkpo int blockers have also been investigated in clinical studies withorwithout a 
chemotherapy backbone in the early  line setting.  The KEYNOTE -021 evaluated the safet y, 
tolerability, and clinical activity of pembrolizumabin combinat ion with platinum doublet 
chemotherapy ( PDC)for treatment-naive advan ced NSCLC (Papadimitrakopoulou et al. 2015).  
Preliminary results in approximately  50 patients showed 28 %and 58% objective response r ates, 
depending on the backbone chemotherapi[INVESTIGATOR_014] ( pembrolizumab/ carboplatin/paclit axel and
pembrolizumab/carboplatin/pemetrexed , respectively ).  Basedon these KEYNOTE [ADDRESS_953562]-line therapy in multiple studies (KEYNOTE-024, 
042,and 189).  KEYNOTE [ADDRESS_953563] of care (SOC) platinum -based chemotherapi[INVESTIGATOR_702347]ïve,advanced or m etastatic NSCLCpatients who are PD -L1 positive. Keynote [ADDRESS_953564] line setting for advanced 
or metastatic non-squamous NSCLC.  Based on the established a nti-tumor activities and 
tolerable safet y profileof anti-angiogenic agents and anti -PD-1 antibodies in 
advanced/metastatic NSCLC (ramucirumab wi th chemotherapy in second line setting in REVEL, 
bevacizumab in combinat ion with PDC in first line setting , pembrolizumab as monotherapy  in 
later line setting in PD -L1+ patients in Keynote 001, pembrolizumabin combinat ion with PDC 
in the first-line setting in Keynote 021, and nivo lumabin NSCLC in Checkmate studies), 
investigat ion of ramucirumab plus pembrolizumab combination is warranted in the first -line 
NSCLC popul ation as a potentially viable treatm ent option that does not contain a chemotherapy 
backbone.  Simultaneously targeting angiogenesis and immune checkpoint blocker, PD -1, may 
potentially further enhance the efficacy  of either agent while maintaining tolerable safet y profile.
As the PD-L1 assay in NSCLC patients has been validated and approved by [CONTACT_3527], PD-L1 positivity is required in the first line NSCLC patients to enhance the potential
for anti-tumor efficacy of the study  treatment.  Pem brolizumab has demonstrated efficacy  as 
monotherapy  in PD-L1-positive NSCLC pat ients (KEYNOTE 001).  Current KEYNOTE [ADDRESS_953565] line setti ng.
I4T-MC-JVDF(b)Clinical Protocol Page 20
LY30098063.Objectives and Endpoints
Objective(s)/Endpoints
Objectives Endpoints
Phase 1a 
and 1bPrimary:
To assess the safety and tolerability of 2dosing 
regimens of ramucirumab plus pembrolizumabDose-limiting toxicities, observed during a 
21-day observation period
Safety 
(include but are not limited to):
TEAEs, SAEs, deaths, laboratory 
abnormalities, vital signs, and physical 
exams)
Secondary:
To characterize the PK of ramucirumab when co-
administered with pembrolizumabPK:
Cminand approximate C max  of 
ramucirumab in serum
Phase 1b Secondary:
To assess the preliminary efficacy of 
ramucirumab plus pembrolizumabEfficacy:
ORR (RECIST 1.[ADDRESS_953566])
DCR, DOR, TTR, PFS, and OS
Tertiary/Exploratory:
To explore the association between biomarkers 
and clinical outcomes
To characterize biomarker measures of 
immune functioning and angiogenesis
To assess  immunogenicity of ramucirumab 
when co-administered with pembrolizumabBiomarkers: research on genetic and 
circulating factors
Immunogenicity: anti-ramucirumab 
antibody
NOTE: For a more complete description of terms and abbreviations, see Attachment 8 .
Abbreviations: Cmax= maximum concentration; C min= minimum concentration; DCR = disease control rate; 
DOR= duration of response; irRECIST= immune -related RECIST; ORR =objective response r ate; OS=overall 
survival;PFS=progression-free survival; PK =pharmacokinetics; RECIST =Response Evaluation Criteria In 
Solid Tumors; SAEs =serious adverse events; TEAEs =treatment -emergent adverse events; TTR = time to 
response.
I4T-MC-JVDF(b)Clinical Protocol Page 21
LY30098064.Study Design
4.1.Overview of Study Design
Study I4T-MC-JVDF is an open -label, mult icenter Phase 1 study to evaluate the safet y and 
preliminary efficacy of ramucirumab in combinat ion with pembrolizumab.  Phase 1a 
(dose-limiting toxicity[DLT] observation) and Phase 1b ( expansion;safety and preliminary 
efficacy) will include pat ients with locally advanced and unresectable or metastatic gastricor 
gastroesophageal junct ion (GEJ) adenocarcino ma(gastric-GEJcancer), NSCLC,transitional cell 
carcinoma of the urothelium (urothelial ca ncer), or biliary  tract cancer (BTC) .
Based on the results of Phase 1, the Sponsor will consider various approaches toward developi[INVESTIGATOR_702348], including but not limited to an adaptive Phase 2/3 trial design, enro lling 
additional patients, a nd/or testing alternat ive dosing levels and schedules.  If sufficient 
tolerability and activity are demonstrated in Phase 1, the protocol will be amended and 
resubmitted accordingly.
FigureJVDF.1illustrates the study  design.
I4T-MC-JVDF(b)Clinical Protocol Page 22
LY3009806Abbreviations:  BTC=biliary tract cancer ; GEJ = gastroesophageal; L = line; n = 
number of patients; NSCLC = non -small cell lung cancer; PK =pharmacokinetics; Ram 
= ramucirumab.
Note: The results of the Phase 1a interim analysis will confirm the dosing regimens to 
be used in Phase 1b .  Dose reductions (ramucirumab), delays, and discontinuations may 
occur per the guidelines in Section 6.6.
FigureJVDF.1 .Illustration of study design.
4.1.1.Phase 1a: Dose -Limiting Toxicity Observation
The DLT observation period of Phase 1a will employ  a 3+3design, enrolling up to [ADDRESS_953567] for one 21-day treatment cycle (see Section 6.1.1for 
selection and timing of doses).

I4T-MC-JVDF(b)Clinical Protocol Page 23
LY3009806The definit ion for DLTsand the criteria used to determine progress of the study are provided in 
Section [IP_ADDRESS].
4.1.2.Phase 1b: Expansion
Ifresults yield an acceptable number of DLTs (≤1) in the observat ion period of Phase 1
a, then 
the Expansio n Phase 1b (Expansion Portion ) will start.
The results of the Phase 1a interim analysis will confirm the dosing regimens to be used in 
Phase1b.  Dose reductions (ramucirumab), delays, and discontinuations may occur per the 
guidelines in Section 6.6.
Patientswill be added to include 7separate expansio n cohorts,wit
h dosing schedules
corresponding to those in DLT Phase 1a, as shown in FigureJVDF.1.  Gastric patients will be 
assignedtoCohort A, A2, or B(Section 6.2).
The final analysis o f safety and preliminary  efficacy will occur approximately [ADDRESS_953568] co mpleted approximately 24 weeks of study  treatment.The Phase 1b data will
provide additional safet y, tolerability, pharmacokinetics (PK) and pharmacodynamics, and 
preliminary efficacy data for the combinat ion.
4.1.3.Study Period and Co ntinued Access Definitions
Terms used to describe the periods during the study are defined below and illustrated in
FigureJVDF.2.
Baseline/Screening :  begins when the informed consent form ( ICF)is signed,and ends 
at the first study  treatment(defined as receiving eit her ramucirumab or pembrolizumab);
if no study treatment is given, baseline/screening ends at discont inuation. Lasts up to 
28days.
Study Period:   begins at the time of first study  treatment and ends at study  completion, 
which occurs approximately [ADDRESS_953569] study treatment
(Section 4.4).
oStudy Treatment Period:   
begins with the dayofthe first patient’s firststudy 
treatment and ends the day that the decision is made to discontinue study  
treatment(discontinuation of both study  drugs; Section 7.1) .  Individual pat ients 
who enroll in Study  JVDF may continue treatment for up to 35 cycles 
(approximately 2 years), until they  have confirmed progressive disease or 
discontinued study  treatment for any other reason.
oPostdiscontinuation Follow -Upconsists of the following 2 phases .
Short-Term(Safety)Follow-Up:begins the day  after the pati ent and the 
investigator agree that the patient will discontinue study  treatmentand 
ends withtheshort-term follow up visit, to occur approximately  30 days 
thereafter.
Long-Term (Survival) Follow-Up:begins the day after short- term 
follow-up is completed and ends with the patient’s death , loss to 
I4T-MC-JVDF(b)Clinical Protocol Page 24
LY3009806follow-up, or overall study  completion, whichever is earlier. The 
long-term follow-up visit will occur approximately 90 days after the 
decision is made to discontinuefrom study treatment .  Subsequent 
follow-up (not a formal vis it) will occur approximately every [ADDRESS_953570] study  treatment
(Attachment 1).
Continued Access Period: begins after study complet ion(final analysis and evaluation 
of the studyendpoints)and ends at end of trial (defined in Sect ion 4.4) . In the continued 
access period, individual patients may continue the current study treatment after study 
completion, as long as they  experience ongoing clinical benefit (details in Section 6.10) .
Sites will be notified when the continued access period is to begin and end.
Patients who are in short -term follow-up when the continued access period begins will co mplete 
the 30-dayshort-term follow-up visit and then di scontinue the study .
Patients who are in long -term follow-up when the continued access period begins will be 
discontinued from long-term follow-up.
FigureJVDF.2. Study period and continued access diagram.End of 
TrialStudy 
CompletionStudy Period Continued 
Access PeriodPatient on 
Study 
Treatment
(Lilly will notify sites when the Continued 
Access Period  begins and ends.)  Short -term 
(Safety)
Follow-
Up Long -term
(Survival )
Follow-Up
Continued 
Access 
Period 
Follow -Up
Final analysis of 
study endpointsLast visit/
scheduled procedure for 
last patientPatient 
Discontinues 
Study 
Treatment
Interim analysesStudy Treatment
Individual patients continue on study treatment 
until a discontinuation criterion is met.Patient 
Discontinues 
Study 
Treatment
If a discontinuation criterion occurs
Expansion Phase 1b 
Analysis of Primary 
Outcome
I4T-MC-JVDF(b)Clinical Protocol Page 25
LY30098064.2.Rationale for Study Design
Thegeneralrationalefor the study  design is described in the Introduction (Section 2). The 
details regard ingdose selectionsare described below .
4.2.1.Dose Selection for Ramucirumab
[IP_ADDRESS]. Rationale for Selection of Ramucirumab Dose Schedule 1(8mg/kg every 
3weeks on Day 1 and Day 8 in Patients with Gastric-GEJCancerand 
BTC)
Ramucirumab Dose Schedule 1 (8 mg/kg on Day s1 and 8;21-daycycle)was based on 
exposure-response analyses in REGARD (8 mg/kg every  2 weeks [Q2W]) and RAINBO W
(8mg/kg on Day s 1 and 15; 28-day cycle).
Efficacy
Exposure- efficacy response analyses performed on data obtained fro m REGARD and 
RAINBOW demonstrated that an increase in exposure is associated with improved efficacy in 
terms of both overall survival ( OS)and progression-free survival ( PFS).  In both studies, patients 
with greater-than-median ramucirumab exposure demonstrated significant ly longer OS and PFS 
(smaller hazard rati o[HR]) as compared to patients with less -than-median ramucirumab 
exposure.
These findings were consistent for all 4 exposure measures tested:  minimum concentration after 
first dose administrati on (Cmin,1), minimum concentration at steady  state (C min,ss), maximum 
concentration at steady  state (C max,ss),and average concentration at steady state (C ave,ss).
Safety
Weekly doses of ramucirumab ranging fro m 2 to 16 mg/kg were evaluated in the Phase 1 
StudyJVBM.  A maximum tol erated dose ( MTD)for weekly dosing was ident ified as 13 mg/kg.  
Every-2-week (6 to 10 m g/kg) and every -3-week (15 to 20 mg/kg) dose regimens were evaluated 
in anotherdose-ranging Study JVBN.  All dose regimens in Study JVBN were well tolerated and 
no MTD was ident ified in this study .
REGARD demonstrated a well -tolerated safet y profile in the gastric-GEJcancer monotherapy 
setting.  Due to the low incidence of hypertension and neutropenia, no safet y-exposure 
relationship was ident ifiedfor these treatment-emergent adverse events.
In RAINBOW, the overall safet y profile was also considered manageable, although i ncreasing 
ramucirumab exposure was correl ated with increased incidence of Grade [ADDRESS_953571] ivity in 
the gastric-GEJindication.  Based on PK simulat ion, Dose S chedule 1 (8 mg/kg on Day s 1 and 
I4T-MC-JVDF(b)Clinical Protocol Page 26
LY30098068; 21-day cycle)may produce C min,ssgreater than the median C min,ssobtained f rom the standard 
8-mg/kg Q2Wregimen in at l east 70% of the p atient population (FigureJVDF.3) and therefore
may produce better clinical efficacy outcomes relative to the 8- mg/kg Q2Wregimen.  The 
ramucirumab-related safety risk in the gastric-GEJcancer indication may not be significantly 
increased using Dose Schedule 1, as this dose is approximately 60% lower than the m aximum 
tolerated weekly  dose identified in the Phase 1 dose -escalation Study JVBM (13 m g/kg weekly).   
Thus, Dose Schedule 1 may further enhance the efficacy in Gastric -GEJ indication, and may be 
the appropriate dosing regimen for BTC as well.
Abbreviations:  C min,ss= minimum concentration at steady state; Q = every; W = week.
Box plots depi[INVESTIGATOR_163368] 5th, 25th, 50th, 75th, and 95th percentiles calculated from 
1000simulation iterations.
FigureJVDF.3. Predicted C min,ss following different dose regimens.
[IP_ADDRESS]. Rationale for Selection of Dose Schedule 2(10mg/kg every 3 weeks)
A ramucirumab dose of 10 mg/kg every 3 weeks (Q3W) in combinat ion with docetaxel  is the 
approved dose in second-lineNSCLC, and has also been studied in second-line urothelial cancer
(JCDC).
In Study JCDC, ram ucirumab 10 mg/kg Q3Win combinat ion with docetaxel  also dem onstrated 
clinical safet y andpreliminary efficacyin previously  treated urothelial cancer patients. No new 
unexpected safety  findings were identified; the Grade ≥3 AEs occurring at a greater frequency in 
the docetaxel -plus-ramucirumab arm  compared with the docetaxel -alone arm were fatigue 
(33%vs.11%), febrile neutropenia (20% vs .11%), diarrhea (7% vs .2%), stomat itis (7% vs.
0%), and thrombocy topenia (7% v s.0%).  Additionally, the preliminary  efficacy resul ts showed 
a median PFS of 10.4 weeks in the docetaxel mo notherapy  arm and 22.0 weeks in the 
docetaxel -plus-ramucirumab arm  (stratified HR, 0.388; p<.001). This improvement in PFS 
represents a meaningful therapeutic benefitand warrants further explorat ion.

I4T-MC-JVDF(b)Clinical Protocol Page 27
LY3009806Thus, Dose Schedule 2 ( ramucirumab 10 mg/kg Q3W) was chosen for gastric-GEJ, NSCLC, and 
urothelial pat ients in Study  JVDF.
4.2.2.Dose Selection for Pembrolizumab
An open-label Phase 1trial (KEYNOTE 001) i s being conducted to evaluate the safet y and 
clinical act ivity of single-agent pembro lizumab (MK -3475).  The dose -escalation portion of this 
trial evaluated 3dose levels, 1 m g/kg, 3 m g/kg, and 10 m g/kg, administered Q2W in patients 
with advanced so lid tumors.  All 3dose levels were well tolerated and no DLTswere observed.  
This first-in-human study  of pembrolizumabshowed evidence of target engagement and 
objective evidence of tumor size reduction at all dose levels (1 mg/kg, 3 mg/k g,and 10 mg/kg 
Q2W).  No MTD has been identified.
In KEYNOTE 001, 2randomized cohort evaluat ions of melanoma patients receiving 
pembrolizumab at a dose of 2 mg/kg versus 10 mg/kg Q3W have been co mpleted, and one 
randomized cohort evaluat ing of 10 mg/kg Q 3W versus 10 m g/kg Q2W has also been 
completed.  The clinical efficacy and safet y data demonstrate a l ack of clinically important 
differences in efficacy response or safet y profile at these doses.  For example, in Cohort B2, 
advanced melano ma patients who had received prior ipi[INVESTIGATOR_702349] 2 mg/kg versus 10 mg/kg Q3W.  The objective response rate ( ORR)
was 26% (21/81) in the 2- mg/kg group and 26% (20/76) in the 10 -mg/kg group.  The proportion 
of patients with drug-related AE, Grade 3-5 drug-related AE, serious drug- related AE, death ,or 
discontinuat ion due to an AE was comparable between groups or lower in the 10 -mg/kg group.  
In Cohort B3, advanced melano ma patients (irrespective of prior ipi[INVESTIGATOR_224] ) were 
randomized to receive pembro lizumabat 10 mg/kg Q2W versus 10 mg/kg Q3W.  The ORR was 
30.9% (38/123) in the 10 -mg/kg Q2W group and 24.8% (30/121) in the 10 -mg/kg Q3W group 
(APaT).  The proportion of patients with drug-related AE, Grade 3-5 drug-related AE, seri ous 
drug-related AE, death ,or discontinuation due to an AE was comparable between groups.
PK data analysis of pembrolizumab administered Q2W and Q3W showed slow sy stemic 
clearance, limited vol ume of distribut ion, and a long half -life (Pembrolizumab IB).  
Pharmacodynamic data (IL -2 release assay) suggested that peripheral target engagement is 
durable (>21 day s).  Theseearly PK and pharmacodynamic data provide scient ific rationale for 
testing a Q3W dosing schedule.  Because Q3W dosing is more conv enient for pati ents, Q3W 
dosing will be further studied.
The rationale for further explorat ion of 2 mg/kg and com parable doses of pembrolizumab in 
solid tumors is based on: 1) similar efficacy and safet y of pembrolizumab when dosed at either 
2mg/kg or 10 mg/kg Q3W in melano ma patients, 2) the flat exposure -response relat ionships of 
pembrolizumab for both efficacy and safet y in the dose ranges of 2 mg/kg Q3W to 10 mg/kg 
Q3W, 3) the lack of effect of tumor burden or indication on distribut ion behavior of 
pembrolizumab(as assessed by  [CONTACT_702375]) ,and 4) the assumpt ion that the 
dynamics of pembrolizumabtarget engagement will not vary  meaningfully  with tumor type.
The choice of 200 mg Q3W as an appropriate dose for the switch to fixed dosing is b ased on 
simulations performed using the populat ion PK model of pembrolizumabshowing that the fixed 
I4T-MC-JVDF(b)Clinical Protocol Page 28
LY3009806dose of 200 mg Q3Wwill provide exposures that 1) are optimally consistent with those obtained 
with the 2 mg/kg dose Q3W, 2) will maintain individual patien t exposures in the exposure range 
established in melano ma as associated with maximal efficacy response ,and 3) will maintain 
individual pat ients exposure in the exposure range established in melano ma that are well 
tolerated and safe.
A fixed-dose regimen w ill simplify the dosing regimen to be more convenient for physicians and 
to reduce potential for dosing errors.  A fixed dosing scheme will also reduce complexit y in the 
logistical chain at treatment facilit ies and reduce wa stage.
4.3.Benefit/Risk Assessment
This study will provide benefi t-risk data on the co administration of pembro lizumab with 
ramucirumab.  An assessment of the hypothesized benefits and risks of co -administration is 
described in the Introduction (Section 2), and more details are included in the ramucirumab and 
pembrolizumab IBs .
4.4.End of Study/Trial Definition
Studycompletion for Phase [ADDRESS_953572] patient has 
discontinued study  treatment and com pleted any  applicable cont inued access fo llow-up(last 
patient last visit) .  Section6.1describes the maximum duration of study treatment.
I4T-MC-JVDF(b)Clinical Protocol Page 29
LY30098065.Study Population
Prospective approval o f protocol deviations to recrui tment and enro llment criteria (also known as 
protocol waivers or exempt ions) is not permitted.
5.1.Inclusion Criteria
Patients are eligible to be included in the study  only if they meet allof the following criteria:
[1]Have diagnosis with one of the fo llowing types of cancer:
a)Gastric-GEJ cancer (Cohort A [2nd-3rdLine] and Cohort B [2nd-3rdLine])
Histopathologically confirmed gastric or gastroesophageal junct ion (GEJ) 
adenocarcino ma (GEJ: Siewert Ty pe I, II,and III)
Metastatic disease or locally  advanced, unresectable di sease
Documented disease progressi on to at least one prior line of systemic therapy  
and no more than two (2). Prior therapy  for advanced di sease must include a 
platinum and/orfluoropyrimidine.  Prior therapy  in an adjuvant or 
neoadjuvant setting is not conside red as a prior line of systemic 
chemotherapy, unless pat ient has rapi[INVESTIGATOR_702350] ≤ 6months 
of last dose in this setting.  If it is ≤ 6months,it will be regarded as a prior 
line of treatment.
b) Biliary Tract Cancer (Cohort A1 [2nd-3rdLine]) 
Have a histologically  or cytologically confi rmed diagnosis of non -resectable, 
recurrent, or metastatic biliary tract adenocarcinoma (intrahepat ic or 
extrahepat ic cholangiocarcino ma, gallbladder cancer, or Ampula of Vater).
Have adequate biliary  drainage (per invest igator’s discretion), with no 
evidence of ongoing infection.
Documented disease progressi on to at least [ADDRESS_953573] include gemcitabine and cisplat in.  Prior 
therapy in an adjuvant or neoadjuvant setting is not considered as a prior line 
of systemic chemotherapy , unless pati ent has rapi[INVESTIGATOR_702351] ,as defined 
by ≤ [ADDRESS_953574] doseof chemotherapy.
c) First-Line Gastric -GEJCancer (Cohort A 2)
Histopathologically confi rmed gastric or gastroesophageal junct ion (GEJ) 
adenocarcino ma (GEJ:  Siewert Type I, II, and III)
Metastatic disease or locally  advanced, unresectable di sease
No prior systemic chemotherapy for the treatm ent of the subject's advanced or 
metastatic (patients whose disease has progressed after>[ADDRESS_953575] dose of systemic treatment in the adjuvant/neoadjuvant setting are 
eligible).
Patients are ineligible for or re fuse standard chemo therapy approved for first 
line treatment
d) Second Line and later NSCLC (Cohort C [2nd-4thLine]) 
I4T-MC-JVDF(b)Clinical Protocol Page 30
LY3009806Histologically confirmed nonsquamous or squamous NSCLC
Metastatic disease or locally  advanced, unresectable di sease
Documented disease progression to at least one prior line of systemic therapy  
and no more than three (3).  Prior therapy  for advanced disease must include a 
platinum.  Prior therapy  in an adjuvant or neoadjuvant setting is not 
considered as a prior line o f systemic chemotherap y, unless patient has rapi[INVESTIGATOR_702352]  ≤ 6months of last dose in this setting.  If it is 
≤ 6months,it will be regarded as a prior line of treatment.
Patients with known EGFR or ALK mutations are eligible only if they  have 
received at least one line of prior targeted therapy  for these mutations.
A brain scan via co mputed tomography [CT] with contrast or magnet ic 
resonance imaging [MRI] is to be performed to confirm absence of 
intracranial metastasis.
e) Urothelial Cancer (Cohort D [2nd-4thLine])
Histologically confirmed transit ional cell carcino ma of the urothelium 
(bladder, urethra, or renal pelvis). Patients with mixed patho logy are eligible 
only if they have predominantly transit ional cell tumor based on local 
pathology review.
Metastatic disease or l ocally advanced, unresectable di sease
Documented disease progressi on to at least one prior line of systemic therapy  
and no more than three (3). Prior therapy  for advanced disease must include a 
platinum.  Prior therapy  in an adjuvant or neoadjuvant setting is not 
considered as a prior line o f systemic chemotherapy , unless patient has rapi [INVESTIGATOR_702353]  ≤ 6months of last dose in this setting.  If it is 
≤ 6months,it will be regarded as a prior line of treatment.
Prior treatment with intravesicular chemotherapy, bacillus Calmette -Guérin 
(BCG), or plat inum given as a radiat ion-sensitizing agent will not be 
considered as a systemic line of treatment.
A brain scan via CT with contrast or MRI is to be performed to confirm 
absenceof intracranial metastasis.
f) First-Line NSCLC (Cohort E)
Histologically confirmed nonsquamous or squamous NSCLC
No prior systemic chemotherapy  or radiotherapy for the treatm ent of the 
subject's advanced or metastatic (patients whose disease has progressed 
after>[ADDRESS_953576] dose of systemic treatment in the 
adjuvant/neoadj uvant setting are eligible ).
Patients are ineligible for or refuse standard chemo therapy approved for first 
line treatment
Metastatic disease or locally  advanced , unresectable di sease
Tumorspecimen evaluable for PD- L1 expressio n by [CONTACT_702376]-L1 expressio n level of at least 1%is 
required to be eligible
I4T-MC-JVDF(b)Clinical Protocol Page 31
LY3009806A brain scan via co mputed tomography (CT)with contrast or m agnetic 
resonance imaging (MRI)is to be performed to confirm absence of 
intracranial metastasis.
[2]Have the presence o f measurable disease based on the Response Evaluat ion 
Criteria In Solid Tumors Version1.1 (RECIST 1.1 ; Eisenhauer et al . 2009; 
Attachment 6) as determined by [CONTACT_702377].  Tum or lesions situated in 
a previously  irradiated area are considered measurable if progression has been 
demonstrated in such lesio ns.
[3]Have provided signed informed consent and areamenable to compliance with 
protocol schedules and testing
[4]Havesubmitted an evaluable tissue sample for biomarker analysis fro m a 
newly obtained core or excisio nal biopsy of a tumor l esion prior to 
enrollment.  Formalin-fixed paraffin embedded tu mor tissue sample blo cksare 
preferred.  Repeat samples may be required if adequate tissue is not provided.
Notes:  
Patients for whom newly obtained samples cannot be obtained ( for example,
inaccessible or patient safet y concern) m ay submit an archived specimen only 
upon agreem ent from the Sponsor. General guidance for archival samples is
inthe biomarker sect ion(Section 8.4.2).  See Criterion 1f for addit ional 
requirements for patients with 1st-Line NSCLC.
[5]Have an Eastern Cooperative Onco logy Group Performance Status (ECOG 
PS) of 0 or 1 at the time of enroll ment(Attachment 4 )
[6]Have urinary  protein that is <[ADDRESS_953577] ick or routine urinalysis.  If urine 
dipstick or routine analysis indicates proteinuria ≥2+, then a [ADDRESS_953578] demonstrate <2 g of protein in 24 hours to allow 
participation in the study.
I4T-MC-JVDF(b)Clinical Protocol Page 32
LY3009806[7]Have adequate organ funct ion, as defined in the table below, with all 
screening labs performed wit hin 28 days of treatment initiation
Note: adequate organ funct ion should be confirmed within [ADDRESS_953579] dose 
on Cycle 1 Day  1.
System Laboratory Value
Hematologic
Absolute neutrophil count (ANC) ≥1.5 x 109/L
Platelets ≥100 x 109/L
Hemoglobin≥9 g/dL or ≥5.6 mmol/L (packed red blood cell transfusions are 
not allowed within one week prior to baseline hematology 
profile)
Renal
Creatinine OR
Measured or calculated creatinine 
clearance (see Attachment 5 )≤1.5xULN OR
≥60 mL/min
Hepatic
Total bilirubin ≤1.5xULN
AST (SGOT) and ALT (SGPT)≤2.5xULN OR
≤[ADDRESS_953580] for patients with liver metastases
Coagulationb
International Normalized Ratio (INR) or 
Prothrombin Time (PT)INR ≤1.5xULN or PT ≤ [ADDRESS_953581] unless patient
is receiving anticoagulant therapy as long as INR or PT is 
within therapeutic range of intended use of anticoagulants
Partial Thromboplastin Time (PTT) or 
Activated Partial Thromboplastin Time 
(aPTT)PTT or aPTT ≤ [ADDRESS_953582] unless patientis 
receiving anticoagulant therapy as long as PTT or aPTT is 
within therapeutic range of intended use of anticoagulants
Thyroid
TSH, T3, and T4 TSH within the normal limits OR
Total T3 or free T3 and free T4 are within the normal limits.
Abbreviations:  ALT = alanine aminotransferase; aPTT = activated partial thromboplastin time; AST =aspartate 
aminotransferase ; INR=international normalized ra tio; PT=prothrombin time; PTT =partial thromboplastin 
time; TSH =thyroid-stimulating hormone; ULN =upper limit of normal.
aCreatinine clearance should be calculated per institutional standard.
bPatients on full -dose anticoagulation must be on a stab le dose (minimum duration 14 days) of oral anticoagulant 
or low molecular weight heparin.  If receiving warfarin, the patient must have an INR ≤ 3.0 and no active 
bleeding (i.e., no bleeding within [ADDRESS_953583] dose of study treatment) or patholo gical condition present 
that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices).  Patients on 
anticoagulation therapy with unresected primary tumors or local tumor recurrence following resection are not 
eligible.
[8]Be males or females at least 18 years of age on day of signing informed 
consent
[9]Have an ant icipated life expectancy o f ≥3 months
I4T-MC-JVDF(b)Clinical Protocol Page 33
LY3009806[10]Haveresolution, except where otherwise stated in the inclusio n criteria, of all 
clinically significant toxic effects of prior systemic cancer therapy , surgery, or 
radiotherapy to Grade ≤[ADDRESS_953584] itute (NCI) Commo n 
Terminology Criteria for Adverse Events (CTCAE), Version 4.0 (v4.0)
[11]For malepatients, aresterile (including vasectomy confirmed by [CONTACT_447] -
vasectomy semen analysis) or agree to use a reliable method of birth control 
and to not donate sperm during the study  and for at least [ADDRESS_953585] dose of study treatment
Note:  Abstinence is acceptable if this is the established and preferre d contracepti on 
for the patient.
[12]Forfemale patient s,aresurgically sterile, arepostmenopausal, or agree to use 
a highly effect ive method of birth control (2 methods preferred) during the 
study and for [ADDRESS_953586] dose of study  treatment
Note:  A "highly effect ive method of birth control" is defined in Section 6.8.2.
[13]If female and o f childbearing potential, must have a negative serum or urine 
pregnancy test within 7 days prior to enrollment.
Note: Non-childbearing potential (by [CONTACT_73534]) is defined in 
Section 6.8.2.
Note:  Abstinence is acceptable if this is the established and preferred contraception 
for the patient.
5.2.Exclusion Criteria
Patients will be excluded from  the study  if they meet anyof the following criteria:
[14]Have non
-measurable disease
[15]Have known brain metastases, uncontrolled spi[INVESTIGATOR_53894] n, or 
leptomeningeal disease
[16]Have received equal to or greater than 3 lines of prior systemic anticancer 
therapy for advanced disea se in GEJ patients, and equal to or greater than 4 in 
patients in NSCLC and urothelial cancer patients
[17]Have a serious illness or medical condit ion(s) including, but not limited to, the 
following:
Diagnosis of immunodeficiency or arereceiving systemic steroid therapy 
or any other form  of immunosuppressive therapy  within [ADDRESS_953587] dose of tri al treatment.  The use of physio logic doses of 
corticosteroids may be approved after consultation with the Sponsor.
I4T-MC-JVDF(b)Clinical Protocol Page 34
LY3009806Active autoimmune disease that h as required systemic treatm ent in past 2 
years (that is, with use o f disease-modifying agents, corticosteroids or 
immunosuppressive drugs). Replacement therapy (for example, thyroxine, 
insulin, or physio logic corticosteroid replacement therapy for adrenal or 
pi[INVESTIGATOR_13002] , etc.) is not considered a form o f systemic 
treatment.
Received a prior autologous or allogeneic organ or tissue transplantation
Evidence of act ive, non-infectious pneumo nitis
History of interstitial lung disease
Known human immunodeficiency virus (HIV) infection or acquired 
immunodeficiency  syndrome (AIDS) -related illness
Known act ive Hepat itis B or Hepatit is C infection
Liver cirrhosis at a l evel of Child-Pugh B (or worse)
Liver cirrhosis (any degree) anda history of hepatic encephalopathy or 
clinically meaningful ascites result ing from cirrhosis.  Clinically  
meaningful ascites is defined as ascites result ing from cirrhosis and 
requiring ongoing treatment with diuretics and/or paracentesis.
Have a serious cardiac condit ion, such as congestive heart failure; unstable 
angina pectoris; myocardial infarct ion within the last 6 m onths; 
valvulopathy that is severe, moderate, or deemed clinically  significant; or 
arrhythmias that are symptomatic or require treatmen t (not including 
patients with rate-controlled atrial fibrillat ion)
Active or uncontrolled clinically serious infection
Known psychiatric or substance abuse disorders
Known allergy  or hypersensitivity reaction to any of the treatm ent 
components
Have ongo ing or recent ( ≤6 months) hepatorenal syndro me
[18]History of hematologic malignancy, malignant primary  brain tumor, 
malignant sarcoma, or other malignant priory  solid tum or not under study , 
except:
no evidence of that disease for 5 years
adequately  treatednon-melanomatous skin cancer
curatively  treated cervi cal carcino ma in situ or other noninvasive 
carcinoma or in situ neoplasm
I4T-MC-JVDF(b)Clinical Protocol Page 35
LY3009806[19]Have received any previous systemic therapy  (including invest igational 
agents) targeting VEGF/VEGF receptor, PD-1/PDL-1,or PD-1/PDL-2 
signaling pathways.  Prior therapy  with other immune checkpo int inhibitor, 
including but not limited to, anti -CD137 ant ibody or anti-CTLA-4 antibody , is 
not permitted.  ONLY for NSCLC patients:  prior VEGF/VEGF receptor
treatment is allowed.
[20]Have received a live vaccine wit hin 30 days prior to enrollment .  Seasonal flu 
vaccines that do not contain live virus are permitted.
[21]Have received transfusio n of blood products (including platelets or red blood 
cells) or administration of colony -stimulating factors (including granulocy te 
colony-stimulating factor[G-CSF], granulocy te-macrophage 
colony-stimulating factor[GM-CSF],or recombinant ery thropoietin) within 
4 weeks prior to Cycle 1 Day  1
[22]Have a significant bleeding disorder or vasculi tis or had a Grade ≥3 bleeding 
epi[INVESTIGATOR_5319] 12 weeks prior to enrollment
[23]Have experienced any arterial thrombotic event, including myo cardial 
infarction, unstable angina, cerebrovascular accident, or transient ischemic 
attack, within 6 months prior to enrollment
[24]Have experienced any Grade 3 or 4 venous thromboembo lic event (VTE) that 
is considered by  [CONTACT_702378], within 6months prior 
to enrollment
[25]Have a history  of gastrointest inal perforation and/or fistula within 6 months 
prior to enrollment
[26]Have a bowel obstruction, history  or presence of inflammatory  enteropathy  or 
extensive intestinal resect ion (hemico lectomy or extensive small intestine 
resection, either condi tion with chronic diarrhea), Crohn's disease, ulcerative 
colitis, or chronic diarrhea
[27]Haveuncontrolled hypertensio n, as defined as Grade >2 CTCAE Version 4.0
(clinically , the patient continues to experience elevated blood pressure 
[systolic >160 mmHg and/or diastolic >100 mmHg] despi[INVESTIGATOR_158317])
[28]Arereceiving chronic therapy  with any of the fo llowing within 7 days prior to 
enrollment: 
nonsteroidal ant i-inflammatory agents (NSAIDs; such as indo methacin, 
ibuprofen, naproxen, or similar agents)
other anti -platelet agents (such as clopi[INVESTIGATOR_7745], ticlo pi[INVESTIGATOR_5325], dipyridamole, 
or anagrelide)
Aspi[INVESTIGATOR_702354] 325 mg/day is permitted.
I4T-MC-JVDF(b)Clinical Protocol Page 36
LY3009806[29]Havehad a serious or non -healing wound, ul cer, or bone fracture within 
28days prior to enrollment
[30]Havean elective or a planned major surgery during the course of the trial or 
hasundergone major surgery  within 28 days prior to enrollment, or central 
venous access device placement within 7 days prio r to enrollmen t.
Note:  If patientreceived major surgery, the patientmust have recovered 
adequately from the toxicity and/or complications from the intervention prior 
to starting therapy.
[31]Have had chemotherapy , targeted sm all molecule therapy, or radiat ion therapy 
within 2 weeks and/or monoclonal ant ibody treatment wi thin 4 weeks prior to 
enrollment or not recovered (that is, ≤ Grade 1 or at baseline) fro m previously 
administered agents
Note:  Neuropathy ( ≤ Grade 2) or nonserious and nonlife -threatening toxicities , such 
as alopecia, altered taste, or nail changes, are an exception to this criterion.  
Note: Palliative radiotherapy during the study, if clinically indicated, can be 
considered after consultation w ith the Lilly clinical research physician (CRP).
[32]Are current ly enrolled in a clinical trial invo lving an invest igational product or 
non-approved use of a drug, or concurrent ly enrolled in any other ty pe of 
medical research judged not to be scient ifically or medically co mpatible with 
this studyor discontinued study  drug within 28 days prior to enrollment .  
Patients participating in surveys or observat ional studies are eligible to 
participate in this study .
[33]Are or have an immediate family member ( for example , spouse, parent/l egal 
guardian, sibling ,or child) who is invest igational site or sponsor staff direct ly 
involved with this trial, unless prospective institutional review board ( IRB)
approval (by [CONTACT_66870]) is given all owing except ion to this criterion 
for a specific patient
Additional K ey Exclusion Criteria specific to allGastric-GEJpatients:
[34]Havesquamous cell or undifferent iated gastric-GEJ cancer
[35] Received previous systemic chemotherapy with a cumulative dose of 
>900mg/m2of epi[INVESTIGATOR_464213] >400 m g/m2of doxorubicin
Addition al Key Exclusion Criteria specific to all NSCLCpatients:
[36]Have radio logically documented evidence of majo r blood vessel  invasion or 
encasement by  [CONTACT_67380]
[37] Have radiographic evidence of intratumor cavitation, regardless of tumor 
histology
[38]Have a history of gross hem optysis (defined as bright red blood or 
≥1/2teaspoon) within 2 months prior to enrollment
I4T-MC-JVDF(b)Clinical Protocol Page 37
LY3009806[39]Havepleural effusion, pericardial fluid, or asci tes requiring drainage every  
other week or more frequent ly
[40]Havesuperior vena cava s yndrome
[41]Havepreexisting idiopathic pulm onary fibrosis as evidenced by 
[CONTACT_70182]/X-ray at baseline; have or had any  disease of acute l ung injury , 
idiopathic pulmo nary fibrosis, or pneumoconiosis evident on an X- ray; have 
or had any disease of radiat ion pneumonia or drug -induced pneumo nia
Additional Key Exclusion Criteria specific to First Line NSCLC patients
(Cohort E) :
[42]Epi[INVESTIGATOR_3506] (EGFR) -sensitizing mutation and/or is 
echinoderm microtubule -associated protein -like 4(EML4) gene/ anaplastic 
lymphoma kinase (ALK) gene fusio n positive, or these status never tested .
Additional Key Exclusion Criteria specific to BTC patients(Cohort A 1):
[43]Hasreceived more than 2 lines of therapy  for advanced or m etastatic disease.
[44]TACE or radiotherapy , including use of radioactive beads, is not allowed.  
[45]Received p hotodynamic treatment and does not have measurable or evaluable 
disease at the site.  Except ion:there is clear evidence of disease progression at 
the local site or measurable and progressing disease is present at another site.
[46]Have mixed hepatocellular biliary  tract cancer histology .
Additional Key Exclusion Criteria specific to First Line Gastric -GEJ patients 
(Cohort A 2):
[47]HER2-positive status or HER2 statu s never tested
5.3.Rescreening
Individuals whodonotmeetthecriteriaforparticipation inthisstudy(screenfailure)may be
re-screened, only after di scussion with and permissio n from theLilly CRP or designee.
Repeating laboratory tests during the screening period does not constitute 
re-screening. Screening laboratory  tests may not be repeated more than twice in order to meet 
eligibility during the screening period.
I4T-MC-JVDF(b)Clinical Protocol Page 38
LY30098066.Treatment
6.1.Treatments Administered
Ramucirumab and pembrolizumab will be administere d per TableJVDF.2.  For Gastric/GEJ, 
Urothelial , 2nd-4thline NSCLC and BTC, patients can receive study  treatmentafterevaluable 
tumor tissue has been shipped to central study  laboratory .  For first line NSCLC, patient can 
receive study  treatmentafterPD-L1expressionhas been confirmed to be at least 1% (Section 
5.1).
Across all study periods, including the continued access period, individual patients will be 
treatedwithramucirumab and/or pembrolizumab , as follows:
until confirmed progressive disease (Section [IP_ADDRESS]), unacceptable toxicit y, or 
discontinuat ion for any other reason
for a maximum duration of study treatment of35 cycles, approximately 2 years
TableJVDF.2. Phase 1 Treatment Regimens/Dosing Schedule
Tumor Type Drug Dose 
(IV)Dose 
FrequencyDose Day
(21-day 
cycle)
Schedule 1 (Gastric -GEJ, BTC)Ramucirumab 8 mg/kg Q3W Day 1, Day 8 
Pembrolizumab 200 mg Q3W Day 1
Schedule 2 (Gastric -GEJ, NSCLC or 
Urothelial)Ramucirumab 10 mg/kg Q3W Day 1
Pembrolizumab 200 mg Q3W Day 1
Abbreviations: BTC= biliary tract cancer ; GEJ = gastroesophageal junction; IV = intravenous; NSCLC = non -small 
cell lung cancer; Q3W =every 3 weeks.
NOTE: Ramucirumab will be administered prior to pembrolizumab for ever y cycle(Section 6.1.1).
6.1.1.Selection and Timing of Doses
The ramucirumab and the pembro lizumab Pharmacy Manuals contain specific instructions for 
premedication, the preparation of infusio n,and administration of each infusio n solutions, 
separately .
A cycle is defined as an interval of 21days (a del ay of a cycledue to holidays, weekends, bad 
weather, or other unforeseen circum stances will be permitted up to 7 days and not counted as a 
protocol deviation).
The actual  doses of ramucirumab administered will be determined by [CONTACT_95850]'s 
weight at the beg inning of each cycle. If the patient’s weight fluctuate sby [CONTACT_726] 10% from 
the weight used to cal culate the pri or dose, the dosemustbe recalculated.  Recalculat ion of the 
ramucirumab dose for wei ght fluctuati ons of <10% is permitted but not requi red.
Ramucirumab will be administered prior to pembrolizumab, over an approximately 60-minute 
intravenous ( IV)infusion.  The maximum ramucirum ab infusion rate is 25 mg/min.
I4T-MC-JVDF(b)Clinical Protocol Page 39
LY3009806Pembrolizumab 200 mg (fixed dose ) will be administered overa 30-minute IV infusio n.  Sites 
should make every  effort to target infusio n timing to be as close to 30 minutes as possible.  
However, given the variabilit y of infusion pumps from  site to site, a window between - 5 minutes 
and +10 minutes is permitted ( that is, infusion time is 30minutes -5 min/+10 min).
The first 2 cycleswill require a 1- hr observat ion period i) between ram ucirumab and 
pembrolizumab administration ,and ii) after pembrolizumab infusion.  For all cycles thereafter,
no observat ion period will be required unless cli nically indicated .  
[IP_ADDRESS]. Phase 1a: Dose -Limiting Toxicity Observation
For the 21 -day Phase 1a DLT observat ion period, the following criteria will be used to determine 
the progress of the study :
If none of the init ial 3 patients within a dose schedul e develops a DLT, 
ExpansionPhase1b will start.
If 1 of the init ial 3 patients within a dose schedule develops a DLT, 3 add itional patients 
will be added.
If ≤1 of 6 patients within a dose schedule develops a DLT, Expansi on Phase 1b will start.
If 2 or more patients developa DLT, enrollment will stop and an alternat ive dose level 
may be considered (in which case the protocol would be amended) .
No intra-patientdose escalation or reduction is allo wed during DLT observat ion.  For the 
purpose of patient management, DLT s will lead to dose interruption during the observation 
period.  Dose m odifications will be allowed after the observat ion period.
For either group, if dropouts, dose interruptions, or reductions occur that result in a patient being 
nonevaluable for DLTs (“evaluable” is defined in Section 6.7), additional patients will be 
enrolled to achieve the minimum o f 3 evaluable patients.  The need for patient replacement will 
be determined based on consultation wit h the investigator and Lil ly CRP/clinical research 
scientist ( CRS).  Patients who withdraw fro m the study during the DLT period for reasons other 
than a DLT may be replaced wit hin the same dose level.
[IP_ADDRESS].1. Definition of Dose -Limiting Toxicities
A DLT is defined as one of the fo llowing AEs reported during theDLT observat ion period, if 
considered to be definitely , probably, or possibly related to either study regimen by [CONTACT_1275]; and fulfills any one of the following criterion using NCICTCAE Versio n4.0:
1. Nonhematologic toxicityas follows:
a)Grade 4 nonlaboratory  toxicity
b) Grade 3 nonlaboratory  toxicity (for example, nausea, vo miting,and diarrhea) lasting 
>3 days despi[INVESTIGATOR_44782]
c)Any Grade 3 or Grade 4 laboratory value if:
i) Medical intervent ion is required to treat the patient, or
ii) The abnorm ality persists for >1 week.
I4T-MC-JVDF(b)Clinical Protocol Page 40
LY3009806Note: Liver function abnormalit y: For patients with liver metastasis who begin 
treatment with Grade 2 asparatate aminotransferase ( AST)or alanine amino 
transferase ( ALT), if ASTor ALT increases by  [CONTACT_55559] 50% 
relative to baseline and lasts for at least 7 days
2.Hematologic toxicity, as follows:
a)Grade 4 toxicit y lasting≥ 7 days, or
b)Grade 3 thrombocy topenia if associated with bleeding and requires platelet
transfusio n, or
c)Febrile neutropenia Grade 3or Grade 4
3.Grade 5 toxicit y (that is, death)
4.Any other significant toxicit y deemed by  [CONTACT_702379], for example:
a)Any toxicit y that is possibly  related to study  treatment that requires the 
withdrawal of the patient from the study during Cycl e 1, or
b)A delay of > 14 days due to persistent Grade ≥ 2 toxicit ies in initiating Cycle 2, 
with the excepti on of Grade 2 fat igue
Any infusion or hypersensitivity reactions occurring during the infusio n of the drug are not 
considered dose -related and therefore will NOT be considered to be a DLT.
After each of the 3patients in a dose schedule completesthe observat ion period, a safety analysis 
will occur; the data will be reviewed by  [CONTACT_702380]/CRS , andthe 
findings documented, indicating whether each dose schedule is or is not well tolerated .  The 
results will inform the decisi on whether or not to mo ve onto Expansio n Phase 1b.
6.1.2.Investigator Responsibilities
The invest igator or his/her designee is responsible for the fo llowing:
explaining the correct use of the drugs and planned duration of each individual’s 
treatment to the site personnel,
verifying that instructions ar e followed properly, 
maintaining accurate and appropriate records, including those of investigational product 
(IP)dispensing and collection, 
ensure appropriate supply, storage, handling, distribut ion and usage of trial treatments in 
accordance with the protocol and any applicable laws and regulations ,
and returning all unused medicat ion to Lilly or its designee at the end of the study .
Note: In some cases, sites may destroy  the material if, during the invest igator site select ion, the 
evaluator has verif ied and documented that the site has appropriate facilit ies and wri tten 
procedures to dispose clinical trial materials.
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953588] a com plaint 
or problem with the IP so that the situation can be assessed.
6.2.Treatment Assignment
Patients meeting all inclusio n/exclusio n criteria will be assigned toa dose schedule based upon 
their diagnosis at baseline ( TableJVDF.2). Study drug will be allocated to patients using an 
interactive web response system .
6.3.Blinding
This is an open -label study .
6.4.Packaging and Labeling
All IP materials will be provided by [CONTACT_11007]. Clinical tri al materials will be labeled according to 
the country’s regulatory  requirements.  Ramucirumab and pembro lizumab vials should be stored
under refrigeration at 2°C to 8°C (36°F to 46°F) .
6.5.Preparation/Handling/Storage
Refer to the respective IBs f or detailed informat ion about preparation, handling, and storage of 
ramucirumab and pembrolizumab.
6.6.Dose Adjustments ,Delays, and Discontinuation
Doses of either study drug may need to be del ayed, reduced ( ramucirumab only), or discontinued 
to managespecific AEsor other toxi cities.
When a study  drug is delayed, if possible and appropriate, patients should resume study 
treatment within 21 days, wi th every effort made to start on Day  1 of the next dosing schedule .
6.6.1.Ramuciruma b Dose Adjustments, Delays,and Discontinuation
The ramucirumab dose may need to be delayed and/or reduced if the patient experiences an 
adverse event, including an adverse event of special interest (AESI) (Section8.[IP_ADDRESS]).Doses 
may be delayed to allow time for the patient to recover fro m the event. Certain AEsrequire 
immediate and permanent discontinuationof study treatm ent. Any patient who requires a dose 
reduction will continue to receive a reduced dose unt il discontinuation fro m ramucirumab or 
discontinuat ion from the study.  Any patient who has had [ADDRESS_953589] possibly related to 
ramucirumab.
I4T-MC-JVDF(b)Clinical Protocol Page 42
LY3009806TableJVDF.3. Ramucirumab Dose Reductions a
Dose Schedule 1:
Gastric-GEJ/BTC
(21-day Cycle)Dose Schedule 2
Gastric-GEJ/NSCLC/Urothelial
(21-day Cycle)
Starting dose 8 mg/kg
on D1, D810 mg/kg
on Day [ADDRESS_953590] dose reduction 6 mg/kg
on Day 1, Day 88 mg/kg
on Day 1
Second dose reduction 5 mg/kg
on Day 1, Day 86 mg/kg
on Day 1
Abbreviations:  BTC = biliary tract cancer; D = Day; GEJ = gastroesophageal; NSCLC = non -small cell lung cancer.
aRamucirumab dose reductions are allowed between cycles and within a given cycle.
I4T-MC-JVDF(b) Clinical Protocol  Page [ADDRESS_953591]  
 Adverse Event 
NOTE: All Specific Adverse Events Listed are defined as AESIs in Section  [IP_ADDRESS].1 ). CTCAE 
Grade Dose-Modification Guidelines 
NOTES:  Dose reductions to occur as defined in  Table JVDF.3 . 
Treating physicians can modify or discontinue ramucirumab more conservatively than in the guidance below.  
    
1. Infusion-related reaction    
1.a. Infusion-related reaction  2 Interrupt and reduce the infusion rate by 50% for the duration of the infusion and for all 
future infusions. 
   Prior to all future infusions of ramucirumab, premedicate with:  an intravenous histamine H1 antagonist, such as diphenhydramine hydrochloride 
 dexamethasone or equivalent 
 acetaminophen/paracetamol 
1.b. Infusion-related reactio n 3-4 Immediately and permanently discontinue ramucirumab 
2. Hypertension    
2.a. Hypertension (n on-life-threatening and 
associated with symptoms) NOTE:  Hypertension should be monitored prior to each ramucirumab infusion. 3  Delay ramucirumab until the hypertension is controlled with medication and is resolved to Grade 0-2. o If controlled with medication and resolved to Grade 0-2, then may resume ramucirumab at current dose. 
o If NOT controlled with medication and not resolved to Grade 0-2 within a reasonable timeframe, discontinue ramucirumab at investigator’s discretion. 
2.b. Uncontrolled hypertension, hypertensive crisis, 
or hypertensive encephalopathy  4 Immediately and permanently discontinue ramucirumab. 
I4T-MC-JVDF(b) Clinical Proto col Page [ADDRESS_953592] (continued)
Adverse Event
NOTE: All Specific Adverse Events L isted are 
defined as AESIs in Section [IP_ADDRESS].1).CTCAE 
GradeDose-Modification Guidelines
NOTE: Dose reductions to occur as defined inTableJVDF.3.
3.Proteinuria
3.a.Proteinuria = 2+ (dipstick or routine urinalysis) a Administer ramucirumab at the current dose if clinically indicated.
Obtain 24 -hour urine protein resultswithin 3 days prior to the next ramucirumab 
dose.
oIf urine protein is <2 g/24 h, administer ramucirumab at the patient's current 
dose.
oIf urine protein is 2 g/24 h, modify the ramucirumab dose based on 24 -hour 
collection.  See Proteinuria 2g/24 h (24 -hour urine collection) , Line 3.c in 
this table.
3.b.Proteinuria >2+ (dipstick or routine urinalysis) a Delay ramucirumab until urine protein returns to <2 g/24 h.
Obtain 24 -hour urine protein results within 3 days prior to the next ramucirumab 
dose.
oIf urine protein is <2 g/24 h, no further dose delay or dose reduction is 
required.
oIf urine protein remains 2 g/24 hand is not resolved within a reasonable 
timeframe, discontinue ramucirumab at investigator’s discretion.
3.c.Proteinuria 2 g/24 h (24 -hour urine collection) a First or second occurrence :  delay ramucirumab until urine protein returns to 
<2 g/24 h.
oIf urine protein returns to <2 g/24 h, reduce ramucirumab dose.
oIf urine protein remains 2g/24hand is not resolved within a reasonable 
timeframe, discontinue ramucirumab at investigator’s discretion.
Third occurrence :  discontinue ramucirumab.
3.d.Proteinuria >3 g/24 h orin the setting of nephrotic 
syndromeaImmediately and permanently discontinue ramucirumab .
4.Arterial thromboembolic events, venous 
thromboembolic events3 or 4 Immediately and permanently discontinue ramucirumab.
5.Bleeding/hemorrhage 3 or 4 Immediately and permanently discontinue ramucirumab.
6.Gastrointestinal perforation Immediately and permanently discontinue ramucirumab.
I4T-MC-JVDF(b) Clinical Proto col Page 45
LY3009806Adverse Event
NOTE: All Specific Adverse Events Listed are 
defined as AESIs in Section8.[IP_ADDRESS]).CTCAE 
GradeDose-Modification Guidelines
NOTE: Dose reductions to occur as defined in TableJVDF.3.
7.Reversible posterior leukoencephalopathy 
syndromeImmediately and permanently discontinue ramucirumab .
8.Congestive heart failure 3-4Immediately and permanently discontinue ramucirumab .
9.Fistula formation Immediately and permanently discontinue ramucirumab .
10.Impaired wound healing
10.a.Prior to planned surgery Withhold ramucirumab.
10.bAfter surgery Resume ramucirumab based on clinical judgment .
10.c.Wound-healing complications developed during 
study treatmentDelay ramucirumab dosing until the wound is fully healed.
11.Liver injury/liver failure
11.a.Hepatic encephalopathy and/or hepatorenal 
syndrome resulting from liver cirrhosisImmediately and permanently discontinue ramucirumab .
12Hypothyroidism 2-4Therapy with ramucirumab can be continued while treatment for the thyroid disorder 
is instituted.
13Otheradverse events considered at least possibly 
related to ramucirumabb
13.aNon-life threatening and reversible 3 May delay ramucirumab until resolved to Grade 0 -1.
If resolvedto Grade 0 -1, may reduce ramucirumab dose .
If NOTresolved to Grade 0 -1within a reasonable timeframe, discontinue 
ramucirumab at investigator’s discretion
13.bAdverse Event 4Permanently d iscontinue treatment immediately , with the exception of Grade 4 fever 
or Grade 4 laboratory abnormality, in which case:
First occurrence: Delay ramucirumab until resolved to Grade 0 -1.
oIf resolved to Grade 0 -1, may resume ramucirumab original dose at the 
discretion of the investigator.
oIf NOTresolved to Grade 0 -1within a reasonable timeframe, discontinue 
ramucirumab at investigator’s discretion .
Second occurrence: Delay ramucirumab until resolved to Grade 0 -1.
oIf resolved to Grade 0 -1, reduceramucirumab dose.
oIf NOTresolved to Grade 0 -1within a reasonable timeframe, discontinue 
ramucirumab at investigator’s discretion .
I4T-MC-JVDF(b) Clinical Proto col Page [ADDRESS_953593] (concluded)
Abbreviations:  AESI = adverse event of special interest; CTCAE = Common Terminology Criteria for Adverse Events; NCI = Natio nal Cancer Institute.
aPerform urinalysis within [ADDRESS_953594] dose delays or reductions related to the persistence or mild worsening of those symptoms or laboratory values.  Grade 2 toxicities which represent 
clinically significant worsening of symptoms from bas eline, ramucirumab dose may be delayed at the discretion of the investigator.  If the toxicity is resolved 
to Grade0-1, may reduce ramucirumab dose.  If the toxicity is n ot resolved to Grade 0-1,maydiscontinue ramucirumab.
I4T-MC-JVDF(b)Clinical Protocol Page 47
LY30098066.6.2.Pembrolizumab Dose Delays and Discontinuation
Adverse events (both nonserious and serious) associated with pembro lizumab exposure may 
represent an immuno logic etiology.  These AEsmay occur shortly after the first dose or several 
months after the last dose of treatment.  Pembrolizumab must be withheld (dose reductions are 
not permitted) for drug-related toxicit ies and severe or life -threatening AEs.  See Section [IP_ADDRESS]
for supportive care guidelines, including use of corticosteroids.   TableJVDF.5presents the 
guidelines for treatm ent delays and discontinuation of pembro lizumab for specific A Es 
associated with pembrolizumab treatment .
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953595] Possibly
Related to Pembrolizumab
Adverse Event CTCAE 
GradeTreatment Delay and Discontinuation
1Diarrhea/Colitis 2-3Delay pembrolizumab until resolved to Grade 0 -1.
If resolved to Grade [ADDRESS_953596] dose, then resume pembrolizumab .
Within [ADDRESS_953597] dose, if toxicity does not resolve to Grade 0 -1 *or* with inability to 
reduce corticosteroid to <10 mg/day of prednisone or equivalent per within [ADDRESS_953598], ALT, or Bilirubina2Delay pembrolizumab until resolved to Grade 0 -1.
If resolved to Grade [ADDRESS_953599] dose, then resume pembrolizumab .
If NOT resolved to Grade [ADDRESS_953600] dose, then discontinue pembrolizumab .
3-4Immediately and permanently discontinue pembrolizumab .See exceptions below.
3Type 1 Diabetes M ellitus (if new 
onset) or H yperglycemia associated 
with evidence of beta cell failureT1DM or 
3-4Delay pembrolizumab until patients are clinically and metabo lically stable.
If clinically and metabo lically within [ADDRESS_953601] dose, then resume pembrolizumab .
If NOT clinically and metabo lically stable within [ADDRESS_953602] dose, then immediately and 
permanently discontinue pembrolizumab .
4Hypophysitis 2-4Delay pembrolizumab until resolved to Grade 0 -1.
If resolved to Grade [ADDRESS_953603] dose, then resume pembrolizumab.
Within [ADDRESS_953604] dose, if toxicity does not resolve to Grade 0 -1 *or* with inability to 
reduce corticosteroid to <10 mg/day of prednisone or equivalent per within 12 weeks, 
immediately and permanently discontinue pembrolizumab.
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953605] Possibly Related to Pembrolizumab (co ntinued)
Adverse Event CTCAE 
GradeTreatment Delay and Discontinuation
5Hyperthyroidism 2Therapy with pembrolizumab can be continued; n on-selective beta -blockers (e.g. ,
propranolol) are suggested as initial therapy for hyperthyroidism 
(Section6.[IP_ADDRESS]).
3Delay pembrolizumab until resolved to Grade 0 -1.
If resolved to Grade [ADDRESS_953606] dose, then resume 
pembrolizumab .
Within [ADDRESS_953607] dose, if toxicity  does not resolve to Grade 0 -1 *or* 
with inability to reduce corticosteroid to ≤10 mg/day of prednisone or 
equivalent per within 12 weeks, immediately and permanently discontinue 
pembrolizumab .
4Immediately and permanently discontinue pembrolizumab .
Hypothyroidism 2-4Therapy with pembrolizumab can be continued while treatment for the thyroid 
disorder is instituted.
6Infusion Reaction 2First occur rence: Stop infusion of pembrolizumab until resolved to Grade 0 -1.
oIf resolved to Grade 0 -1 within 1 hour of stoppi[INVESTIGATOR_348025], then restart 
infusion at 50% of the original rate (e .g.,from 100 mL/hr to 50 mL/hr) .
oIf NOT resolved to Grade 0 -
1 within 1 hour of stoppi[INVESTIGATOR_348025], delay 
pembrolizumab until symptoms resolve , and premedicate for the next 
scheduled dose .
Second occurrence: If toxicity develops despi[INVESTIGATOR_250896], immediately and 
permanently discontinue pembrolizumab.
3-4Immediately and permanently discontinue pembrolizumab .
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953608] Possibly Related to Pembrolizumab (continued)
Adverse Event CTCAE 
GradeTreatment Delay and Discontinuation
7Pneumonitis 2 Delay pembrolizumab until resolved to Grade 0 -1.
If resolved to Grade [ADDRESS_953609] dose, if toxicity does not resolve to Grade 0 -1 *or* with 
inability to reduce corticosteroid to ≤10 mg/day of prednisone or equivalent per 
within 12 weeks, immediately and permanently discontinue pembrolizumab.
3-4 Immediately and permanently discontinue pembrolizumab.
8Renal Failure or Nephritis 2 Delay pembrolizumab until resolved to Grade 0 -1.
If resolved to Grade [ADDRESS_953610] dose, then resume 
pembrolizumab .
Within [ADDRESS_953611] dose, if toxicity does not resolve to Grade 0 -1 *or* with 
inability to reduce corticosteroid to ≤10mg/day of prednisone or equivalent per 
within 12 weeks, immediately and permanently discontinue pembrolizumab .
3-4 Immediately and permanently discontinue pembrolizumab .
9Other Adverse Eventsb3 or severe Delay pembrolizumab until resolved to Grade 0 -1.
If resolved to Grade [ADDRESS_953612] dose, then resume 
pembrolizumab .
Within [ADDRESS_953613] dose, if toxicity does not resolve to Grade 0-1 *or* with 
inability to reduce corticosteroid to ≤10mg/day of prednisone or equivalent per 
within 12 weeks, immediately and permanently discontinue pembrolizumab .
4 Immediately and p ermanently discontinue pembrolizumab .
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953614] Possibly Related to Pembrolizumab (co ncluded)
Abbreviations:  AE = adverse event; ALT = alanine aminotransferase ; AST = aspartate aminotransferase; CTCAE = Common Terminology Criteria for Adverse 
Events; T1DM = type 1 diabetes mellitus.
Note:  Permanently discontinue for any severe or Grade [ADDRESS_953615] or ALT increases by [CONTACT_119556] 50% relative to 
baseline and lasts for at least 1 week ,then patients should be discontinued.
bPatients with intolerable or persistent Grade 2 drug -related AE (s)may hold study  medicatio n at physician discretion.  Permanently discontinue 
pembrolizumab for persistent Grade [ADDRESS_953616] 
dose.
I4T-MC-JVDF(b)Clinical Protocol Page 52
LY30098066.6.3.Dose Delays for Reasons Not Related to Study Treatment
Dosing interruptions of either study drug are also permitted forreasons not related to study 
treatment (for example , elective surgery, unrelated medical events, patient vacat ion, and/or 
holidays).
Patients should resume the delayed study drug(s)within 21 days of the scheduled interruption,
with every effort made to start on Day  1 of the next dosing schedule, unless otherwise discussed 
with the Sponsor.  The reason for interruption should be documented on the case report form 
(CRF).
6.7.Treatment Compliance
The study  medication will be administered only at the invest igational sites by [CONTACT_702381].  As a result, treatment compliance is ensured.
During Phase 1a, DLT -evaluable populat ion is defined as all enro lled patients in DLT Phase 1a
who either completed [ADDRESS_953617] igator(s) and the Lilly CRP/CRS to ensure adequate 
PK data, unl ess accrual to that cohort has stopped due to a DLT.
6.8.Lifestyle and/or Dietary Requirements
6.8.1.Diet
Patients shoul d maintain a normal diet unless modificat ions are required to manage an AE such 
as diarrhea, nausea ,or vomiting.
6.8.2.Contraception
Based on ramucirumab’s mechanism o f action, it is likely that ramucirumab will  inhibit 
angiogenesis and may potentially  result in adverse effects during pregnancy and postnatal 
development.
Pembrolizumab may have adverse effects on a fetus in utero.  Furthermore, it is not known if 
pembrolizumab has transient a dverse effects on the composit ion of sperm.
Therefore, 1)non-pregnant, non -breast-feeding women may only be enro lled if they  are willing 
to use a highly effect ive methodof birth control  or are considered to be of non -childbearing 
potentialand 2)only men may be enrolled who use a reliable method of birth control, or who are 
sterile (including confirmed vasectomy) and do not donate sperm (Section 5.1).
I4T-MC-JVDF(b)Clinical Protocol Page 53
LY3009806For female patients, n on-childbearing potential (by [CONTACT_119536] m edical reasons) is defined as any 
one of the fo llowing:
≥45 years of age and has not had menses for greater than 2 y ears
Amenorrheic for < 2 y ears without a hysterectomy and oophorectomy  and a
follicle-stimulating hormone(FSH) val ue in the postm enopausal range upon pretrial 
(screening) evaluat ion(FSH level >40 m IU/mL)
At least [ADDRESS_953618] be confirmed with medical records of the actual procedure ;otherwise,the 
patientmust be willing to use an adequate barrier method throughout the study , starting 
with the screening visit through [ADDRESS_953619] dose of study  treatment.
not heterosexually act ive for the duration of the study
A “highly effective method of birth control” is defined as one that resul ts in a low failure rate 
(that is, <1% per y ear) when used consistent ly and correctly, such as implants, injectables, 
combined oral contraceptives, some intrauterine contraceptive devices, sexual abst inence, or a 
vasectomized partner.
Two birth control  methods are preferred, and can be either 2 barrier methods or a barrier method 
plus a horm onal method to prevent pregnancy. The following are considered adequate barrier 
methods of contraception: diaphragm, condom (by [CONTACT_3969]), copper intrauterine device, 
sponge, or spermicide as per local regulations or guidelines.
Appropriate hormonal contraceptives will include any registered and marketed con traceptive 
agent that contains an estrogen and/or a progestational agent (including oral, subcutaneous, 
intrauterine, or i ntramuscular agents).  For patients using a hormonal c ontraceptive method, 
information regarding pembrolizumaband its potential effect on the contraceptive should be 
addressed.
Patients shoul d start using birth control from study Visit [ADDRESS_953620] dose of study treatment.
Patients should be informed that taking the study  medication may involve unknown risks to the 
fetus (unborn baby ) if pregnancy were to occur during the study .  If there is any quest ion that a 
patientwill not reliably comply wit h the requiremen ts for contracepti on, that patientshould not 
be entered into the study .
6.9.Concomitant Therapy
A list of restricted and excluded conco mitant therapi [INVESTIGATOR_702355] 7.  All premedicat ion, supportive care, and concomitant medicat ion must be reported 
on the CRF at each visit.
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953621] (AESI).  
See TableJVDF.4and TableJVDF.5for dose reductions (ramucirumab only), delays, or 
discontinuat ions for AEs considered to be at least possibly related to study  treatment
(pembrolizumab or ramucirumab) .
[IP_ADDRESS]. Infusion-Related Reactions -Ramucirumab and Pembrolizumab
Infusion-related reacti ons (IRRs) have been i dentified as events of interest for b oth ramucirumab 
and pembro lizumab. In the event of an IRR, blood samples will be collected for both PK and 
immunogenicit y analysis f or each drug at the follo wing time po ints:  (i) as close as possible to 
the onset of the IRR, (ii) at the resolution of the IRR, and (iii) 30 days fo llowing the IRR.
IRRs may occur during or following ramucirumab or pembro lizumab administration.  Patients 
should be closely monitored for signs and symptoms indicat ive of an IRR from the init iation of 
the infusion in an area where resuscitat ion equipment and other agents (such as epi[INVESTIGATOR_702356]) are readily  available.
Signs and symptom s usually develop during or shortly  after infusion and generally resolve 
within 24 hours. Symptoms of IRRs include rigors/tremors, back pain/spasms, chest pain and/or 
tightness, chills, flushing, dy spnea, wheezing, hypoxia, and paresthesia.  In severe cases, 
symptoms include bronchospasm, supraventricular tachycardia, and hypotensio n.
The first 2 cycles will require a 1-h our observat ion period i) between ramucirumab and 
pembrolizumab administration ,and ii) after pembrolizumab infusion.  For all cycles thereafter,
no observat ion period will be required unless clinically indicated.   If the patient shows no 
evidence of an IRR wit h the first 2 cycles of each study  drug, no observat ion period is requi red 
for subsequent cycles, unless clinically  indicated.  In the event an IRR occurs thereafter, the 1 -
hour observation should be reinstituted.
[IP_ADDRESS].1. Infusion -Related R eactions -Ramucirumab
TableJVDF.4presents ramucirumab dose modification and supportive care guidelines for 
patients who experience an IRR associated with ramucirumab .
For the first 2 ramucirumab infusio ns, measure blood pressure and pulse at the following time 
points:  (i ) within 15 minutes prior to the infusio n,(ii) after completion of the infusio n,and (iii) 
at the end of the 1-hour post-infusion observat ion period.  For all subsequent infusio ns of 
ramucirumab, measure bl ood pressure and pul se prior to the infusion.Measure other vital signs 
as clinically indi cated.
I4T-MC-JVDF(b)Clinical Protocol Page 55
LY30098066.[IP_ADDRESS]. Infusion -Related Reactions -Pembrolizumab
TableJVDF.5presents pembro lizumab dose modificat ion and supportive care guidelines for 
patients who experience an IRR associated with pembrolizumab.  For Grade 3 -4 IRRs, the 
patientis immediately and p ermanently discont inued from pembrolizumab.
[IP_ADDRESS]. Supportive Care for Ramucirumab
[IP_ADDRESS].1. Supportive Care by [CONTACT_702368]
[IP_ADDRESS].1.1. Hypertension
An increased incidence of severe hypertension (CTCAE Grade 3) has been reported in patients 
receiving ramucirumab compared with placebo.  In most cases, hypertensio n was controlled 
using standard ant ihypertensive treatment.  Preexisting hypertensio n should be controlled before 
starting ramucirumab treatment.
Monitoring of blood pressure is required during , and shoul d occur prior to, ramucirumab therapy.  
Every attempt should be made to control blood pressure to systolic <140 mm Hg and diastolic 
<90 mm Hg prior to starting treatment with ramucirumab.  Routine clinical and laboratory  
monitoring is required in pat ients who again develop hy pertension or experi ence a deteri oration 
in previous hypertensio n.
[IP_ADDRESS].1.2. Proteinuria
Proteinuria is an adverse effect for all therapi[INVESTIGATOR_702357]/VEGF Receptor [ADDRESS_953622], 
including ramucirumab.  In ramucirumab clinical trials, the majorit y of events were Grade 1 or 2.  
Monitoring for the development or worsening of proteinuria during ramucirumab therapy  is 
required.  Discontinue ram ucirumab if the pat ient experiences proteinuria >3 g/24 hours or 
nephrotic syndrom e.
[IP_ADDRESS].1.3. Thromboembolic Events
[IP_ADDRESS].1.3.1. Arterial Thromboembolic Events
Serious, sometimes fatal arterial thromboembo lic events, including myocardial infarct ion, 
cardiac arrest, cerebrovascular accident, and cerebral ische mia, have been reported in clinical 
trials.
[IP_ADDRESS].1.3.2. Venous Thromboembolic Events
Venous thromboembo lic events are associated with cancer; however, the incidence o f VTEs 
likely varies depending on the ty pe of cancer, stage, and intensit y of imaging.  Addit ionally, 
VTEs have been associated with so me antiangiogenic therapy , although the inci dence vari es 
depending on the ty pe of therapy , use of concomit ant chemotherapy  agents, and specific disease 
state.  VTEs have been reported from clinical studies investigating ram ucirumab, parti cularly in 
the context of metastatic disease or in regio ns adjacent to implanted venous access devices.
I4T-MC-JVDF(b)Clinical Protocol Page 56
LY30098066.[IP_ADDRESS].4. Bleeding/Hemorrhage
Ramucirumab is an ant iangiogenic therapy  and has the potential to increase the risk of severe 
bleeding.  Severe GI he morrhages, including fatal events, have been reported in pat ients with 
gastric-GEJ cancer treated with ramucirumab in combinat ion with paclitaxel.
Serious hemorrhagic AEs have been reported from clinical studies invest igating ramucirumab.  
Hemorrhagic com plications are associated with some malignancies (that is, variceal bleeding 
from portal hypertensio n in hepatocellular carcino ma, lower GI hem orrhage from  bowel 
metastases in ovarian carcino ma),although the rate of these complicat ions varies considerably.   
As detailed in the ramucirumab IB, the incidences of hemorrhagic events to date, significant 
background incidence of bleeding in so me malignancies, and use of conco mitant antiplatelet 
therapy in some of the reported cases preclude any definit ive associ ation between bleeding and 
ramucirumab, al though ongoing surveillance and ident ification (and exclusio n) of patients with 
high bleeding risk remain essent ial and are detailed in the inclusio n/exclusio n criteria.
[IP_ADDRESS].1.5. Gastrointestinal Perforation
Patients with unresected (or recurrent) primary  tumorsormesenteric or peritoneal disease who 
participate in this clinical study  may be at increased risk for GI perforation due to the nature of 
the disease (metastatic gastric -GEJ cancer).
An infrequent incidence of GI per forations has been associated with so me antiangiogenic 
therapeutic agents, m ost specifically in the context of colorectal cancer (treated with combinat ion 
regimens, including ant i-VEGF ant ibodies and cyt otoxic chemotherapy) and in advanced ovari an 
cancer. These events may be associated with extensive abdominal/peritoneal disease burden.  
Gastrointestinal perforation has been reported from clinical studies invest igating ramucirumab.  
The incidences of these events to date and presence of significant comorbi dities and risk factors 
preclude any definitive association wit h ramucirumab, al though ongoing surveillance remains 
essential.  More information about GI perforation may be found in the IB.
[IP_ADDRESS].1.6. Reversible Posterior Leukoencephalopathy Syndrome
Reversible poste rior leukoencephalopathy syndrome (RPLS) is a clinical and radiologic 
syndrome typi[INVESTIGATOR_702358] -imaging 
findings of subcortical edema invo lving the posterior circulat ion, particularly the occi pi[INVESTIGATOR_33934] 
(Hinchey et al. 1996).  The symptoms of RPLS mo st often include generalized seizures, 
headache, delirium, and cortical blindness, although these may vary significant ly and 
occasionally include focal  neurological deficits (Hinchey et al . 1996; Gar g 2001; Lee et al. 
2008).  MRI represents the most reliable method for diagnosis (Lee et al. 2008).  Clinical 
symptoms and MRI abnormalit ies usually  recover wi thin days to weeks with proper 
management, although permanent neurologic dysfunct ion has been rep orted (Hinchey  et al. 
1996; Tajima et al. 1999; Garg 2001; Lee et al. 2008).
Across the clinical program to date, [ADDRESS_953623] been reported : One case occurred in 
each arm of the recently completed double -blind, rando mized, placebo-controlled Phas e 3 
StudyRAISEevaluating ramucirumab in co mbination with FOLFIRI versus FOLFIRI in 
combination with placebo for pati ents with metastatic colorectal cancer.
I4T-MC-JVDF(b)Clinical Protocol Page 57
LY3009806RPLS should be identified and treated prompt ly in order to minimize potential for permanent 
neurological damage.  Treatment encompasses careful control of blood pressure, withdrawal of 
potentially causative medication, and administration of ant iconvulsant agents to those 
experiencing seizures (Stott et al. 2005).
[IP_ADDRESS].1.7. Congestive Heart Failure
An increased risk of congest ive heart failure (CHF) has been associated with so me 
antiangiogenic therapeut ic agents, particularly in patients with metastatic breast cancer 
previously treated with anthracyclines.  A small number of CHF events (including fatal) were 
alsoreported in patients who had received ramucirumab after prior treatment with anthracyclines 
in the Phase [ADDRESS_953624] ing coronary artery disease or CHF.  Ramucirumab should be 
discontinued in the event of any Grade 3 or 4 events consistent with CHF.
[IP_ADDRESS].1.8. Fistula Formation
Because fistula format ion has been associated with antiangiogenic agents, patients may be at 
increased risk for the development of fistula when treated with ramucirumab.  Some fistulas can 
be resolved with surgical procedures; however, fistulas can be fatal.  The impact on the quali ty of 
life of having a fistula varies according to the locatio n and extent of the fistula (Chen and Cleck 
2009).
[IP_ADDRESS].1.9. Surgery and Impaired Wound Healing
Because ramucirumab is an ant iangiogenic therapy, it may have the potential to adversely affect 
wound healing.  Ram ucirumab did not im pair wound healing in a study  conducted in animals; 
however, the impact of ramucirumab on serious or nonhealing wounds has not been evaluated in 
humans.
[IP_ADDRESS].1.10. Liver Failure and Other Significant Liver Injury
Liver failure or other significant liver injury events, such as hepatic encephalopathy, have been 
observed in patients receiving ramucirumab.  Patients with 1) cirrhosis at a l evel of Child-Pugh 
Class B (or worse) or 2) cirrhosis (any  degree) and a history  of hepatic encephalopathy o r 
clinically meaningful ascites result ing from cirrhosis shoul d not be enrolled in clinical trials with 
ramucirumab.  “Clinically meaningful ascites” is defined as ascites result ing from cirrhosis and 
requiring ongoing treatment with diuretics and/or parac entesis.  See Site Guidance document for 
Hepatic Monitoring/Drug-Induced Liver Injury .
[IP_ADDRESS].2. Supportive Care Agents forRamucirumab -Guidelines
Supportive care measures may include but are not limited to antiemet ic agents, opi[INVESTIGATOR_702359], appetite stimulants, and granulocy te and ery throid growth factors.  
Guidelines regarding the use of specific supportive care agents are presented below.
I4T-MC-JVDF(b)Clinical Protocol Page 58
LY30098066.[IP_ADDRESS].1. Antiemetic A gents
Although emesis is not an expected side effect of ramucirumab , the use of ant iemetic agents is 
permitted at the discretion of the invest igator.  Acceptable ant iemetic agents include 5 -HT3
receptor antagonists ( for example , ondansetron), dopamine receptor antagonists ( for example , 
metoclopramide), corti costeroids (for example , dexamethasone ), and others.
[IP_ADDRESS].2.2. Analgesic A gents
The use of analgesic agents is permitted at the discretion of the invest igator.  Opi[INVESTIGATOR_702360] (including acetaminophen /paracetamol); however, use 
of NSAIDs and/or aspi[INVESTIGATOR_702361] (Attachment 7 ).
[IP_ADDRESS].2.3. Appetite Stimulants
The use of appet ite stimulants is permitted at the discretion of the invest igator.  Examples
include megestrol acetate, dronabino l, and others.
[IP_ADDRESS].2.4. Granulocyte -Colony Stimulating Factors
The as-needed use of G-CSFsis permitted at the discretion of the invest igator based on 
American Societ y of Clinical Oncology (ASCO) gui delines (Smit h et al. 2006)(Attachment 7) .
[IP_ADDRESS].2.5. Erythroid Growth Factors
The as-needed use of ery throid-stimulating factors (for example , erythropoietin) is permitted at 
the discretion of the invest igator based on ASCOguidelines (Rizzo et al . 2008)(Attachment 7) .
[IP_ADDRESS].2.6. Other Supportive Care A gents
The use of benzodiazepi[INVESTIGATOR_1651], antidepressants, laxatives, and other agents that may be helpful in 
controlling disease -related symptom s are also permitted and encouraged, except as prohibited in
Attachment 7.
[IP_ADDRESS]. Supportive Care for Pembrolizumab
Supportive care guidelines for the management of specific AEswith potential immunol ogic 
etiology are outlined below. Where appropriate, these guidelines include the use of oral or 
intravenous treatment with corticosteroids as well as addi tional anti-inflammatory agents if 
symptoms do not improve with administration of corticosteroids.  Several courses of steroid 
tapering may be necessary, as symptoms m ay worsen when the steroid dose is decrea sed. For 
each disorder, attem pts should be made to rul e out other causes such as metastatic disease or 
bacterial or viral infection, which might require addit ional supportive care. The treatment 
guidelines are intended to be applied when the investigator determines the events to be related to 
pembrolizumab.
If after the evaluat ion the event is determined not to be related, the invest igator does not need to 
follow the treatment guidance as outlined below.  
It may be necessary  to perform  conditional procedures such as bronchoscopy , endoscopy , or skin 
photography  as part of evaluat ion of the event. 
I4T-MC-JVDF(b)Clinical Protocol Page 59
LY30098066.[IP_ADDRESS]. Pneumonitis -Pembrolizumab
Apply the fo llowing supportive care guidance for pneumo nitis: 
For Grade 2 events, treat with systemic corticosteroids (prednis one 1 to 2 m g/kg/day or 
equivalent).  When symptoms improve to Grade 0 -1, steroid taper should start and be cont inued 
over no less than 4 weeks.
For Grade 3 -4 events, immediately treat with intravenous steroids (methylpredniso lone 125mg) 
followed by [CONTACT_5019] -dose oral steroids (prednisone 1 to 2 mg/kg/day  or dexamethasone 4 mg every 
4 hours).  Administer addit ional anti-inflammatory measures, as needed.
Add prophylact ic antibiotics for opportuni stic infections,in the case o f prolonged steroid 
administration.
[IP_ADDRESS].2. Diarrhea/Colitis -Pembrolizumab
Patientsshould be monitored carefully for signs and symptom s of enterocolit is (such as diarrhea, 
abdominal pain, and blood or m ucus in stool , with or without fever) and of bowel perforation 
(such as peritoneal signs and il eus).
All patientswho experience diarrhea/co litis should be advised to drink liberal quant ities 
of clear fluids.  If sufficient oral fluid intake is not feasible, fluid and electroly tes should 
be substituted via IV infusio n.  For Grade 2 or higher diarrhe a, consider GI consultat ion 
and endoscopy  to confirm  or rule out colit is.
For Grade 2 diarrhea/colitis , administer oral corticosteroids (prednisone 1 to 
2mg/kg/day or equivalent) .
For Grade 3 or 4 diarrhea/colitis (orGrade 2 diarrhea ), treat with intravenous steroi ds 
(methylpredniso lone 125 mg)followed by [CONTACT_5019]-dose oral steroids(prednisone 1 to 2 
mg/kg/day  or dexamethasone 4 m g every 4 hours) .
When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued ove r no less than 4 weeks.
[IP_ADDRESS].3. Type 1 Diabetes Mellitus or Hyper glycemia -Pembrolizumab
For Grade 3-4 hyperglycemia or n ew onset type 1 diabetes mellitus (T1DM), including diabet ic 
ketoacidosis (DKA) or ≥ Grade 3 hyperglycemia, if associated with ketosis (ketonu ria) or 
metabolic acidosis (DKA) ,supportive care guidance is as fo llows:
Insulin replacement therapy  is recommended for T 1DMand for Grade 3 -4 hyperglycemia 
associated with metabolic acidosis or ketonuria.
Evaluate patients with serum glucose and a metabol ic panel, urine ketones, glycosylated 
hemoglobin, and C -peptide.
[IP_ADDRESS].4. Hypophysitis -Pembrolizumab
Apply the following supportive care guidance for hypophysit is:
For Grade 2events, treat with corticosteroids. When symptoms improve to Grade 1 or 
less, steroid taper should be started and continued over no less than 4 weeks. 
Replacement of appropriate hormones may be required as the steroid dose is tapered.
I4T-MC-JVDF(b)Clinical Protocol Page 60
LY3009806For Grade 3-4events, treat with an init ial dose of IV corticosteroids fo llowed by [CONTACT_79918]. When symptoms improve to Grade 1 or less, steroid taper should be 
started and continued over no less than 4 weeks. Replacement of appropri ate hormones 
may be required as the steroid dose is tapered.
[IP_ADDRESS].5. Hyperthyroidism or Hypothyroidism -Pembrolizumab
Thyroiddisorders can occur at any  time during treatment. Monitor patients for changes in 
thyroid function (at the start of treatment, periodically  during treatm ent, and as indicated based 
on clinical evaluation) and for clinical signs and symptoms of thyro id disorders.Apply the 
following supportive care guidance:
Grade 2hyperthyroidism events and Grade 2-4hypothyroidism:
oIn hyperthyroidism, non-selective beta-blockers (for example, propranolo l) are 
suggested as init ial therapy.
oIn hypothyroidism, thyroid hormone replacement therapy, with levothyroxine or 
liothyroinine, is indicated per standard of care.
Grade 3-4hyperthyroidism 
oTreat with an initial dose of IV corti costeroid followed by [CONTACT_78019]. 
When symptoms improve to Grade 1 or less, steroi d taper should be started and 
continued over no less than 4 weeks. Replacement of appropriate hormones may 
be required as the steroid dose is tapered.
[IP_ADDRESS].6. Hepatic Events-Pembrolizumab
See Site Guidance Document for Hepati c Monitoring/Drug -Induced Liver Injury .  Apply the 
following supportive care guidance for hepatic events:
For Grade 2events, monitor liver funct ion tests more frequent ly until returned to 
baseline values (consider weekly).
oTreat with IV or oral  corticosteroids.
For Grade 3-4events, treat with IVcorticosteroids for 24 to 48 hours.
When symptoms improve to Grade 1 or less, a steroid taper should be started and 
continued over no less than 4 weeks.
[IP_ADDRESS].7. Renal Failure or Nephritis -Pembrolizumab
Apply the fo llowing supportive care g uidance for renal failure or nephrit is:
For Grade 2events, treat with corticosteroids.
For Grade 3-4events, treat with systemic corticosteroids.
When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 w eeks.
6.10.Continued Access Period
The continued access period begins after study  completion and ends at end of trial 
(FigureJVDF.2and Section 4.4).
Attachment 1presents the schedule of events, including AE /serious adverse event ( SAE)data
collection and a continued access follow
-up visit, to occur 30 day s after discontinuation from the 
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953625].
Patients receiving IP sand experiencing ongoing clinical benefit , without disease progressi on, 
and no undue risks may continue to receive IP after study completionin the continued access 
period until one of the criteria for discont inuation is met, including unacceptable toxicit y or 
pregnancy (Section7.1).  Patientsmay receive a maximum o f 35 cycles(approximately  2 years)
of study treatment.
Lillywill notify invest igators when the continued access period begins and ends.
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953626] 
procedures performed as shown in the Time and Events Table (Attachment 1).
If a patient withdraws informed consent, he or she must not be contact[CONTACT_454863] n and consent.  Lilly may cont inue to use previously co llected 
medical research data prior to the withdrawal consistent with the original authorizat ion.
7.1.Discontinuation from Study Treatment
Patients are consi dered to have discont inued from study treatment when BOT H pembro lizumab 
and ramucirumab will no longer be administered.
Details regarding discontinuation due to an AE or due to pregnancy are found in Sect ion 6.6, 
Section 8.2.1,  and Section [IP_ADDRESS]).  Patients will be discont inued from study treatment if they  
meet any of the following addit ional criteria:
enrollment in any other clinical trial invo lving an IP or enrollment in any other type of 
medical research judged not to be scient ifically or medically co mpatible with this study
The patient, for any  reason, requi res treatm ent with another therapeuti c agent that has 
been demo nstrated to be effective for treatment of the study  indication, discontinuation 
from the study occurs pri or to introducti on of the new agent .
The investigator decides that the patient should be discontinued fro m study treatment.
The patient requests that the patient be withdrawn fro m study treatment.
The patient is significant ly noncompliant with study procedures and/or treatment .
disease progressi on(must be confi rmed if patient is clinically stable [Section [IP_ADDRESS]])
Discontinuation o f treatment may be considered for patients who have attained a 
confirmed CR that have been treated for at least [ADDRESS_953627] obtain 
documented approval  from theSponsor CRP to allow the inadvertent ly enrolled pat ient to 
continue in the study  with or without treatm ent with study drug(s).
7.2.Discontinuation from the Study
Patients will be discontinued from the study in the following circumstances:
The investigator dec ides that the patient should be discontinued fro m the study.
The patient requests that the patient be withdrawn fro m the study.
I4T-MC-JVDF(b)Clinical Protocol Page 63
LY3009806The patient beco mes pregnant during the study. See Section 8.2.1.3regarding reporting 
requirements on fetal outcome and breast feeding.
Lilly stops the study  or stops the patient’s participation in the study  for medical, safety , 
regulatory, or other reasons consistent wi th applicable laws, regulat ions, and good 
clinical practice (GCP).
7.2.1.Patients Who are Lost to Follow -Up
A patient will be considered lost to fo llow up if he or she repeatedly fails to return for scheduled 
visits and is unable to be con tacted by [CONTACT_3452].  Site personnel are expected to make 
diligent attempts to contact [CONTACT_57986] a scheduled visit or who the site is 
otherwise unable to follow.
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953628] ions below and shown in 
the Time and Events Table ( Attachment 1) .
8.1.Efficacy
8.1.1.Efficacy Assessments at Baseline and during Study Treatment
RECIST 1.1 (Attachment 6 )will be applied as the primary  measure for assessment of tumor 
responseanddate of di sease progressi on.  Local tumor imaging (investigator assessment with 
site radiological reading) will  be used.
Tumor imaging shoul d be performed by [CONTACT_4654], whic h is preferred for the majorit y of patients, as 
the more comm only used modality.  Magnet ic resonance imaging (MRI) should only be used 
when CT is contraindicated or for imaging in the brain.  The same imaging technique should be 
used for a patient througho ut the trial.  Imaging shoul d include the chest, abdomen, and pelvis.
The subsect ions below describe in detail the tumor imaging and assessment measures at baseline 
and during study  treatment(one or both study  drugs,Section4.1.3).
[IP_ADDRESS]. Baseline Tumor Imaging
Initial tumor imaging at screening must be performed within 21days prior to the date of 
enrollment(assignment to t reatment) or within [ADDRESS_953629] 1.1.
Scans performed as part of routine clinical management are acceptable for use as initial tumor 
imaging if they are of diagnostic qualit y and performed within protocol required time frame as 
described above .
[IP_ADDRESS]. Tumor Imaging During Study Treatment
During study  treatment, tumor response will be assessed every  6 weeks (± 7 days) by 
[CONTACT_1697], with confirmatory  assessment ob tained at the next routine scheduled imaging 
timepoint (that i s, after 6 weeks ±7 days).  After 24 weeks, tumor assessment will be conducted 
every 12 weeks (± 7 day s).
Per RECIST 1.1, partial or complete respon se should be confirmed by a repeat tumor imaging 
assessment not less than [ADDRESS_953630] 
indication of respon se, or at the next scheduled scan ( that is,6 weeks + 7 dayslater), whichever 
is clinically  indicated.
Continue to perform imaging unt il whichever of the fo llowing occurs first:
disease progression confirmed by [CONTACT_702382]
I4T-MC-JVDF(b)Clinical Protocol Page 65
LY3009806the start of ne w anticancer treatment
withdrawal o f consent
death
end of trial
[IP_ADDRESS]. Immune -Related RECIST (irRECIST)
Immunotherapeutic agents such as pembro lizumab may produce ant itumor effects by 
[CONTACT_134981] -specific immune responses.  The response pattern s seen wit h 
such an approach may  extend bey ond the typi[INVESTIGATOR_702362] h cytotoxic 
agents, and can manifest a clinical response after an init ial increase in tumor burden or even the 
appearance of new lesio ns.  Standard RECIST may not p rovide an accurate response assessment 
of immunotherapeutic agents such as pembrolizumab.  Therefore, for Study JVDF, RECIST 1.1 
will be adapted to account for the unique tumor response characteristics seen wit h treatment of 
pembrolizumab ( immune-related RECIST [irRECIST]).  irRECIST will be applied as detailed 
below for treatment-related decisions, and the result ing data will be included in the clinical
database.
Ifradiologic imaging verifies init ial progressive disease ( PD), tumor assessment should be 
repeated approximately 4 weeks later in order to confirm PD with the option of continuing study 
treatment per bel ow while await ing radiologic confirmation of progression.
If repeat imaging shows < 20% target lesio ncompared to nadir, stable or improved previous new 
lesion (if identified as cause for init ial PD), and stable/improved non -target disease (if i dentified 
as cause for init ial PD), treatment may be cont inued / resumed.
If repeat imaging confirms PD due to any  of the scenarios list edbelow, patients will be 
discontinued fro m study treatment.  In determining whether or not the tumor burden has 
increased or decreased, site study  team should consider all target lesi ons as well as non -target 
lesions (seeSite Guidance Docum ent for RECIST/irRECIST ).
Scenarios where PD is confirmed at repeat imaging:
Target lesio ns remains ≥ 20% and at least 5 -mm absolute increase compared to nadir .
Non-target disease result ing in init ial PD is worse (qualitative) .
New lesion resulting in initial PD is worse (qualitative).
Additional new lesion(s) since last evaluat ion
In patients who have init ial evidence of radio logical PD, it is at the di scretion of the treating 
physician whether to continue a patienton study treatment until repeat imaging is obtained.  This 
clinical judgment decisio n should be based on the patient’s overall clinical condit ion, including 
performance status, clinical symptoms, and laboratory  data.  Patients may receive study
treatment while wait ing for confirmat ion of PD if they are clinically stable as defined by [CONTACT_70135]:
absence of signs and symptoms indicat ing disease progression
no decline in ECOG performance status
absence of rapid progression of disease
I4T-MC-JVDF(b)Clinical Protocol Page 66
LY3009806absence of progressive tum or at critical anatomical si tes (for example , cord 
compression) requiring urgent alternat ive medical intervention
When feasible, patients should not be discontinued from study treatment until progressio n is 
confirmed by [CONTACT_702383].  This all owance to conti nue treatm ent despi[INVESTIGATOR_702363] a transient 
tumor flare in the first few months after the start of immunotherapy , but with subsequent disea se 
response.  Patients whoare deemed clinically unstable are not required to have repeat imaging 
for confirmation of PD.
TableJVDF.6summarizes the guidance for imaging and treatment after the first radio logic 
evidence of PD.
TableJVDF.6. Imaging and Treatment after First Radiologic Evidence of 
Progressive Disease
Clinically Stable Clinically Unstable
Imaging Treatment Imaging Treatment
First radiologic 
evidence of PDRepeat imaging 
approximately 4 
weeks later at site 
to confirm PDMay continue 
study treatment at 
the investigator’s 
discretion while 
awaiting 
confirmatory scanRepeat imaging 
approximately 4 
weeks later to
confirm PD, per 
investigator 
discretion onlyDiscontinue 
treatment 
Repeat scan 
confirms PDNo additional 
imaging required Discontinue 
treatment No additional 
imaging required N/A
Repeat scan shows 
SD, PR,or CRContinue regularly 
scheduled imaging 
assessments every 
6 weeks Continue study 
treatment at the 
investigator’s 
discretion Continue regularly 
scheduled imaging 
assessments every 
6 weeks May restart study  
treatment if 
condition has 
improved and/or 
clinically stable 
per Investigator’s 
discretion 
Abbreviations:  CR = complete response ; N/A = not applicable; PD = progressive disease; PR = partial response; 
SD=stable disease.
NOTE:Discontinuation of study treatment may be considered for patients who have attained a confirmed CR that 
have been treated for at least [ADDRESS_953631] 2 treatment cycles beyond the date 
when the initial CR was declared.
In determining whether or not the tumor burden has increased or decreased, study  site 
investigators should consider all target lesio ns as well as non -target lesions (see Procedure 
Manual).  Patients that are deemed clinically unstable are not required to have repeat tum or 
imaging for confirmat ion.  If radio logic progressi on is confirmed by [CONTACT_702384] ,then the 
patientwill be discont inued from study treatment.  Ifradiologicprogression is not confirmed, 
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953632] their next tumor imaging 
according to the protocol schedule o f every 6weeks (± 7 days).
8.1.2.Efficacy Assessments during Post discontinuation Follow -Up
Postdiscontinuati on follow-up during the study  period will be conducted per the Time and 
Events Table ( Attachment 1 ).
Tumor assessments m ay continue for patients who are withdrawn fro m the study for reasons 
other than disease progression every [ADDRESS_953633] of care.
8.1.3.Efficacy Measure s
The objective response rate (ORR) is the proportio n of enrolled patients who have received 
any amount of either study drug, have at least [ADDRESS_953634] 
overall response of co mplete response (CR) or partial response (PR).  The ORR will be assessed 
based on RECIST 1.1 (Eisenhauer et al. 2009) and irRECIST .
Time-to-response (TTR) is the time fro m the date of first study  treatment until the first 
evidence of aconfirmed CR or PR, as defined in Section [IP_ADDRESS].
Duration of response (DoR) is defined only for responders (patients with a confirmed CR or 
PR).  It is measured from the date of first evidence of a confirmed CR or PR to the date of 
objective progression or the date of death due to any cause, whichever is earlier.  If a responder 
is not known to have died or have object ive progressio n as of the dat a inclusio n cutoff date, D oR 
will be censored at the date of the last complete object ive progression -free disease assessment.
Disease Control Rate (DCR) is defined as the proportion of enro lled patients who have a best 
overall response of CR, PR, or stable disease (SD).
Progression -free survival (PFS) is defined as the time fro m the date offirst study  treatment 
until the date of the first observe d radiographically docum ented PD or death due to any  cause, 
whichever i s earlier.  The censoring is taken in the following order:
-if a patient does not have a complete baseline disease assessment, then the PFS time will 
be censored at the enro llment date, regardless of whether or not object ively determined 
disease progressi on or death has been observed for the patie nt; otherwise,
-if a patient is not known to have died or have objective progression as of the data 
inclusion cutoff date for the analysis, the PFS time will be censored at the last complete 
objective progression -free disease assessment date.
TTR, DoR,DCR,and PFS will be assessed based on RECIST 1.1.   Exploratory analysis o f TTR, 
DoR,and PFS may be conducted using irRECIST.
Overall survival (OS), including [ADDRESS_953635] study treatment until death due to any cause.  If the patient was alive at the data inclusio n 
cutoff date for the analysis (or was lost to follow -up), OS will be censored on the last date the 
patient was known to be alive.
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953636] igator.
The timing of all safet y evaluations is shown in the Time and Events Table ( Attachment 1) .  
TableJVDF.7presents a summary o f AE and SAE reporting guidelines and shows which
database or storage system is used.
I4T-MC-JVDF(b)Clinical Protocol Page 69
LY3009806TableJVDF.7. Adverse Event and Serious A dverse Event Reporting Guidelines
PeriodTypes of AEs/SAEs to 
be ReportedaCollection 
DatabasebLilly 
Safety 
System
Baseline (pretreatment) Preexisting conditions x
All AEs x
SAEs related to protocol 
proceduresx X
Study treatment period All AEs x
All SAEs x X
Short-term postdiscontinuation follow -up (30 day s) All AEs x
All SAEs x X
Long-term postdiscontinuation period
Through post -discontinuation follow -up visit (90 day s)All SAEs x X
Additional long -term discontinuation follow up (every 90 
days to study  completion) All SAEs related to 
protocol procedures or 
IPx X
Continued access period All AEs x
All SAEs x X
Continued access follow -up (30 day s; or sooner, to occur 
when patient begins a new anti -cancer therapy)All AEs x
All SAEs x X
After the patient is no longer participating in the study 
(that is, no longer receiving study treatment and no longer 
in follow-up)AllSAEs related to 
protocol procedures or 
IP that the investigator 
becomes aware ofX
Abbreviations:  AEs = adverse events; CRF = case report form; IP=Investigational Product (ramucirumab or 
pembrolizumab); SAEs = serious adverse events.
aAlthough not strictly adverse events, pregnancy and breastfeeding are reported as SAEs.  The reporting period 
starts after receiving IP (s)and ends [ADDRESS_953637].
Any clinically  significant findingsfrom electrocardi ograms (ECGs), labs, vital sign 
measurements, or other procedures that result in a diagnosis should be reported to Lilly or its 
designee.
After the informed consent form (ICF) is signed, s tudy site personnel  will record the occurr ence 
and nature of each patient’s preexist ing condit ions, including clinically  significant si gns and 
symptoms of the disease under treatment in the study .  Site personnel will record the occurrence 
and nature of any AEs and any change in the preexist ing condition(s).  Progression of the cancer 
under study  is not consi dered an adverse event unless it is considered to be drug -related by [CONTACT_1275].  All AEs related to protocol procedures are reported to Lillyor its designee.
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953638] igator decides whether he or she interprets the observed AEs as reasonably possibly 
related to disease, to the studyregimen, study procedure, or other concomitant treatment or 
pathologies.To assess the relat ionship of the AE to the IP, the followingis defined:
Reasonably Possibly Related:Reasonable possibilit y that there is a cause and effect 
relationship between the IP, study device,and/or study  procedure and the AE.
The invest igator answers yes/no when making this assessment.
Patients will be evaluated for AEs at each visit and will be instructed to call their physician to 
report any  AEs between visit s.
NCI-CTCAE v 4.0 will serve as the reference document for choosing appropriate termino logy 
for, and grading the severit y of, all AEs and other s ymptoms.  For AEs without matching 
terminology within the NCI -CTCAE v 4.0 criteria, the investigator will be responsible for 
selecting the appropriate system organ class and assessing severit y grade based on the intensit y 
of the event.
In addition to collecting the AE verbat im and the CTCAE severit y grade, AE verbat im text will 
also be m apped by [CONTACT_240234] (MedDRA) dictionary.
If a patient’s dosage is reduced or treatment is discontinued as a result of an AE, study  site 
personnel must clearly  report to Lillyor its designee via CRFthe circumstances and data leading 
to any such dosage reduction or discont inuation of treatm ent.
[IP_ADDRESS]. Reporting Ramucirumab Adverse Events of Special Interest and 
Pembrolizumab Events of Clinical Interest
[IP_ADDRESS].1. Infusion -Related Reactions -Ramucirumab and Pembrolizumab
Any treatment -related IRRs are defined according to the CTCAE Versio n4.0 definit ion (General 
Disorders and Administration Site Condi tions).  Symptoms occurring during or following 
infusion of invest igational therapy may also be defined according to AE categories such as 
allergic reaction, anaphylaxis, or cy tokine release syndrom e (Immune System Disorders ).  In the 
setting of symptoms o ccurring during or fo llowing infusio n of investigat ional therapy , 
investigators are encouraged to use the AE term “infusion-related reaction” and any  additional 
terms (including those not listed here) that best describe the event.
[IP_ADDRESS].2. Adverse Events of Special Interest-Ramucirumab
Section [IP_ADDRESS].[ADDRESS_953639] ions arise concerning AESIs.
I4T-MC-JVDF(b)Clinical Protocol Page 71
LY30098068.[IP_ADDRESS]. Events of Clinical Interest -Pembrolizumab
The 2 categories of ECIs include:
1. an overdose of pembrolizumab (≥1000 mg [5 times the dose ]) not associated with clinical 
symptoms or abnormal laboratory  results. 
2.An elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of 
normal (ULN) and an elevated total  bilirubin lab val ue that is greater than or equal to 2X 
ULNand, at the same time, an alkaline phosphatase lab value that is less than 2X ULN, 
as determined by  [CONTACT_13149] -specified laboratory  testing or unscheduled laborato ry 
testing. Please refer to the Site Guidance Document for Drug -induced Liver Injury.
ECIs identified from the date of first dose through 90 day s following discontinuation of study 
treatment, or 30 day s after the init iation of a new ant icancer therapy , whichever is earlier ,need to 
be reported to the Sponsor (ECIs that are SAEs are reported within 24 hours, per 
Section8.2.1.2).
[IP_ADDRESS]. Serious Adverse Events
An SAE is any  adverse event from  this study  that results in one of the fo llowing outcom es:
death
a life-threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacity
initial or prolonged inpatient hospi[INVESTIGATOR_11298]
congenital ano maly/birth defect
considered significant by [CONTACT_81121], including, but not limited 
to: 
oIs a new cancer (that is, not a condition under study.  NOTE: metastases are not 
considered to be a new cancer). 
oIs associated with an overdose (as defined in Section [IP_ADDRESS].3 for pembrolizumab 
and greater than the appropriate absolute dose based on the patient’s weight as 
specified in Section 6.1.1).
Important m edical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_409232], based upon appropriate 
medical judgment, they  may jeopardize the patient and may require medical or surgical 
intervention to prevent one o f the outcomes listed in this definit ion.
Serious adverse event collect ion begins after the patient has signed informed consent and has 
received IP and ends [ADDRESS_953640] alert Lillyor its designee of any seriousadverse event (SAE) within 
[ADDRESS_953641] igator awareness of the event via a Sponsor-approved method.  If study site 
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953642] 
also immediately provide official notificat ion on study -specific SAE forms.
This 24-hour notificat ion requirement refers to the init ial SAE informat ion and all fo llow-up 
SAE informat ion.
Planned surge ries should not be reported as SAEs unless the underlying medical condit ion has 
worsened during the course of the study .
Planned hospi [INVESTIGATOR_702364]’s medical history  at the tim e of study enrollment should not be considered SAEs.
Serious adverse events due to disease progression, including death, should not be reported unless 
the investigator deems them to be possibly related to the IPs.
The invest igator does not need to actively monitor patients for AEs once the trial has ended, 
unless provided otherwise in the protocol; however, if an invest igator becomes aware of an SAE 
occurring after the patient’s participat ion in the trial has ended, and the investigator believes that 
the SAE is related to a protocol  procedure or IPs ,the invest igator should report the SAE to the 
Sponsor, and the SAE will be entered in the Lilly Safet y System.
Information on SAEs expected in the study  population independent of drug exposure and that 
will be assessed by  [CONTACT_702385].
[IP_ADDRESS]. Pregnancy
Cases of pregnancy that occur during maternal or paternal exposures to IPs (ramucirumab or 
pembrolizumab) should be reported within [ADDRESS_953643] be reported as AEs.  Data on fetal outcome 
(including and breast feeding)are collected for regulatory  reporting and drug safet y evaluation.  
The following addi tional measures will be taken in the case of pregnan cy:
A patient who becomes pregnant will be immediately removed fro m the study.
It is theresponsibilit y of investigators or their designees to report any pregnancy or 
lactation in a patient(spontaneously reported to them) that occurs during the trial or 
within 120 days o f completing the trial or 30 day s following cessat ion of treatm ent if the 
patientinitiates new ant icancer therapy , whichever is earlier.
All patients who become pregnant must be contact[CONTACT_702386]’s status documented to the complet ion/terminat ion of the pregnancy; the 
investigator will make every  effort to obtain permissio n to follow the outcome o f the 
pregnancy and report the condit ion of the fetus or newborn to the Sponsor.
[IP_ADDRESS]. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse react ions (S[LOCATION_003]Rs) are serious events that are not listed 
in the Development Core Safet y Informati on in the IB and that the invest igator ident ifies as 
I4T-MC-JVDF(b)Clinical Protocol Page 73
LY3009806related to the IP sor study procedure.  [LOCATION_002] 21 CFR 312.32 and European Unio n Clinical 
Trial Directive 2001/20/EC and the associated detailed guidances or national regul atory 
requirements in participat ing countries require the reporting of S[LOCATION_003]Rs.  Lilly has procedures 
that will be fo llowed for the recording and expedit ed reporting of S[LOCATION_003]Rs that are consistent 
with global regulat ions and associated detailed guidances.
8.2.2.Other Safety Measures
[IP_ADDRESS]. Electrocardiograms
For each patient, 12 -lead digital ECGs will be co llected according to the Time and Events Table 
(Attachment 1) as single ECGs for overread.  Patients must be supi[INVESTIGATOR_17044] [ADDRESS_953644] ion.
Electrocardiograms may be obtained at addit ional times, when deemed clinically necessary .  
Collection of more ECGs than expected at a particular time point is allowed when needed to 
ensure high qualit y records.
Electrocardiograms will be interpreted by  a qualified physician (the investigator or qualified 
designee) at the site as soon after the time of ECG collect ion as possible, and ideally while the 
patient is still present, to determine whether the patient me ets entry criteria and for immediate 
patient management, should any  clinically relevant findings be identified.
After enro llment, if a clinically significant increase in the QT/corrected QT interval fro m 
baseline, or other clinically significant quantitati ve or qualitative change from baseline, is 
present, the invest igator will assess the patient for symptoms (for example, palpi[INVESTIGATOR_53895], near 
syncope, syncope) and to determine if the pat ient can continue in the study .  The invest igator or 
qualified designee is responsible for determining if any change in pat ient management i s needed 
and must document his/her review of the ECG printed at the time of evaluation.
The invest igator (or qualified designee) must document his/her review of the ECG printed at the 
timeof evaluation.  Local ECG findings at baseline and end of treatment, and any on study  
clinically significant abnormal findings ,will be reported into the electronic CRF (eCRF)and any 
alert reports .
[IP_ADDRESS]. Echocardiogram or Multiple -Gated Acquisition Scan
An echocardi ogram (ECHO) or m ultiple-gated acqui sition (MUGA) scan will be performed 
according to the Time and Events Table ( Attachment 1).  Additional evaluations are not required 
but should be perform ed in the setting of cardiac symptoms, at the discretion of the invest igator.
Patients will undergo baseline left ventricular ejectio n fraction (LVEF) determinat ion by [CONTACT_702387]. This evaluation m ay be repeated at any  time during the study  if clinically 
indicated.
8.2.3.Safety Monitoring
The LillyCRP will monitor safety data throughout the course of the study .
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953645], and review:
trends in safety  data
laboratory  analytes(Attachment 3)
adverse events , including ramucirumab AESIand pembro lizumab ECI(Section8.2.1.1).
Details for hepat ic monitoring depend upon the severit y and persistence of observed 
laboratory  test abnorm alities.To ensure patient safet y and comply with regulatory  
guidance, the investi gatormay consult with the Lilly CRP regarding collect ion of specific 
recommended clinical information and fo llow-up laboratory  tests.  See Site Guidance 
Document for Drug-Induced Liver Injury .
8.3.Pharmacokinetics
Pharmacokinet ic samples to determine ramuciru mab PK will be collected as specified in
Attachment 2.
Blood samples will be drawn for all patients for the assessment of ramucirumab concentrati ons
in serum(also known as bio analytical samples) .Sampling times were selected to coincide with 
expected C maxand Cminand with consideration to draw minimum vo lume of blood fro m 
patients and ensuring that the patients do not to need to make an extra visit to provide these 
samples.
Instructions for the collect ion and handling of bioanalyt ical blood sa mples will be provided by 
[CONTACT_1034].  The actual  start and end date and time of ramucirumab infusion administration 
must be recorded on the eCRF.  The actual date and time that each bioanalytical blood sam ple 
was drawn must be recorded on the laboratory  accession page after the sample is drawn.
Ramucirumab concentrati ons in bioanalytical serum samples will be measured using a validated 
assay methodology  in a laboratory  designated by [CONTACT_1034].
Bioanalytical samples collected to m easure ramucirumabconcentration will be retained for a 
maximum o f [ADDRESS_953646] patient visit for the study .
8.4.Biomarkers
Where local regulat ions and ethical review boards ( ERBs)allow, these samples will be collected 
for biomarker research as discussed below and specified in the Sampling Schedule 
(Attachment 2).
All biomarker samples will be coded with the patient number.  These samples and any  data 
generated can be linked back to the patient only by [CONTACT_10991].  Samples will 
be destroy ed according to a process consistent with local regulat ions.
It is possible that bi omarker data for patients in the study  has already been generated from  
samples that were collected and analyzed prior to enro lling in this trial. This may include data 
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953647] ion 8.4.2.
8.4.1.
Genetics
Whole Blood Sample for DNA Collection :
A whole blood sam plewill be collected for pharmacogenet ic analysis where local regulat ions 
and ERBs allow.  These samples are not being collected to create a biobank for conducting 
unspecified disease or populat ion genetic research either now or in the future.
Samples may beused to invest igate variable response to study  treatment and to invest igate 
genetic variants thought to play a role in cancer. Assessment of variable response may include 
evaluation of AEsor differences in efficacy.  These studies may include but are no t limited to the 
VEGF pathway  and immunom odulatory mechanisms to evaluate their associati on with observed 
response to study  treatment.
Samples will be retained for a m aximum of [ADDRESS_953648] ivities.
Samples may be used for research on the drug target s(PD-1 and VEGF Receptor2), disease 
process, pathways associated with cancer, mechanism  of actionof ramucirumab and /or 
pembrolizumab, and/or research method or in validating diagnostic tools or assay (s) related to 
cancer.
Samples will be retained for a m aximum of [ADDRESS_953649] igation of 
variable response that may not be observed unt il later in drug development or when the drug is 
commercially  available.
Required samples for bi omarker research to be collected from all pat ients in this study  as 
specified in the study  schedule are the following:
EDTA plasma
I4T-MC-JVDF(b)Clinical Protocol Page 76
LY3009806peripheral mononuclear blood cells from whole blood
tumor tissue at baseline (see Inclusion Criterion [4] and the paragraph below) . 
For the submissio n of baseline tumor tissue sample, formalin -fixed paraffin-embedded tum or 
tissue sample blo cks are preferred.  If submitting unstained cut slides, freshlycut slides should 
be submitted to the testing laboratory  within 7days from when the slides are cut. In addition, all 
archival samples should be discussed wit h the Sponsor before submissio n.  A formalin-fixed 
paraffin-embedded tum or tissue block obtainedwithin [ADDRESS_953650] recent sy stemictreatment will be considered by  [CONTACT_1034].
Optional samples for bi omarker research that should be collected from pat ients in the study  
where possible are the fo llowing:
tumor tissue/biopsy that becom es available during the study  treatment period
8.5.Samples for Immunogenicity Research
Blood samples for immunogenicit y testing will  be collected to determine ant i-drug antibody  
(ADA) production against ram ucirumab.  The specific time points are listed in Attachment 2. 
Sample collect ion, storage ,and shipment instructions for blood samples will also be provided in 
the Procedures Manual.
Pretreatment and post -treatment samples will be collected and assayed for the presence of ADA 
using an immunoassay.  The number and percent ageof patients with positive antidrug response 
will be summarized. In the event of an IP-related infusio n reaction, every  effort shoul d be made 
to collect a blood sample for anti -ramucirumab antibody  determinat ion, as well as a blood 
sample for ramucirumab serum concentration, as close to the onset of the reaction as possible, at 
the resolution of the event, and [ADDRESS_953651] patient visit for the trial at a 
facility selected by  [CONTACT_702388] o f immune responses to ramucirumab .  
The durati on allows the Sponsor to respond to regulatory  requests related to ramucirumab.
8.6.Health Economic and Outcomes Research
This section is not applicable to this protocol.
I4T-MC-JVDF(b)Clinical Protocol Page 77
LY30098069.Statistical Consideration s and Data A nalysis
9.1.Determination of Sample Size
The primary  objective for the DLT Phase 1a and Expansion Phase 1b is to evaluate safet y and 
tolerability.  The sample size of Expansion Phase 1b was selected to allow adequate assessment 
of safety at the recommended dose sfor ramucirumab and pembrolizumab for each tumor type 
and dose schedule, separately.
The following sample sizes apply  to each phase of the study :
Phase 1a Dose -Limiting Toxicity Observation: up to 12 DLT-evaluable patients
Phase 1b Expansion: 155 patients;
15 patients each for Gastric-GEJ (2nd- 3rdLine) CohortsA and B (2nd- 3rdLine)
25patientseachfor:
oBTC (2nd- 3rdLine) Cohort A1
oGastric-GEJ (1stLine) Cohort A 2
oNSCLC (2nd- 4thLine) Cohort C
oUrothelial (2nd- 4thLine) Cohort D 
oNSCLC (1stLine) Cohort E
The primary  objective of Study  JVDF is the safet y and tolerability oframucirumab in 
combination with pembrolizumab.  During Expansio n Phase 1b, 25 to 30 patients per tumor ty pe 
will be treated, to provide a preli minary assessment of tumor response and an assessment of 
safety.  For each of the tumor ty pes, the ORR values in the simulat ions are provided as a 
reference for estimation o f statistical power rather than a basis of any decisio n criteria.  All 
efficacy endpoints will be utilized to determine next steps of development of the combinat ion.
For Gastric -GEJ and BTC (2nd-3rdline), and NSCLC and Urothelial (2ndto 4thline), the null 
hypothesis is based on the assumption that the ORR is no greater than 10 % to 15% and the target 
treatment effect (alternat ive response rate) of the combinat ion treatment on ORR is greater than 
20% to 30%.  Based on these assumpt ions, a sample size o f n=25to 30 (n=30 for combined 
Gastric Cohorts A and B) provides statist ical power of approximately 60% to 90%, with a 1-
sided 0.20 si gnificance l evel (TableJVDF.8).
I4T-MC-JVDF(b)Clinical Protocol Page 78
LY3009806TableJVDF.8. Summary of Statistical Power for OverallResponse Rates for 
NSCLC 2 -4L, Bladder 2-4L , BTC2-3L, and Gastric 2 -3L 
NSCLC, Bladder,and BTC Gastric (combined preliminary efficacy)
Low 
CaseHigh 
CaseLow 
CaseHigh 
CaseLow 
CaseHigh 
CaseLow 
CaseHigh
Case
N=25 N=25 N=25 N=25 N=30 N=30 N=30 N=30
Null response rate 10% 10% 15% 15% 10% 10% 15% 15%
Alternative 
response rate20% 25% 25% 30% 20% 25% 25% 30%
Power 57.9% 78.6% 62.2% 80.7% 74.5% 90.2% 65.2% 84.0%
Abbreviations:  BTC= biliary tract cancer; L = line ; N = number of patients; NSCLC = non -small cell lung cancer.
Note:  Low case = 10% difference between alternative response rate and null response rate for overall response rate; 
High case = 15 % difference between alternative response rate and null response rate for o verall response rate.
For the first-line NSCLC and Gastric -GEJ, the null hy pothesis is based on the assumpt ion that 
the ORR is no greater than 30% to 35% and the target treatment effect (alternat ive response rate) 
of the combinat ion treatment on ORR is greater than 45% to 55%.  Based on these assumptions, 
a sample size of n=[ADDRESS_953652] ical power of approximately 65% to 90%, with a 1 -sided 
0.20 significance level (TableJVDF.9).
TableJVDF.9. Summary of Statistical Power for Overall Response Rates for 
NSCLC 1L and Gastric 1L
NSCLC (1L) and Gastric (1L; combined preliminary efficacy)
Low Case High Case Low Case High Case
N=25 N=25 N=25 N=25
Null response rate 30% 30% 35% 35%
Alternative 
response rate45% 50% 50% 55%
Power 75.8% 88.5% 65.5% 81.7%
Abbreviations:  1L= First-Line; N = number of patients; NSCLC = non -small cell lung cancer.
Note:  Low case = 15% difference between alternative response rate and null response rate for overall response rate; 
High case = 20% difference between alternative response rate and null response rate for overall response rate.
9.2.General Statistical Considerations
Statistical analysis o f this study  will be the responsibilit y ofLilly.
For the Phase 1a, a 3+3 design will be used to assess the safet y of ramucirumab in combinat ion 
with pembrolizumab(Section [IP_ADDRESS]). Additional patients will be enrolled in a dosing schedule 
to achieve the minimum of 3 evaluable patients ,if dropout s or dose interruptions or reductions occur 
that result in a patient being no n
-evaluable for DLTs .Data will be reviewed by [CONTACT_702389] (3 patients).
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953653] completed approximately  24 weeks of study  treatment or discont inued for any 
reason. Safety and preliminary efficacy  will be analyzed separately  for each cohort (details in 
Section9.8).
Descriptive statistics will be derived where appropriate.  The rate of DLTs will be summari zed 
by [CONTACT_9084]; dose exposure and densit y for each study  drug will be calculated by  [CONTACT_13155].
Pharmacodynamics/Biomarkers
Pharmacodynamic and/or tailoring bio marker analyses will be based on the subset of pat ients 
from the above cohorts from whom a valid assay result (according to laboratory  guideline) has 
been obtained.
General
Additional details will be provided in a separate statistical analysis plan (SAP) for the study .  
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol.
Additional exploratory analyses of the data will be conducted as deemed appropriate.
9.3.Patient Characteristics
Patient characterist ics which will be summarized by [CONTACT_9084]:
Patient demographics will be reported using descriptive statist ics.Demographic data are 
collected and reported to demonstrate that a trial populat ion represents the target patient 
population considered for regulatory approval.
Baseline disease characterist ics will be summar ized by [CONTACT_702390] (for example, for pathological diagnosis [histo logical or cy tological] and 
disease stage).
A detailed description o f patient disposition will be provi ded.  It will  include a summary  
of the number and perc entage of pati ents entered into the study , enrolled in the study , and 
treated as well as number and percentage of patients complet ing the study, or 
discontinuing (overall and by [CONTACT_702391]).
Disease-related therapi[INVESTIGATOR_014] ,including prior anticancer treatm ents, prior radiotherapi[INVESTIGATOR_014] 
(such as t ype of therapy, regimen, and prior surgery)
Other patient characterist ics will be summarized as deemed appropriate.
9.3.1.Concomitant Therapy
Concomitant medicat ions will be summarized for the safet y population.
I4T-MC-JVDF(b)Clinical Protocol Page 80
LY30098069.3.1.1. Postdiscontinuation Therapy
The numbers and percentages of patients reporting postdiscont inuation therapi[INVESTIGATOR_702365], by  [CONTACT_67887] (surgery, radiotherapy , or systemic therapy ), and by [CONTACT_240245].
9.3.2.Treatment Complianc e
The number of dose o missions, reducti ons, and delays, number of cy cles received, and dose 
intensity will be summarized for all treated patients and for both study  drugs.
9.4.Efficacy Analysis : Phase 1b
The objective response rate and disease control rate , and the corresponding confidence interval ,
will be provided by [CONTACT_9084](according to RECIST v1.[ADDRESS_953654] ). Time-to-event variables, 
such as time to response, duration o f response, PFS,and OS will be estimated by [CONTACT_5263] -Meier 
(1958) methodology by [CONTACT_9084].  Presentations o fefficacy may include patientsenrolled in DLT 
Phase 1a with the sametumor type and treatm entschedule.
Individual changes in the tumor burden over time will be presented graphically wit hin a tum or 
type (that is,Waterfall plots) .  Subgroup analysis of interest will be further defined in the SAP. 
Association between tumor PD -L1 expressio n at baseline will also be correlated with clinical 
outcomes such as overall response rate, and further assessed and characterized by  [CONTACT_702392].
9.5.Safety Analyses
All patients who receive at least [ADDRESS_953655] igator 
using CTCAE, Version 4.0.
Safety analyses will include summaries of the fo llowing:
DLTs:  the number of patients who experienced any DLTs during Cycle 1 will be 
summarized by  [CONTACT_702393] 1a
AEs, including severit y and possible rel ationship to study  drug
AEsby [CONTACT_7204] (SOC) by [CONTACT_702394]
Laboratory  and nonlaboratory  AEs by [CONTACT_702395] 
(regardless of causalit y and at least possibly related to study  treatment)
9.6.Pharmacokinetic/Pharm acodynamic Analyses
The sampling schedule for drawing blood samples for ramucirumab PK is provided in
Attachment 2.  Serum concentrations of ramucirumab prior to infusion (C min) and at 1 hour after 
the end of the ramucirumab infusio n (approximately  maximum concentrati ons) will be 
summarized using descript ive statist ics.
Population PK analyses for ramucirumab may be conducted using population PKapproach.  The 
relationship between ramucirumab exposure and selected safety  outcomes may be explored.
I4T-MC-JVDF(b)Clinical Protocol Page 81
LY30098069.7.Other Analysis
9.7.1.Immunogenicity
Immunogenicity (anti-ramucirumab antibody) incidence will be tabulated, and correlation to 
ramucirumab drug l evel, activit y, and safet y will be assessed, as appropri ate, respectively.  The 
measures that will be analyzed include baseline presence and level o f ADA, treatment -emergent 
ADA,levels of neutralizing ADA, and incidence and levels o f ADA related to IRRs.
9.7.2.Biomarker Analysis
Biomarkers will  be summarized and assessed for correlations with clinical outcomes.  Biomarker 
relationshipsby [CONTACT_44847], changesin biomarker levels over time , and differences amo ng dose 
levels or exposure will be explored aspossible.
9.8.Interim Analyses
ForPhase 1a, safety and PK datawill be reviewed on a cohort -by-cohort basis during the study .  
The purpose of these datareviews is to evaluate the safet y and tolerability for each dose schedule 
and determine if a DLT has been observed.  The investigators and the Lilly  study team will 
evaluate the totality ofdata to determine whether or not to move into the Expansion Phase 1b.
Separate interim analyses will occur after all pat ients in each cohort have completed 
approximately  24 weeks of study  treatment or di scontinued for any  reason.  The interim analyses 
may be combined if they are expected to occur within approximately a month, an d interim 
analyses may also be combined wit h the ongoing trial -level safety review or annual safet y review 
for annual safet y update reporti ng.
An independent data monitoring committee may be init iated if one or more addit ional cohorts 
will be expanded to further explore safet y and efficacy  for the ram ucirumab and pembrolizumab 
combination.
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953656] 
throughout the study  and sharing in a timely manner any  new informat ion that may be relevant to 
the patient’s willingness to continue hi s or her participat ion in the trial.
The ICF will be used to explain the potential risks and benefits of study  participation to the 
patientin simple terms before the patientis entered into the study , and to docum ent that the 
patientis satisfied with his or her understanding o f the risks and benefits of participat ing in the 
study and desires to parti cipate in the study .
The invest igator is responsible for ensuring that informed consent is given by [CONTACT_702396] .  This includes obtaining the appropriate signatures and dates on the ICF 
prior to the performance of any protocol procedures and prior to the administration of 
investigat ional product.
10.2.Ethical Review
Lilly or its representatives must approve all ICFs bef ore they are used at invest igative sites(s).  
All ICFs must be co mpliant with the International Conference on Harmonisat ion (ICH)guideline 
on GCP.
The invest igator must give assurance that the ERB was properly const ituted and convened as 
required by [CONTACT_105354].
Documentation of ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study may begin at the investi gative site(s).  The ERB(s) will review the protocol as required.
The study  site’s ERB(s) shoul d be provided wi th the following:
the current IB s and updates during the course of the study
ICF
relevant curri cula vitae
10.3.Regulatory Considerations
This study  will be conducted in accordance wit h:
1) consensus ethics principles derived fro m international ethics gui delines, including the 
Declaration of Helsinki and CouncilforInternational Organizat ionsofMedicalSciences
(CIOMS) Internati onal Ethical Guidelines
2) the ICH GCP Guideline [E6]
3) applicable laws and regulat ions
The invest igator or desi gnee will prom ptly submit the protocol  to applicable ERB(s).
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953657]-party organization.
An identification code assigned to each patient will be used in lieu of the patient’s name [CONTACT_92396]’s identity when reporting AEs and/or other trial -related data.
10.4.Investigator Information
Physicians with a specialt y in oncology will participate as invest igators in this clinical trial.
10.5.Protocol Signatures
The Sponsor’s responsible medical officer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study.
After reading the protocol, each principal invest igator will sign the protocol signatur e page and 
send a copy  of the signed page to a Lilly representative.
10.6.Final Report Signature
[CONTACT_702405], indicating agreement that, to the best of his or her k nowledge, the report accurately 
describes the conduct and results of the study .  The coordinat ing investigator will be the 
investigator with the most enrolled patients; if this investigator is unable to fulfill this funct ion, 
another invest igator will be c hosen by [CONTACT_1034].
The Sponsor’s responsible medical officer and statist ician will approve the final clinical study  
report for this study , confirming that, to the best of his or her knowledge, the report accurately  
describes the conduct and results of the study.
10.7.Complaint Handling
Lilly collects product complaints on invest igational products and drug delivery systems used in 
clinical studies in order to ensure the safet y of study participants, m onitor quality, and to 
facilitate process and product impro vements.
Complaints related to unblinded concomitant drugs are reported directly to the manufacturers of 
those drugs/devices in accordance with the package insert.
The invest igator or his/her designee is responsible for handling the fo llowing aspects of th e 
product complaint process in accordance wit h the instructions provided for this study :
recording a complete descript ion of the product complaint reported and any associated 
AEs using the study -specific co mplaint form s provided for this purpose
faxing the completed product complaint form wit hin [ADDRESS_953658] igation, he/she will return a copy  of the 
product complaint form with the product.
10.8.Data Quality Assurance
To ensure accurate, com plete, and reliable data, Lilly  or its representatives will do the fo llowing:
I4T-MC-JVDF(b)Clinical Protocol Page 84
LY3009806provide instructi onal materi al to the study  sites, as appropriate
sponsor start -up training to instruct the invest igators and study  coordinators.  This 
training will giv e instructi on on the protocol, the complet ion of the CRFs, and study  
procedures.
make periodic visit s to the study  site
be available for consultation and stay  in contact [CONTACT_47556], 
telephone, and/or fax
review and evaluate CRF d ata and use standard computer edits to detect errors in data 
collection
conduct a qualit y review of the database
In addition, Lilly or its representatives will periodically check a sample of the patient data 
recorded against source documents at the study  site.  The study  may be audited by [CONTACT_47551] i ts 
representatives, and/or regulatory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.
To ensure the safet y of participants in the study , and to ensure accurate, complete, and rel iable 
data, the invest igator will keep records of laboratory tests, clinical notes, and patient medical 
records in the patientfiles as original source documents for the study .  If requested, the 
investigator will provide the sponsor, applicable regulatory agencies, and applicable ERBs wit h 
direct access to original source documents.
10.8.1.Data Capture System
An electronic data capture sy stem will be used in this study .  The site maintains a separate source 
for the data entered by  [CONTACT_702397]-provided electronic data capture sy stem.
Case report form data will be encoded and stored in a clinical trial database.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint management sy stem.
10.9.Study and Site Clos ure
10.9.1.Discontinuation of Study Sites
Study site participation may be discont inuedif the Sponsor, the investigator, or the ERB of the 
study sitejudges it necessary  for medical, safet y, regulatory, or other reasons consistent with 
applicable laws, regulations, and GCP.
10.9.2.Discontinuation of the Study
The study  will be discontinued if the Sponsor judges it necessary for medical, safet y, regulatory , 
or other reasons consistent with applicable laws, regulat ions, and GCP.
I4T-MC-JVDF(b)Clinical Protocol Page 85
LY300980611.References
Agaram NP, Shia J, Tang LH, Klimstra DS. DNA mismatch repair deficiency in ampullary 
carcinoma: a morpho logic and immunohistochemical study  of 54 cases. Am J Clin Pathol.
2010;133(5):772 -780. 
Bang YJ, Van Cutsem E, Fey ereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A,
Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial 
Investigators. Trastuzumab in co mbination with chemotherapy versus chemotherapy  alone for 
treatment of HER2 -positive advanced gastric or gastro- oesophageal junct ion cancer (ToGA): a 
phase 3, open -label, rando mised controlled trial. Lancet.2010;376(9742):687-697.
Benckert C, Jonas S, Cramer T, Von Marschall Z, Schäfer G, Peters M, Wagner K, Radke C, 
Wiedenmann B, Neuhaus P, Höcker M, Rosewicz S. Transforming growth factor beta 1 
stimulates vascular endothelial growth factor gene transcript ion in human cho langiocellular 
carcinoma cells. Cancer Res. 2003;63(5):1083 -92.
Bendell J, Powderly JD, Lieu C, Eckhardt SG, Hurwitz HL, Hochster H, Murphy JE, Funke R, 
Rossi C, Wallin JJ, Waterkamp D, Pi[INVESTIGATOR_338492]. Safet y and efficacy  of MPDL3280A (Anti -
PDL1) in co mbination with Bevacizumab and/or FOLFOX in patients with metastatic 
colorectal cancer. General Poster Session , American Society  of Clinical Onco logy 
Genitorurinary Cancers Symposium, 2015. J Clin Oncol 2015 33(suppl) 3. Abstract 704.
Bengala C, Bertolini F, Malavasi N, Boni C, Aitini E, Dealis C, Zironi S, Depenni R, Fontana A, 
Del Giovane C, Luppi G, Conte P. Sorafenib in patients with advanced biliary tract carcino ma: 
a phase II trial. Br J Cancer. 2010;102(1):[ADDRESS_953659] LV, Smit h DC, Leming PD, Topalian SL, Hodi FS, 
SznolM, Harbison C, Ko llia G, Gupta AK, Gettinger S. Nivo lumab (anti-PD-1, BMS-936558, 
ONO-4538) in patients (pts) with advanced non -small-cell lung cancer (NSCLC) : survival and 
clinical act ivity by [CONTACT_62681]. General Poster Session, Lung Cancer -Non-Small Cell 
Metastatic at the American Society  of Clinical Oncology  Annual Meeting, 2014. J Clin Oncol . 
2014;32(suppl):5s. Abstract 8112.
Brahmer JR, Rizvi N, Lutzky  J, Khleif SN, Blake -Haskins A, Li X, Steele K, Rebelatto M, 
Robbins PB, Vasselli J, Ibrahim R, Antonia S. Clinical act ivity and biomarkers of MEDI4736, 
an anti-PD-L1 antibody, in patients with NSCLC. Poster , LungCancer-Non-Small Cell 
Metastatic (Abstract 8021) at the American Society  of Clinical Oncology Annual Meeting, 
2014.
Cancer Therapy  Evaluation Program, Co mmon Termino logy Criteria for Adverse Events, 
Version 4.0, DCTD, NCI, NIH, DHHS. 2009. Publish date:  [ADDRESS_953660]. NatRev 
Clin Oncol . 2009;6(8):465 -477.
I4T-MC-JVDF(b)Clinical Protocol Page [ADDRESS_953661] JK, Pathiraja K, Gause C, Cheng JD, Seiwert T. 
LBA31-A Phase 1b study  of pembrolizumab in patients with human papi[INVESTIGATOR_637696] (HPV) -
positive and negat ive head and neck cancer (HNC). Poster, Cancer Immuno logy and 
Immunotherapy , 2014.  
Cunningham D, Starling N, Rao S, Iveson T, Nico lson M, Coxon F, Middleton G, Daniel F, 
Oates J, Norm an AR; Upper Gastrointestinal Clinical Studi es Group of the National Cancer 
Research Inst itute of the United Kingdo m. Capecitabine and oxaliplat in for advanced 
esophagogastric cancer. N Engl J Med. 2008;358(1):36 -46.
Cockcroft DW, Gault MD. Prediction of creat inine clearance fro m serum creatinine. Nephron. 
1976;16:[ADDRESS_953662] R, Dancey J, Arbuck S, 
Gwyther S, Mooney  M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Laco mbe D, Verweij J. 
New response evaluat ion criteria in so lid tumours: revise d RECIST gui deline (versi on 1.1). 
Eur J Cancer . 2009;45(2):228 -247.
Fury M, Ou SI, Balmanouki an AS, Hansen A, Massarelli E, Blake-Haskins A, Li X, Robbins J, 
Vasselli NH, Segal NH. Clinical activit y and safety  of MEDI4736, an ant i-PD-L1 antibody, in 
patients with head and neck cancer. Ann Oncol . 2014;25(suppl_4):iv340 -iv356.
Garg RK. Posterior leukoencephalopathy  syndrome. Postgrad Med J . 2001;77(903):[ADDRESS_953663] JK, Rangwala R, 
Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE -[ADDRESS_953664] igators. 
Pembrolizumab for the treatm ent of non-small-cell lung cancer. N Engl J Med. 2015 May 
21;372(21):2018 -28. 
Giatromanolaki A, Koukourakis MI, Simopoulos C, Polychronidis A, Sivridis E. Vascular 
endothelial growth factor (VEGF) expressio n in operable gallbladder carcino mas.Eur J Surg 
Oncol.2003 Dec;29(10):879- 83.
Herbst RS, Soria J, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, 
Powderly  JD, Gettinger SN, Kohrt, HEK, Lawrence DP, Rost S, Leabman M, Xiao Y, 
Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS . Predictive correlates of 
response to athe ant i-PD-L1 antibody MPDL3280A in cancer patients. Nature. 
2014;515:563 -567.
Hinchey J, Chaves C, Appi[INVESTIGATOR_179901] B, Breen J, Pao L,Wang A, Pessin MS, Lamy  C, Mas JL, 
Caplan LR. A reversible posterior leukoencephalo pathy syndrome. N Engl J Med . 
1996;334(8):494 -500.
Hodi FS, Lawrence D, Lezcano C, Wu X, Xhou J, Sadada T, X eng W, Giobbie -Hurder A, 
AtkinsMB, Ibrahim N, Friedlander P, Flahert y KT, Murphy GF, Rodi g S, Velazquez EF, 
Mihm MC Jr, Russell S, Dipi[INVESTIGATOR_702366], Yap JT, Ramaiya N, Van den Abbeele AD, Gargana M, 
MecDermott D. Bevacizumab plus ipi[INVESTIGATOR_632555]. Cancer 
Immunol Res. 2014;2(7):632 –642.
I4T-MC-JVDF(b)Clinical Protocol Page 87
LY3009806Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar, J, Santosuosso M, Martin 
MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK, Pozansky 
MC.  Vascular normalizing doses of ant iangiogenic treatment reprogram the 
immunosuppre ssive tumor microenvironment and enhance immunotherapy . Proc Natl Acad 
Sci U S A. 2012;109(43): [ZIP_CODE] -[ZIP_CODE].
Kaplan EL, Meier P. Nonparametric estimat ion of incomplete observat ions. J Amer Stat Assoc . 
1958;53:457 -481.
Kato T, Seto T, Nishio M, Goto K, Atag i S, Hosomi Y, Yamamoto N, Hida T, Maemindo M, 
Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Harada R, Kukuoka M, Yamamoto N . 
Erlotinib plus bevacizumab (EB) versus erlotinib alo ne (E) as first -line treatment for advanced 
EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open -label 
randomized trial. J Clin Oncol. 32:5s, 2014 (suppl; abstr 8005).
Le DT, Uram  JN, Wang H, Bartlett BR, Kemberling H, Ey ring AD, Skora AD, Luber BS, Azad 
NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fi sher GA, Crocenzi TS, Lee JJ, 
Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, 
Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube 
JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 blockade in tumors with 
mismatch -repair deficiency . N Engl J Med. 2015;372(26):2509 -2520. 
Le DT, Uram  JN, Wang H, Kemberling H, Ey ring AD, Bartlett BR, Goldberg RM, Crocenzi TS, 
Fisher GA, Lee JJ, Greten TF, Laheru D, Azad NS, Donehower R, Luber B, Koshi ji M, 
Eshleman JR, Anders RA, Vogelstein B, Diaz LA.  PD -1 blockade in mismatch repair 
deficient non -colorectal gastrointestinal cancers. J Clin Oncol .2016; 34:Suppl 4S Abstr 195.  
Lee JK, Capanu M, O'Reilly EM, Ma J, Chou JF, Shia J, Katz SS, Gansukh B, Reidy-Lagunes D, 
Segal NH, Yu KH, Chung KY, Saltz LB, Abou -Alfa GK. A phase II study  of gemcitabine and 
cisplatin plus sorafenib in pat ients with advanced biliary  adenocarcinomas. Br J Cancer.
2013;109(4):915 -9.
Lee VH, Wijdicks EF, Manno EM, Rabinstein A A. Clinical spectrum of reversible posterior 
leukoencephalopathy  syndrome. Arch Neurol . 2008;65(2):205 -210.
Lordick F.Trastuzumab: a new treatment option for HER2 -positive metastatic gastric and 
gastroesophageal junct ion cancer. Future Oncol. 2011;7(2):187 -99. 
Lubner SJ, Mahoney MR, Ko lesar JL, Loconte NK, Kim GP, Pi[INVESTIGATOR_16611], Philip PA, Pi[INVESTIGATOR_361] J, Yong 
WP, Horvath L, Van Hazel G, Erlichman CE, Holen KD. Report of a mult icenter phase II trial 
testing a co mbination o f biweekly bevacizumab and daily erlotinib in pat ients with 
unresectable biliary  cancer: a phase II Consortium study . J Clin Oncol. 2010;28(21):3491 -7. 
Möbius C, Dem uth C, Aigner T, Wiedmann M, Wittekind C, Mössner J, Hauss J, Witzigmann 
H. Evaluation of VEGF A expressio n and microvascu lar density as prognosti c factors in 
extrahepat ic cholangiocarcino ma. Eur J Surg Oncol. 2007;33(8):1025 -9.
Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppressio n: cancer and 
other tales. Nat Rev Immunol. 2011;11(10):702 -711.
Motz GT, C oukos G. Deciphering and reversing tumor immune suppression. Immunity.
2013;39(1):61 -73.
I4T-MC-JVDF(b)Clinical Protocol Page 88
LY3009806Motzer RJ, Rinia BI, McDermott DF, Redman BG, Kutzel TM, Harrisson MR, 
Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, 
LambertAM, Waxman IM, Hammers HJ. Nivo lumab for metastatic renal cell carcino ma: 
results of a randomized phase II trial. J Clin Oncol . 2014; In press .
Muro K, Bang Y, Shankaran, V, Geva R, Catenacci DVT, Gupta S, Eder JP, Berger R , 
Gonzales EJ, Ray A, Dolled-Filhart M, Emancip ator K, Pathi raja K, Lunceford JK, Cheng JD, 
Koshiji M, Chung, HC. Relationship between PD- L1 expressio n and clinical outcomes in 
patients with advanced gastri c cancer treated with the ant i-PD-1 monoclonal antibody 
pembrolizumab (Pe mbro; MK -3475) in KEYNOT E-012. General Poster Session A (Board 
#A3, Abstract 03) at the American Societ y of Clinical Oncology Gastrointestinal Cancers 
Symposium, 2015.
O'Donnell PH, Plimack ER, Bellmunt J, Berger R, Montgomery RB, Heath K, Dolled -Filhart M, 
Pathiraja K, Gause CK, Cheng JD, Perini RF, Gupta S . Pembrolizumab for advanced 
urothelial cancer: Results of a phase IB study . General Poster Sessi on, American Societ y of 
Clinical Onco logy Genitourinary Cancers Symposium , 2015. J Clin Oncol . 
2015;33(suppl)7:A296.
Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, 
Langer B, Starnawski M, Kang YK. Bevacizumab in combinat ion with chemotherapy as first-
line therapy  in advanced gastri c cancer: a randomized, double -blind, placebo-controlled phase 
III study. J Clin Oncol. 2011;29(30):3968 -76. 
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicit y 
and response criteria of the eastern cooperative oncology  group. Am J Clin Oncol . 
1982;5:[ADDRESS_953665], Im E, Gadgeel SM. Pembrolizumab (pembro; 
MK-3475) plus platinum doublet chemotherapy (PDC) as front -line therapy for advanced non -
small cell lu ng cancer (NSCLC): KEYNOTE -021 Cohorts A and C. 2015 ASCO Annual 
Meeting. J Clin Oncol. 2015;33 (suppl; abstr 8031)
Pasini F, Fraccon AP, DE Manzoni G. The role of chemotherapy in metastatic gastric cancer.
Anticancer Res. 2011;31(10):[ADDRESS_953666], Kohli M, Tang S, Zhang H, Hamid O, Kauh JS, Walgren RA, Chi KN. 
Interim results of a rando mized phase 2 study  of docetaxel  with ramucirumab versus docetaxel 
in a second-line advanced or metastatic urothelial carcino ma. General Poster Session B (Board 
#A7, Abstract 295) at the American Societ y of Clinical Oncol ogy Genitorurinary  Cancers 
Symposium, 2015.
Poole RM. Pembro lizumab: First Global Approval. Drugs.2014.
Rizzo JD, Somerfield MR, Hagerty  KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF,
Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Licht in AE; American 
Society of Clinical Oncology; American Society  of Hematology. Use of epoetin and 
darbepoetin in pat ients with cancer: 2007 American Society  of Clinical Onco logy/American 
Society of Hematology clinical pract ice guideline update. J Clin Oncol . 2008;26(1):132 -149. 
Erratum in: J Clin Onco l. 2008;26(7):1192.
I4T-MC-JVDF(b)Clinical Protocol Page 89
LY3009806Sandler A, Gray  R, Perry MC, Brahmer J, Schiller JH, Dowlat i A, Lilenbaum R, Johnson DH. 
Paclitaxel -carboplatin alone or with bevacizumab for non -small-cell lung cancer. N Engl J 
Med. 2006;355(24):[ADDRESS_953667] -line therapy in pat ients with 
advanced non -squamous non-small-cell lung cancer harbourin g EGFR m utations (JO25567): 
an open-label, rando mised, mult icentre, phase 2 study . Lancet Oncol. 2014;15(11):[ADDRESS_953668] J, Cross SJ, Demetri G, Desch CE, Pi[INVESTIGATOR_4607], Schiffer CA, 
Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, 
WolffAC. Update of recommendat ions for the use of white blood cell growth factors: an 
evidence-based clinical pract ice guideline. J Clin Oncol . 2006;24(19) :3187-3205.
Stott VL, Hurrell MA, Anderson TJ. Reversible posterior leukoencephalopathy syndrome: a 
misnomer reviewed . Intern Med J . 2005;35(2):83 -90.
Tajima Y, Isonishi K, Kashiwaba T, Tashiro K. Two similar cases o f encephalopathy , possibly a 
reversible posterior leukoencephalopathy  syndrome: serial findings of magnet ic resonance 
imaging, SPECT and angiography. Intern Med. 1999;38 (1):54-58.
Tang D, Nagano H, Nakamura M, Wada H, Marubashi S, Miyamoto A, [COMPANY_005] Y, Umeshita K, 
Dono K, Monden M. Clinical and patho logical features of Allen's t ype C classificat ion of 
resected combined hepatocellular and cho langiocarcinoma: a comparative study with 
hepatocellular carcino ma and cho langiocellular carcino ma. J Gastrointest Surg. 
2006;10(7):987 -98.
Terme M, Colussi O, Marcheteau E, Tanchot C, Tartour E, Taieb J. Modulation of immunity by 
[CONTACT_622476]. Clin Dev Immunol. 2012;2012:492920.
Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, Duggan M, Cunningham D, 
Anthoney DA, Corrie P, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees 
C, Beare S, Dive C, Bridgewater JA. Cediranib or placebo in combinat ion with cisplatin and 
gemcitabine chem otherapy for patients with advanced biliary  tract cancer (ABC -03): a 
randomised phase 2 trial. Lancet Oncol. 2015;16(8):[ADDRESS_953669] M, Pointet AL, Latreche S, Bergaya S, 
Benhamouda N, Tanchot C, Stockmann C, Combe P, Berger A, Zinzindohoue F, Yagita H, 
Tartour E, Taieb J, Terme M. VEGF- A modulates expressio n of inhibitory  checkpoints on 
CD8+ T cells in tumors. J Exp Med. 2015;212(2):139 -148.
Yasuda S, Sho M, Ya mato I, Yoshiji H, Wakatsuki K, Nishiwada S, Yagita H, Nakajima Y. 
Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 
2 (VEGFR2) induces synergist ic anti-tumour effect in vivo. Clin Exp Immunol . 
2013;172(3):500 –506.
Yi JH, Thongprasert S, Lee J, Doval DC, Park SH, Park JO, Park YS, Kang WK, Lim HY. A 
phase II study  of sunitinib as a second -line treatment in advanced biliary tract carcino ma: a 
multicentre, mult inational study. Eur J Cancer. 2012;48(2):196 -201
I4T-MC-JVDF(b)Clinical Protocol Page 90
LY3009806Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, Hirohashi S, Shibata T. 
Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expressio n in 
cholangiocarcino ma. Br J Cancer. 2008;98(2):[ADDRESS_953670] cancers and correlat ion of changes in 
18-fluorodeoxy glucose PET wi th clinical outcom e: a phase 2 study . Lancet Oncol.
2010;11(1):48 -54. 
I4T-MC-JVDF(b)Clinical Protocol Page 91
LY3009806Attachment 1. Protocol JVDFTime and Events Table s
I4T-MC-JVDF(b) Clinical Protocol Page 92
LY3009806Time and Events Table: Baseline, Study Treatment, and Postdiscontinuation Follow -Up Periods
Study Period Notes
Baseline
(within 28 days prior 
to enrollment)Treatment 
(21-day cycles)
±7 daysPostdiscontinuation 
Follow-UpThe firststudytreatment will be administered within 7 days 
following enrollment.
Postdiscontinuation follow -up begins when the decision is 
made that the patient will no longer continue study 
treatment.
Procedure ≤28 
days≤21 
days≤7 
daysDay 1Day8Short-Term 
Follow-Up 
Visit 
(30 ±7 days)Long-Term 
Follow-Up 
Visit
(every 90 ±7 
days)Day 8 procedures are o nly for Cohort A , A1, and A2
(Gastric-GEJ or BTC Ram 8 mg/kg, Days 1 and 8).
Long-term follow -up should be attempted at regularly 
scheduled intervals (every 90 days [±7 days]) until death, 
lossto follow-up,or study completion (whichever occurs 
first).
Informed consent
form (ICF)X Obtain ICF prior to any study -specific procedures.  If the 
ICF is revised during the course of the study, re -consenting 
of patients may be required if deemed necessary by [CONTACT_702398].
Inclusion/exclusion
criteriaX
Medical history X Including preexisting conditions and historical illnesses
ECGX X Baseline, short -term follow –up, and when clinically 
indicated
Echocardiogram or 
MUGA scanX Baseline, and when clinically indicated
ECOG Performance 
StatusX X X A time window of -[ADDRESS_953671] dose of study treatment.
Physical exam X X X A time window of ±[ADDRESS_953672] to the other study 
visit procedures is permitted.
I4T-MC-JVDF(b) Clinical Protocol Page 93
LY3009806Study Period Notes
Baseline
(within 28 days 
prior to 
enrollment)Treatment 
(21-day 
cycles)Postdiscontinuation 
Follow-UpThe first study treatment will be administered within 7 days following 
enrollment.
Postdiscontinuation follow -up begins when the decision is made that the 
patient will no longer continue study treatment.
Procedure ≤28 
days≤21 
days≤7 
daysDay 
1Day
8Short-Term 
Follow-Up 
Visit 
(30 ±7 days)Long-Term 
Follow-Up 
Visit
(every 90 ±7 
days)Day 8 procedures are o nly for Cohort A , A1, and A2(Gastric-GEJ or 
BTC Ram 8 mg/kg, Days 1 and 8).
Long-term follow -up should be attempted at regularly scheduled 
intervals (every 90 days [±7 days]) until death, loss to follow -up, or study 
completion (whichever occurs first).
Height, 
weightX X Measure height at baseline only. Measure weight at the beginning of 
each cycle . Recalculate the ramucirumab dose if weight change is ≥10% 
compared to previous measurement(s ).
Vital signs X X X For the first 2 ramucirumab infusions, measure blood pressure and pulse
as follows :  (i) within 15 minutes prior; (ii) after infusion completion; 
and (iii) at the end of the [ADDRESS_953673]-infusion observation period.  Measure 
blood pressure and pulse prior to each subsequent ramucirumab infusion.  
Measure other vital signs as clinically ind icated.
AE 
collection; 
CTCAE 
gradingX During short -term follow -up, all AEs/SAEs will be collected.
At the 90-day long -term follow -up visit, all SAEs will be collected.  
Thereafter , during long -term follow -up, only SAEsthat are related to 
study regimenor protocol procedures will be collected.
I4T-MC-JVDF(b) Clinical Protocol Page 94
LY3009806Study Period Notes
Baseline
(within 28 days 
prior to 
enrollment)Treatment 
(21-day 
cycles)Postdiscontinuation 
Follow-UpThe first study treatment will be administered within 7 days 
following enrollment.
Postdiscontinuation follow -up begins when the decision is made 
that the patient will no longer continue study treatment.
Procedure ≤28 
days≤21 
days≤7 
daysDay 
1Day
8Short-Term 
Follow-Up 
Visit 
(30 ±7 days)Long-Term 
Follow-Up 
Visit
(every 90 ±7 
days)Day 8 procedures are o nly for Cohort A , A1, and A2(Gastric-GEJ 
or BTC Ram 8 mg/kg, Days 1 and 8).
Long-term follow -up should be attempted at regularly scheduled 
intervals (every 90 days [±7 days]) until death, loss to follow -up, or 
study completion (whic hever occurs first).
Laboratory 
AssessmentBaselinelaboratoryassessments can be used for Cycle [ADDRESS_953674] be reviewed prior 
to start of cycle.  
Hematology X X X Local only.  Within 3 days prior to Day 1 of each cycle .
Chemistry X X X Local and central: Local chemistry laboratory testing will be used 
to determine patient eligibility and decisions for treatment.  
Central chemistry laboratory testing will be used for subsequent 
scheduled analyses.
Within 3 day s prior to Day 1 of each cycle.
UrinalysisX X X Local only. Within 3 days prior to Day 1 of each cycle . 24-hr 
urine protein analysis if urine protein is ≥2+ at baseline, >2+ during 
study treatment .
T3, free T4, 
TSHX X X Centraland local as needed . At baseline, w ithin 3 days prior to 
Day 1 ofCycle 3,Day 1 of Cycle 6, and every 2 cycles thereafter ; 
and more frequently if clinically indicated .
Coagulation X X X Local only . Within [ADDRESS_953675] X X Local only. Required for women of child -bearing potential. If 
required per local regulations and/or institutional guidelines, testing 
can occur at other times during the study treatment period.
I4T-MC-JVDF(b) Clinical Protocol Page 95
LY3009806Study Period Notes
Baseline
(within 28 days 
prior to enrollment)Treatment 
(21-day 
cycles)Postdiscontinuation 
Follow-UpThe first study treatment will be administered within 7 days 
following enrollment.
Postdiscontinuation follow -up begins when the decision is made 
that the patient will no longer continue study treatment.
Procedure ≤28 
days≤21 
days≤7 
daysDay 
1Day
8Short-Term 
Follow-Up 
Visit 
(30 ±7 
days)Long-Term 
Follow-Up 
Visit
(every 90 ±7 
days)Day 8 procedures are o nly for Cohort A , A1, and A2(Gastric-GEJ 
or BTC Ram 8 mg/kg, Days 1 and 8).
Long-term follow -up should be attempted at regularly scheduled 
intervals (every 90 days [±7 days]) until death, loss to follow -up, 
or study completion (w hichever occurs first).
Efficacy 
Assessment
Tumor imaging and 
assessmentX X X X Assessments previously obtained as part of routine clinical care 
may be used as the baseline as sessment if performed within 
21days prior to enrollment. Imaging is not required on Cycle 1 
Day 1.  SEE FOOTNOTE .
Survival informatio n X X Follow-up for the collection of survival data and subsequent 
anticancer treatments should be attempted at regularly scheduled 
intervals (every 90 days [±7 days]) for up to [ADDRESS_953676] dose .  This follow -up might be a phone call to the 
patient, her/his family, or local doctor.
Additional 
Analyses
Tumor tissue X New biopsy at baseline (recent to C ycle 1 Day 1 ) is required .  For 
first line NSCLC, PD -L1 >=1% is required.  Tumor tissue 
collection during the treatment period is optional, and can be 
provided if available, for example in case of a clinically -indicated 
biopsy.
Genetics Whole 
BloodSample X Collect 1 sample prior to treatment onCycle 1 Day 1.
Biomarker
Pharmacokinetics
ImmunogenicitySee Attachment 2 .
I4T-MC-JVDF(b) Clinical Protocol Page 96
LY3009806Study Period Notes
Baseline
(within 28 days 
prior to enrollment)Treatment 
(21-day 
cycles)Postdiscontinuation 
Follow-UpThe first study treatment will be administered within 7 days 
following enrollment.
Postdiscontinuation follow -up begins when the decision is 
made that the patient will no longer continue study treatment.
Procedure ≤28 
days≤21 
days≤7 
daysDay 
1Day
8Short-Term 
Follow-Up 
Visit 
(30 ±7 days)Long-Term 
Follow-Up 
Visit
(every 90 ±7 
days)Day 8 procedures are o nly for Cohort A , A1, and A2(Gastric-
GEJ or BTC Ram 8mg/kg, Day s1 and 8).
Long-term follow -up should be attempted at regularly 
scheduled intervals (every 90 days [±7 days]) until death, loss 
to follow-up, or study completion (whichever occurs first).
Administration of 
Study DrugsAdminister ramucirumab first per the dose schedule to which 
the patient is allocated.  For first 2 cycles,implement a 1 -hr 
observation period i) between ramucirumab and 
pembrolizumab administration ,and ii) after pembroliz umab 
infusion.  For all cycles thereafter, no observation period will 
be required unless clinically indicated.
Administer 
Ramucirumab
BTC 8mg/kg X X
Gastric-GEJ 
8mg/kgX X
Gastric-GEJ 
10mg/kgX
NSCLC 10 mg/kg, X
Urothelial 10 mg/kg X
Administer 
Pembrolizumab
200mgfixed X
I4T-MC-JVDF(b) Clinical Protocol Page 97
LY3009806Time and Events Table (concluded)
Abbreviations:  AE = adverse event; Att. = attachment; BTC = biliary tract cancer ; CT = computed tomography; CTCAE = Common Terminology Criteria for 
Adverse Events; ECG =electrocardiogram; ECOG PS=Eastern Cooperative Oncology Group performance status; E RB = ethical review board; Gastric-
GEJ= Gastric -Gastroesophageal Junction; ICF=informed consent form; MRI = magnetic resonance imaging; MUGA = multiple -gated acquisition; NSCLC = 
non-small cell lung cancer; PD=progressive disease; Prot. Ref. = protocol reference; Ram = ramucirumab; SAE= serious adverse event ; TSH = thyroid -
stimulating hormone .
FOOTNOTESRegarding Tumor Assessment:
During treatment cycles, perform tumor assessment and imaging as follows:  (i) every 6 weeks (±7 days) for the first 6 months after enrollment , and 
(ii)every 12weeks (±7 days) thereafter.  Perform as scheduled even if study treatment is delayed, except when tumor assessment and imaging are not 
feasible in the opi[INVESTIGATOR_702367]’s clinical status.
If radiologic imaging verifies initial progressive disease (PD), tumor assessment should be repeated approximately 4 weeks la ter in order to confirm PD 
with the option of continuing study treatment while awaiting radiologic confirmation of progress ion (Section [IP_ADDRESS]).
During the short -termand long-term follow -up periods, for patients who discontinue study treatment without objectively measu red PD, continue to 
perform tumor assessment and imaging every [ADDRESS_953677] of care.
I4T-MC-JVDF(b) Clinical Protocol Page 98
LY3009806Time and Events Table: Continued Access Period
Continued Access PeriodNotes
Continued 
Access
Treatment
(21-day cycles)Continued 
Access 
Follow-UpDay 1 and Day  8 assessments are performed only if study drug dosing is scheduled to occur on that 
day.
Continued access follow -up begins 1 day  after the patient and the investigator agree that the patient 
will no longer continue treatment in the continued access period and lasts approximately 30 days.
Efficacy assessments will be performed at the investigator’s discretion based on the standard of care.
Relative Day within a 
Cycle Day 1Day 8
Procedures
Weight X
Administer 
Ramucirumab
BTC 8 mg/kg X X
Gastric-GEJ 8mg/kg X X
Gastric-GEJ 10mg/kg X
NSCLC 10 mg/kg X
Urothelial 10 mg/kg X
Administer 
Pembrolizumab 
200 mg (fixed)
All treatment cohorts X
AE Collection, 
CTCAE GradingX X X Data on SAEs that occur before the end of trial will be stored in the collection database and the Lilly 
Safety System.  After the patient is no longer participating in the study (that is, no longer receiving 
study treatment and no longer in follow -up), only  SAEs that the in vestigator is made aware of and are 
related to study regimen or protocol procedures will be collected.   
Immunogenicity and 
PK SampleIf a patient experiences an IRR to ramucirumab, blood samples for immunogenicity and PK analysis 
will be taken at the following time points:  (1) as soon as possible after the onset of the IRR, (2) at the 
resolution of the IRR, and (3) 30 days after the IRR.
Abbreviations:  AE = adverse event; BTC=biliary tract cancer; CTCAE = Common Terminology Criteria for Adverse Events; GEJ = gastroesophageal junction; 
IRR = infusion -related reaction; NSCLC = non -small cell lung cancer; PK = pharmacokinetics; SAE =serious adverse events .
I4T-MC-JVDF(b) Clinical Protocol Page 99
LY3009806Attachment 2. Protocol JVDF Phar macokinetic, 
Immunogenic ity, and Biomarker Sampling Schedules
PK and immunogenicit y (IK) samples will be collected for ramucirumab only , in both Phase 1a 
and Phase 1b portions of the study . Predose samples should be taken as close as possible to the 
startof first infusio n, that isramucirumabinfusion, but can be drawn up to 1 hour (60 minutes) 
prior start of infusion, and exact clock reading should be recorded.  Postdose (post end-of-
infusion) samples for PK for ramucirumab should be drawn preferablyat1 hour (±15 minutes)
after the end of the ramucirumab infusio n,and exact clock reading for the sample draw should be 
recorded.
Preferred time windows for each ramucirumab PK/IK sample collection arealso provided in the 
tables in this sect ion. While best effort should be done to draw the blood sample for 
ramucirumab PK/IK within the time window provided, it is more important to ensure predose 
sample is actually collected before the start of ramucirumabinfusion and post -dose samples 
(post-end of infusio n samples) are collected after ramucirumab infusion has actually co mpleted.  
It is also equally important to record actual date and time of blood collection for ramucirumab 
PK/IK sample on the Requisit ion Form afterdrawing the sample ( that is,do not record not 
planned time of collection). Sample co llection for PK/IK must be fro m the opposite arm to that 
used for study  drug infusi on. If drug was administ ered via a central venous catheter, the sample 
collection should be from a different si te.
In addition, if a patient experiences an infusio n-related reacti on (IRR), bl ood samples for anti-
ramucirumab ant ibodyand PK shoul d be drawn.  Samples will be taken at the following t ime 
points:  (1) as soon as possible after the onset of the IRR, (2) at the resolut ionof the IRR, and 
(3)30 days after the IRR.
I4T-MC-JVDF(b) Clinical Protocol Page 100
LY3009806TableATT.2.1. Schedule 1 (Gastric GEJ Cohort A  [2nd-3rdLine]and Gastric GEJ A 2[1stLine]; and BTC Cohort A 1[2nd-
3rdLine]):  Pharmacokinetic (PK), Immunogenicity (IK), and Biomarker Collection Timepoints fo r 
Ramucirumab for Schedule 1 D osing Regimen (1h Infusion Ramucirumab followed by 0.5h Infusion 
Pembrolizumab on Day 1 and 1h Infusion Ramucirumab on Day 8, every 3 weeks )
Visit/Cycle DayStudy 
DaySample Time 
(relative to start 
of Ram 
infusion)
(HR:MIN) aRam PKf
(Serum)Ram 
Immunogenicitye,f
(Serum)Biomarker
EDTA
Plasma PBMCs
Cycle 1 Day  1 (1-hr 
observation period between 
Ram and Pem infusions)1 0:00 hrPredose 
sampleb,dX(collect prior to start of first infusion) X X X
2.00 hrPostdose 
samplec,d X(collect approx. 1 hr after Ram 
infusion ends)
Cycle 1 Day  8 (Ram only ) 8 0:00 hr Predose 
sampleb,d  X(collect prior to start of infusion) X X
Cycle 2 Day  1 22 0:00 hr Predose 
sampleb,d  X (collect prior to start of first infusion) X X X
Cycle 3 Day  1 43 0:00 hr Predose 
sampleb,dX (collect prior to start of first infusion) X X
Cycle 4 Day  1 64 0:00 hr Predose 
sampleb,dX (collect prior to start of first infusion) X X X
Cycle 5 Day 1 85 0:00 hr Predose 
sampleb,dX (collect prior to start of first infusion) X X X
Cycle 7 Day  1 127 0:00 hr Predose 
sampleb,dX(collect prior to start of first infusion) X X X
Cycle 7 Day  8 (Ram only ) 134 0:00 hr Predose 
sampleb,d  X(collect prior to start of infusion) X X
Cycle 9, Day  1 169 0:00 hr 
Predoseb,dX(collect prior to start of first infusion) X X X
2:00 hr 
Postdosec,dX(collect approx. 1 hr after Ram 
infusion ends )
[ADDRESS_953678] treatment DC AnytimegX X X X
I4T-MC-JVDF(b) Clinical Protocol Page 101
LY3009806Schedule 1 (Gastric GEJ Cohort A [2nd -3rd Line] and Gastric GEJ A2 [1st Line]; and BTC Cohort A1 [2nd -3rd Line]):  Pharmacokinetic (PK), 
Immunogenicity (IK), and Biomarker Collection Timepoints for Ramucirumab for Schedule 1 Dosing Regimen (1h Infusion Ramucirumab followed by 
0.5h Infusion Pembrolizumab on Day 1 and 1h Infusion Ramucirumab on Day 8, every 3 weeks) (concluded)
Note: Ram and Pem infusions are given every 3 weeks. 1-hr Ram infusion is given prior to half -hour Pem infu sion. There is one -hour observation 
period (for infusion reactions) between Ram and Pem infusions at Cycle 1 Day 1 visit. Each cycle is a 21-day cycle.
Abbreviations: DC = Discontinuation ; eCRF = electronic case report form; GEJ = gastroesophageal junct ion; IK = immunogenicity; IRR = infusion -related 
reaction; Pem =pembrolizumab; PMBC = peripheral blood mononuclear cells; PK=pharmacokinetics; Ram =ramucirumab.
aAll sample times are relative to start of first (Ram) infusion.
bPredose sample for Ram PK,IK, and biomarkers should be preferably collected within [ADDRESS_953679] infusion , and within 15 minutes of one 
another.
cTwo-hour sample for Ram PK should be preferably collected at 1hr ±15minutes from the end of Ram infusion.
dWhile best effort should be done to draw the blood sample for PK/IK within the time windows provided above, it is more import ant to ensure predose sample 
is actually collected before the start of first infusion and postdose samples are collected after the infusion has actually completed. It is also equally important 
to record ACTUAL date and time of blood collection for PK/IK sample on the Requisition Form AFTER drawing the sample and to a ccurately record the 
ACTUAL infusions start and end dates and times on the eCRF to be able to use the data for analyses.  Sample collection for PK/IK must be from the opposite 
arm to that used for study drug infusion. If drug was administered via a central venous catheter, the sample collection should be from a different site.
eIn the event of an IRR, blood samples will be collected for both PK and IK analysis at the following time points:  (i) as close as possible to the onset of the 
IRR, (ii) at the resolution of the IRR, and (iii) [ADDRESS_953680] AC TUAL date and time of blood collection for PK/IK sample on the Requisition Form AFTER drawing the sample .
I4T-MC-JVDF(b) Clinical Protocol Page 102
LY3009806TableATT.2.2. Schedule 2 (Gastric-GEJ Cancer Patients Cohort B [2nd-3rdLine], NSCLCCohort C [2nd-4thLine], 
Urothelial Cancer Cohort D [2nd-4thLine]**
, and NSCLC Cohort E [1stLine]): Pharmacokinetic (PK), 
Immunogenicity (IK), and Biomarker Collection Timepoints for Ramucirumab for Schedule 2 Dosing 
regimen (1h infusion Ramucirumab followed by 0.5h infusion Pembrolizumab on Day 1 every 
3weeks)
Sample Time 
(relative to start 
of Ram 
infusion)
(HR:MIN) aBiomarker Collection
Visit/Cycle DayStudy 
DayRam PKf 
(Serum)Ram 
Immunogenicitye,f  
(Serum)EDTA
Plasma PBMCs
Cycle 1 Day  1 (1-hr 
observation period between 
Ram and Pem infusions)10:00 hrPredose 
sampleb,d  X(collectprior to start of first infusion) X X X
2.00 hrPostdose 
samplec,dX(collectapprox. 1 hr after Ram infusion ends)
Cycle 2 Day  1 220:00 hr Predose 
sampleb,d  X (collectprior to start of first infusion) X X X
Cycle 3 Day  1 430:00 hr Predose 
sampleb,dX (collectprior to start of first infusion) X X
Cycle 4 Day 1 640:00 hr Predose 
sampleb,dX (collectprior to start of first infusion) X X X
Cycle 5 Day 1 850:00 hr Predose 
sampleb,dX(collectprior to start of first infusion) X X X
Cycle 7 Day  1 1270:00 hr Predose 
sampleb,dX (collect prior to start of first infusion) X X X
Cycle 9 Day  1  1690:00 hr 
Predoseb,dX(collect prior to start of first infusion) X X X
2:00 hr 
Postdosec,dX(collect approx. 1 hr after Ram infusion ends)
[ADDRESS_953681] treatment DC AnytimefX X X X
I4T-MC-JVDF(b) Clinical Protocol Page 103
LY3009806Schedule 2 (Gastric -GEJ Cancer Patients Cohort B [2nd -3rd Line], NSCLC Cohort C [2nd -4th Line], Urothelial Cancer Cohort D [2nd -4th Line]**, 
and NSCLC Cohort E [1st Line]): Pharmacokinetic (PK), Immunogenicity (IK), and Biomarker Collection Timepoints for Ramucirumab for Sche dule 
2 Dosing regimen (1h infusion Ramucirumab followed by 0.5h infusion Pembrolizumab on Day 1 every 3 weeks) (concluded)
Notes: 
Ram and Pem infusions are given Q3W. 1-hr Ram infusion is given prior to half -hour Pem infusion. There is one hour observation period (for infusion 
reactions) between Ram and Pem infusions at Cycle 1 Day 1 visit. Each cycle is a 21 -day cycle.
Abbreviati ons:  DC = Discontinuation; eCRF = electronic case report form; GEJ = gastroesophageal junction; IK = immunogenicity; IRR = infusion -related 
reaction; NSCLC = non -small cell lung cancer; Pem=pembrolizumab; P BMC = peripheral blood mononuclear cells; PK =pharmacokinetics; 
Ram=ramucirumab.
aAll sample times are relative to start of first (Ram) infusion.
bPredose sample for Ram PK ,IK,and biomarkers should be preferably collected within [ADDRESS_953682] infusion, and within 15 minutes of one 
another.
cTwo-hour sample for Ram PK should be preferably collected at 1 hr ±[ADDRESS_953683] effort should be done to draw the blood sample for PK/IK within the time windows provided above, it is more import ant toensure predose sample 
is actually collected before the start of first infusion and post dose samples are collected after the infusion has actually completed. It is also equally important 
to record ACTUAL date and time of blood collection for PK/IK sample on the Requisition Form AFTER drawing the sample and to accurately record the 
ACTUAL infusions start and end dates and times on the eCRF to be able to use the data for analyses.  Sample collection for PK /IK must be from the opposite 
arm to that used for s tudy drug infusion. If drug was administered via a central venous catheter, the sample collection should be from a different site.
eIn the event of an IRR, blood samples will be collected for both PK and IK analysis at the following time points:  (i) as close as possible to the onset of the 
IRR, (ii) at the resolution of the IRR, and (iii) [ADDRESS_953684] ACTUAL date and time of blood collection for PK/IK sample on the Requisition Form AFTER drawing the sample.
I4T-MC-JVDF(b) Clinical Protocol Page 104
LY3009806Attachment 3. Protocol JVDFClinical Laboratory  Tests
Hematology -Local only Clinical Chemistry- Local and Centrala
Hemoglobin
Hematocrit
Erythrocyte count (RBC)
Leukocytes (WBC)
Absolute Neutrophil Count 
Lymphocytes
Monocytes
Eosinophils
Basophils
PlateletsSerum Concentrations of:
Sodium
Magnesium
Potassium
Total bilirubin
Direct bilirubin (if total bilirubin is above ULN)
Alkaline phosphatase
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Blood urea nitrogen (BUN)
Creatinine
Uric acid
Calcium
Glucose, random
Albumin
Cholesterol
Creatine kinase (CK)
Chloride
Total protein
Phosphorus
Lactate dehydrogenase (LDH)Thyroid Function Tests -Central Only
Thyroid-stimulating hormone (TSH)
Total triiodothyronine (T3)
Free tyroxine (T4)
Urinalysisb-Local Only
Protein
Specific gravity
Blood
Glucose
Pregnancy Test Urine or Serumc–Local Only
β-human chorionic gonadotropin (β -hCG)
Coagulation TestdLocal Only
Prothrombin time (PT) /INR
Partial thromboplastin time (PTT) or activated PTT 
(aPTT)
Abbreviations:  INR= International Normalized Ratio; RBC = red blood cells; ULN = upper limit of normal; 
WBC= white blood cells.
a.Local chemistry laboratory testing will be used to determine patient eligibility and decisions for treatment.  
Central chemistry laboratory testing will be used for subsequent scheduled analyses.
bA microscopic exam is required for abnormal results.  If urinalysis indicates proteinuria ≥2+at baseline or during 
the treatment period, a 24 hour urine collection (to assess protein) must be obtained.
c.Minimum sensitivity 25 IU/L or equivalent units of β -human chorionic gonadotropin (β -HCG), for women of 
childbearing potential (WOCBP).  If urine pregnancy results cannot be confirmed as negative, a serum pregnancy 
test will be required .
d.For both prothrombin time and partial thromboplastin time, the laboratory for each is selected at baseline, and 
should be f ollowed during the study period.
I4T-MC-JVDF(b) Clinical Protocol Page 105
LY3009806Attachment 4. Protocol JVDFECOG Performance Status
ECOG Performance Status
Activity Status Description
0 Fully active, able to carry  on all pre -disease performance 
without restriction
1 Restricted in physically strenuous activit y but
ambulatory  and able to carry  out work of a light or 
sedentary  nature, e.g., light house work, office work
2 Ambulatory  and capable o f all selfcare but unable to 
carry out any work activit ies. Up and about more than 
50% of waking hours
3 Capable of only limited selfcare, confined to bed or chair 
more than 50% of waking hours
4 Completely disabled. Cannot carry  on any selfcare. 
Totally confined to bed or chair
5 Dead.
Source:  Oken et al. 1982.
I4T-MC-JVDF(b) Clinical Protocol Page 106
LY3009806Attachment 5. Protocol JVDFCreatinine Clearance Formula
Note:  This formula is to be used for calculat ing creatinine clearance (CrCl) fro m local 
laboratory results only.
For serum creatinine 
concentration in mg/dL:
CrCl =
(mL/min) (140 –agea) (wt)    0.85 (if female) , or1.0 (if male)
72serum creatinine (mg/dL)
For serum creatinine concentration in mol/L:
CrCl  =
(mL/min)(140 –agea) (wt)  0.85 (if female) , or1.0 (if male)
0.81serum creatinine (mol/L)
aage in years, weight (wt) in kilograms.
Reference:  Cockcroft and Gault 1976.
I4T-MC-JVDF(b) Clinical Protocol Page [ADDRESS_953685] Criteria 1.1
Response and progression will be evaluated in this study  using the international criteria proposed 
by [CONTACT_702399] (RECIST): Revised RECIST 
Guideline (ver sion 1.1; Eisenhauer et al. 2009).
Measurability of Tumor at Baseline
Tumor lesions/lymph nodes will be categorized at baseline as measurable or nonmeasurable.  
Measurable disease is defined by  [CONTACT_92379] l east 1 measurable l esion.
Measurable
Tumorlesions:  Measured in at least 1 dimensio n (longest diameter in the plane of measurement 
is to be recorded) with a minimum size of:
10 mm by  [CONTACT_702400] (CT) or m agnetic resonance imaging (MRI) 
scan (slice thickness 5 mm) 
10 mm caliper measureme nt by [CONTACT_461] (non-measurable lesio ns if cannot 
be accurately measured with calipers)
[ADDRESS_953686] X-ray.
Malignant lymph nodes:  To be considered pathologically enlarged and measurable, a lymph 
node must be 15 mm in short axis when assessed by  [CONTACT_70182] (CT scan thickness recommended 
to be 5 mm).
Nonmeasurable 
All other lesio ns, including small lesio ns (longest diameter <10 mm or pathological lymph nodes 
with 10 to <15 mm short axis) as well as truly nonmeasurable lesio ns.  Lesio ns considered truly  
non-measurable include:  leptomeningeal disease, ascites, pleural/pericardial effusio ns, 
lymphangitis cut is/pulmonis, inflammatory  breast disease, lymphangit is involvement of skin or 
lung, abdo minal masses/abdo minal organo megaly identifiedby [CONTACT_92381].
Special Considerations for Lesion Measurability
Bone Lesions :
Bone scan, PET scan or plain films are not consi dered adequate imaging 
techniques to measure bone lesio ns.
Lytic bone lesions or mixed ly tic-blastic lesions, with identifiable soft tissue 
components, that can be evaluated by  [CONTACT_240263], can be considered measurable lesio ns if the so ft tissue component 
meets the definit ion of measurability.
Blastic bone lesions are non -measurable.
I4T-MC-JVDF(b) Clinical Protocol Page 108
LY3009806Cystic Lesions :
Simple cysts should not be considered as malignant lesions (neither 
measurable nor nonmeasurable)
Cystic lesions thought to represent cystic metastases can be considered as 
measurable lesions, if they meet the definit ion of measurabilit y.  If noncyst ic 
lesions are presented in the same patients, these are preferred for select ion as 
target lesio ns.
Lesions with Prior Local Treatment :
Tumor lesions situated at a previ ously irradiated area , or in an area subjected to other 
loco-regional therapy, are non -measurable unless there has been demo nstrated 
progression in the lesio n.
Baseline Documentation of Target and Non -Target Lesion
Target Lesions
When more than 1 measurable lesio n is present at baseline, all lesio ns up to a maximum o f 
5lesions total (and a maximum of 2 lesions per organ) representative of all invo lved organs 
should be identified as target l esions and will  be recorded and m easured at baseline. For Study 
JVDF (Sect ion [IP_ADDRESS]) , total of 10 lesions (and a maximum o f 5 lesions per organ) coul d be 
collected if clinically relevant.  Non-nodal Target lesio ns should be selecte d on the basis o f their 
size (lesions with the longest diameter), be representative of all invo lved organs, and can be 
reproduced in repeated measurements.  Measurable lymph nodes are target lesio ns if they meet 
the criteria of a short axi s of [ADDRESS_953687] form (CRF) in millimeters (or decimal fractions of cent imeters [cm]).
Nontarget Lesions
All other lesio ns (or sites of disease) are ident ified as nontarget lesio ns (chosen based on their 
representativeness o f involved organs and the ability to be reproduced in repeated measurements) 
and should be recorded at baseline.  Measurement of these lesio ns are not required but should be 
followed as ‘present,’ ‘absent,’ or in rare cases ‘unequivocal progr ession.’  In addit ion, it is 
possible to record mult iple nontarget lesio ns involving the same organ as a single item on the 
CRF (for example, mult iple liver metastases recorded as 1 liver lesio n).
Lymph nodes with short axis 10 mm but <[ADDRESS_953688] a short axis <10 mm are considered nonpathological and are not recorded or 
followed.
Specifications by [CONTACT_92383], using a ruler or calipers if c linically 
assessed.  All baseline evaluat ions should be performed as closely as possible to the beginning of 
treatment and never more than 4 weeks before the beginning of the treatment.
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesio n at baseline and during fo llow-up.  Imaging-based evaluat ion is 
I4T-MC-JVDF(b) Clinical Protocol Page 109
LY3009806should always be done rather than clinical examination unless the lesio n(s) being fo llowed 
cannot be imaged but are assessed by [CONTACT_461].
An adequate vo lume of a suitable contrast agent should be given so that the metastases are 
demonstrated to best effect and a consistent method is used on subsequent examinat ions for any 
given patient.  If prior to enrollment it is known a patient is not ab le to undergo CT scans with IV 
contrast due to allergy  or renal insufficiency , the decisi on as to whether a non -contrast CT or 
MRI (with or without IV contrast) should be used to evaluate the patient at baseline and follow -
up should be guided by  [CONTACT_702401].
Clinical Lesions:  Clinical lesio ns will only be considered measurable when they are superficial 
and 10 mm diameter as assessed using calipers (for example, skin nodules).  For the case of
skin lesio ns, docum entation by [CONTACT_6775] , including a rul er to estimate the size of the 
lesion is recommended.  When lesio ns can be evaluated by [CONTACT_51752], 
imaging evaluat ion should be undertaken since it is more object ive andmay be reviewed at the 
end of the study .
Chest X-ray:  Chest CT is preferred over chest X- ray when progressi on is an important endpoint.  
Lesions on chest X -ray may be considered m easurable if they  are clearly defined and surrounded 
by [CONTACT_6776].
CT and MRI:  CT scan is the best currently available and reproducible method to measure lesions 
selected for response assessment.  Measurability of lesions on CT scan is based on the assumption that 
CT slice thickness is [ADDRESS_953689] slice thicknes s >5 mm, the minimum size for a 
measurable lesion should be twice the slice thickness.  MRI is also acceptable in certain situations (for 
example, for body scans).  If there is concern about radiation exposure at CT, MRI may be used instead of 
CT in select ed instances.
Ultrasound:   Ultrasound should not be used to measure lesion size.  Ultrasound examinat ions 
cannot be reproduced in their ent irety for independent review at a later date and, because they are 
operator dependent, it cannot be guaranteed that t he same technique and measurements will be 
taken from one assessment to the next.  If new lesions are identified by  [CONTACT_92388] , confirmation by [CONTACT_462] i s advised.
Endoscopy, Laparoscopy :  The utilization of these techniques fo r objective tumor evaluation is 
not advised.  However, such techniques can be useful to confirm co mplete pathol ogical response 
when biopsies are obtained or to determine relapse in trials where recurrence fo llowing com plete 
response or surgical resect ion is an endpo int.
Tumor Markers :  Tumor markers alone cannot be used to assess tumor response.  If markers are 
initially above the upper normal limit, they  must normalize for a patient to be considered in 
complete response (CR).  Specific guidelines for both prostate -specific ant igen (PSA) response 
(in recurrent prostate cancer) and CA-125 response (in recurrent ovarian cancer) have been 
published .
I4T-MC-JVDF(b) Clinical Protocol Page 110
LY3009806Cytology, Histology : These techniques can be used to different iate between partial responses 
(PR) and complete response (CR) in rare cases if r equired by [CONTACT_990]  (for example, resi dual 
lesions in tum or types such as germ cell tumors, where known residual benign tumors can 
remain).  When effusio ns are known to be a potential adverse effect of treatment (for example, 
with certain taxane co mpounds or angiogenesis inhibitors), the cy tological confirmat ion of the 
neoplastic origin of any effusio n that appears or worsens during treatment can be considered if 
the measurable tumor has met criteria for response or stable disease (SD) in order to different iate 
between response (or SD) and progressive disease (PD).
Pet Scan (FDG -PET, PET CT) :  PET is not recommended for lesio n assessment. If a new lesio n 
is found by [CONTACT_10052], another assessment must be done by  [CONTACT_4654], unless the PET CT i s of diagnostic 
quality.  If CT is done to confirm the results of the earlier PET scan, the date of progression must 
be reported as the earlier date of the PET scan.
Bone Scan :  If lesions measured by [CONTACT_92390], it is necessary  to repeat 
the bone scan when tryi ng to identify a complete response (CR) or partial response (PR) in target 
disease or when progression in bone is suspected.
Response Criteria
Evaluation of Target Lesions
Complete Response (CR):   Disappearance of all target lesio ns.  Any patho logical lymph nodes 
(whether target or non -target) must have reduct ion in short axis to <[ADDRESS_953690] norm alized.
Partial Response (PR):   At least a 30% decrease in the sum o f diameter of target l esions, taking 
as reference the baseline sum diameters.
Progressive Disease (PD):   At least a 20% increase in the sum of the diameters of target lesio ns, 
taking as reference the smallest sum on study  (including the baseline sum if that is the smallest).  
In addition to the relat ive increase of 20%, t he sum must also demonstrate an abso lute increase 
of at least 5 mm.   The appearance of 1 or more new lesio ns is also considered progression.
For equivocal findings of progression (for example, very  small and uncertain new l esions; cystic 
changes or necrosis in exist ing lesions), treatment may cont inue until the next scheduled 
assessment.  If at the next scheduled assessment, progression is confirmed, the date of 
progression should be the earlier date when progressio n was suspected.
Stable Disease (SD ):  Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum diameters while on study .
Not Evaluable:  When an incomplete radiologic assessment of target lesions is performed or 
there isa change in the method of measurement from baseline that impacts the ability to 
make a reliable evaluation of response.
Evaluation of Nontarget Lesions
Complete Response:   Disappearance of all nontarget lesio ns and normalizat ion of tumor marker 
level.  All lymph nodes must be non -pathological or normal in size (<10mm short axis).
I4T-MC-JVDF(b) Clinical Protocol Page 111
LY3009806Non-CR/ non-PD:  Persistence of 1 or more nontarget lesio ns and/or maintenance o f tumor 
marker level above the norm al limits.
Progressive Disease: Unequivocal progression o f existing nontarget lesio ns.  The appearance o f 
1 or more new lesions is also consi dered progression.
Not Evaluable :When a change in method of measurement from baseline occurs and impacts the 
ability to make a reliable evaluat ion of response .
Evaluation of Best Overall Response
The best overall response is the best response recorded fro m the start of the study  treatment until 
the earliest of object ive progression or start of new anticancer therapy, taking into accoun t any 
requirement for confirmat ion.  The pati ent’s best overall response assignment will depend on the 
findings of both target and nontarget disease and will also take into considerat ion the appearance 
of new lesio ns.  The Best Overall Response will be calculated via an algorithm using the 
assessment responses provided by  [CONTACT_92391].
Time Point Response
It is assumed that at each protocol -specified t ime point, a response assessment occurs.  ( When no 
imaging/measurement is done at all at a particular time point, th e patient is not evaluable (NE) at 
that time po int.)  Table [ADDRESS_953691] measurable disease at baseline.
Table1. Time Point Response: Patients with Target ( Non-target) Disease
Target Lesions Non-Target Lesions New Lesions Overall Response
CR CR No CR
CR Non-CR/non-PD No PR
CR Not evaluated No PR
PR Non-PD or not all evaluated No PR
SD Non-PD or not all evaluated No SD
Not all evaluated Non-PD No NE
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
Abbreviations:  CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease; 
NE=inevaluable.
Table [ADDRESS_953692] nonmeasurable disease only .
I4T-MC-JVDF(b) Clinical Protocol Page 112
LY3009806Table2. Time Point Response:  Patients with Nontarget Disease Only
Nontarget Lesions New Lesions Overall Response
CR No CR
Non-CR/non-PD No Non-CR/non-PDa
Not all evaluated No NE
Unequivocal PD Yes or No PD
Any Yes PD
Abbreviations:  CR = complete response; PD = progressive disease; NE = inevaluable ; SD = stable disease .
anon-CR/non -PD is preferred over SD for nontarget disease.
Frequency of Tumor Re -Evaluation
A baseline tumor evaluat ion must be performed within [ADDRESS_953693] therapy  is not known, fo llow-up every 6-8 weeks is 
reasonable.  Normally , all target and non -target sites are evaluated at each assessment using the 
same method.  However, bone scans may need to be repeated only when CR is ident ified in 
target disease or when progression in bone is sus pected.
Confirmatory Measurement/Duration of Response
Confirmation :
The main goal of confirmat ion of object ive response in clinical trials is to avoid overest imating 
the response rate observed.  The confirmat ion of response is particularly important in 
nonrandomized trials where response (CR/PR) is the primary  end point.  In this setting, to be 
assigned a status of PR/CR, changes in tumor measurements must be confirmed by [CONTACT_62442] [ADDRESS_953694] occur; assessment of 
nontargets is not required.
However, in randomized trial (Phase 2 or 3) or studies where SD or progression is the primary 
endpoints, confirmat ion of response is not required.  But, eliminat ion of the requirement may 
increase the importance of central review to protect against bias, in particular of studies which 
are not blinded.
In the case of SD, fo llow-up measurements m ust have met the SD criteria at least once after start 
of treatment at a minimum int erval not l ess than 6 weeks measured from [first dose] .
Duration of Overall Response
The durati on of overall response is measured from the time measurement criteria are first met for 
CR or PR (whichever is first recorded) until the first date that disease is recurrent or object ive 
progression is observed (taking as reference for PD the smallest measurements recorded on 
study).
I4T-MC-JVDF(b) Clinical Protocol Page [ADDRESS_953695] ively documented.
Duration of Stable Disease
Stable disease is m easured from  the start of the treatment (in rando mized trials, from date of 
randomization) until the criteria for objective progressio n are met, taking as reference the 
smallest sum on study (if the baseline sum is the smallest, that is the reference for calculat ion of 
PD).
Independent Review of Response and Progression
When object ive response (CR + PR) is the primary end point, and when key drug development 
decisions are based on the observat ion of a minimum number of responders, it is recommended 
that all claimed responses be reviewed by [CONTACT_13461](s) independent of the study .  If the study  is a 
randomized trial, ideally reviewers should be blinded to treatment assignment.
I4T-MC-JVDF(b) Clinical Protocol Page 114
LY3009806Attachment 7. Protocol JVDF Restricted and Prohibited 
Concomitant Therapy
The table below describes medications, treatments, and drug classes restricted or prohibited, with 
exceptions and condit ions for useduring the study  treatment period (there are no prohibited 
therapi[INVESTIGATOR_199897]-up period). Patients who, in the assessment by  [CONTACT_3170], 
require the use of any of the prohibited treatments for clinical management should be remo ved 
from the trial.  Patients may receive other supportive therapy  or vaccinat ions that the invest igator 
deems to be medically necessary .
Generally, m edications or live vaccinations specifically prohibited in the exclusio n criteria are 
not allowed during the ongoing trial.
I4T-MC-JVDF(b) Clinical Protocol Page 115
LY3009806TherapyAs 
NeededChronic 
Use Exceptions or Conditions for Use
Anti-platelet therapy yes no Chronic use of aspi[INVESTIGATOR_155752] 325 mg/day is permitted.
Anticoagulation therapy no Yes, with 
restrictionsAt enrollment, patients on full -dose anticoagulation must be on 
a stable dose (minimum duration 14 days) of oral anticoagulant 
or low molecular weight heparin or similar agent .  If on 
warfarin, the patient must have an INR ≤ 3 and no active 
bleeding or pathological condition present that carries a high 
risk of bleeding (e .g., tumor involving major vessels or known 
varices).
Anti-cancer biological 
therapyno no
Chemotherapy no no
Colony-stimulating 
factorsyes no Follow local guidelines.
Erythroid growth factors yes no Follow local guidelines.
Experimental medicines 
or investigational 
agentsno no Otherthan ramucirumab or pembrolizumab
Glucocorticoids no no Systemic glucocorticoids are permitted to modulate symptoms 
from an event of suspected immunologic etiology.  The use of 
physiologic doses of corticosteroids may be approved after 
consultation with the Sponsor.  
Note:  Inhaled steroids are allowed for management of asthma.
Immunotherapy 
(including 
vaccinations)no no Other than pembrolizumab OR inhaled ster oids
Live vaccines are NOT allowed within [ADDRESS_953696] 
study treatment and while participating in the trial.   Examples of 
live vaccines include, but are not limited to, the following: 
measles, mumps, rubella, chicken pox, yellow fever, rabies, 
BCG, and typhoid (oral) vaccine. Seasonal influenza vaccines 
for injection are generally killed virus vaccines and are a llowed. 
However, intranasal influenza vaccines (e.g. ,Flu -Mist®) are 
live attenuated vaccines, and are not allowed.
NSAIDs yes no Chronic use of aspi[INVESTIGATOR_155752] 325 mg/day is permitted.
In addition, in certain medical situations , NSAIDs may be the 
best treatment option (for example, for pain management) . 
Increased risk of bleeding should be considered by [CONTACT_702402]. 
Radiation therapy no no Localized radiation therapy to a symptomatic, solitary lesion or 
to the brain may be allowed after consultation with the Sponsor.
Abbreviations:  INR = international normalized ratio; NSAIDs=nonsteroidal anti -inflammatory drugs.
I4T-MC-JVDF(b) Clinical Protocol Page [ADDRESS_953697] a causal 
relationship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally  associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
AESI adverse event of special interest
ALT alanine aminotransferase
ANC absolute neutrophil count
ASCO American Society of Clinical Oncology
AST aspartate aminotransferase
audit A systematic and independent examination of the trial -related activities and documents 
to determine whe ther the evaluated trial -related activities were conducted, and the data 
were recorded, analyzed, and accurately reported according to the protocol, applicable 
standard operating procedures (SOPs), good clinical practice (GCP), and the applicable 
regulatory requirement(s).
BCG bacillus Calmette -Guérin
blinding/maskingA procedure in which one or more parties to the trial are kept unaware of the treatment 
assignment(s).  Unless otherwise specified, blinding will remain in effect until final 
database lock.
A single-blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the patient are not.  
A double-blind study is one in which neither the patient nor any of the investigator or 
sponsor staff who are involved in the treatment or clinical evaluation of the patients are 
aware of the treatment received.
Cave,ss average concentration at steady state
CHF congestive heart failure
Cmax,ss maximum concentration at steady state
Cmin,[ADDRESS_953698] dose administration
Cmin,ss minimum concentration at steady state
I4T-MC-JVDF(b) Clinical Protocol Page 117
LY3009806collection database A computer database where clinical trial data are entered and validated.
complaintA complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the trial -related requirements, good clinical practice (GCP) 
requirements, and the applicable regulatory requirements.
continued access 
periodThe period between study completion and end of trial during which patients on study 
treatment (ramucirumab and/or pembrolizumab) who continue to experience clinical 
benefit and no undue risks may continue to receive study treatment until one of the 
criteria for discontinuation is met. 
CR complete response
CRC colorectal cancer
CrCl creatinine clearance
CRF/eCRF case report form/electronic case report form
Sometimes referred to as clinical report form:  A printed or electronic form for 
recording study participants’ data during a clinical study, as required by [CONTACT_760].
CRP clinical research physician
Individual responsible for the medical conduct of the study.  Responsibilities of the 
CRP may be performed by a physician, clinical research scientist, global safety 
physician, or other medical officer.
CRS clinical researc h scientist
CSFs colony-stimulating factors
CT computed tomography
CTCAE Common Terminology Criteria for Adverse Events
CTLA-[ADDRESS_953699]
I4T-MC-JVDF(b) Clinical Protocol Page [ADDRESS_953700] been assigned to a treatment.
enterPatients entered into a trial are those who sign the informed consent form directly or 
through their legally acceptable representatives.
ERB/IRB ethical review board/institutional review board
A board o r committee (institutional, regional, or national) composed of medical and 
nonmedical members whose responsibility is to verify that the safety, welfare, and 
human rights of the patients participating in a clinical trial are protected.
EU European Union
FOLFIRI irinotecan, 5-fluorouracil, and folinic acid
FSH follicle-stimulating hormone
GCP good clinical practice
G-CSF granulocyte colony -stimulating factor
GEJ gastroesophageal junction
GI gastrointestinal
GM-CSF granulocyte macrophage colony-stimulating factor
HIV human immunodeficiency virus
HR hazard ratio
IB Investigator’s Brochure
ICF informed consent form
ICH International Conference on Harmonisation
IK immunogenicity
Informed consent A process by [CONTACT_9444] a patient voluntarily confirms his or her willingness to participate 
in a particular trial, after having been informed of all aspects of the trial that are relevant 
to the patient’s decision to participate.  Informed consent is documente d by [CONTACT_3553] a 
written, signed, and dated informed consent form.  
INR internatio nal normalized ratio
I4T-MC-JVDF(b) Clinical Protocol Page 119
LY3009806interim analysis An interim analysis is an analysis of clinical trial data, separated into treatment groups, 
that is conducted before the final repor ting database is created/locked.
investigational 
product (IP)A pharmaceutical form of an active ingredient substance or placebo being tested, or 
used as a reference, in a clinical trial.  Investigational product (IP) includes a product 
with a marketing a uthorization when:
1.used or assembled (formulated or packaged) in a way different from the 
authorized form ,
2.used for an unauthorized indication, or 
3.used to gain further information about the authorized form.
In this study, the IPs are ramucirumab and pembrolizumab. 
investigator A person responsible for the conduct of the clinical trial at a trial site.  If a trial is 
conducted by a team of individuals at a trial site, the investigator is the responsible 
leader of the team and may be called the principal investigator.
IRR infusion-related reaction
irRECIST immune-related Response Evaluation Criteria In Solid Tumors
IV intravenous
legal representative An individual, judicial, or other body authorized under applicable law to consent on 
behalf of a prospective patient to the patient’s participation in the clinical study.
Lilly Safety System Global safety database that tracks and reports serious adverse and spontaneous events 
occurring while using a drug/drug delivery system.
mAb monoclonal antibody
MedDRA Medical Dictionary for Regulatory Activities
MMR mismatch -repair
MRI magnetic resonance imaging
MTD maximum tolerated dose
MUGA multiple-gated acquisition
NCI National Cancer Institute
I4T-MC-JVDF(b) Clinical Protocol Page [ADDRESS_953701] (non -IP)A non-investigational product (non-IP) is a product that is not being tested or used as a 
reference in the trial but is provided to patients and used in accordance with the 
protocol.
Examples of  non -IPs include the fol lowing:
Concomitant or rescue/escape medication for preventive, diagnostic, or therapeutic 
reasons
Concomitant or rescue/escape medication to ensure that adequate medical care is 
provided for the patient
A product used in accordance with the protocol to in duce a physiological response.
NSAID non-steroidal anti -inflammatory drug
NSCLC non-small cell lung cancer
ORR overall response rate
OS overall survival
patient A study participant who has the disease or condition for which the investigational 
productis targeted.
PBMC peripheral blood mononuclear cells
PD progressive disease
PD-1 programmed death -1 T-cell co-receptor
PET positron emission tomography
PFS progression -free survival
PK pharmacokinetic(s)
PR partial response
Q2W every [ADDRESS_953702] Response Evaluation Criteria In Solid Tumors
reporting database A point-in-time copy of the collection database.  The final reporting database is used to 
produce the analyses and output reports for interim or final analyses of data.
re-screen to screen a patient who was previously declared a screen failure for the same study
RPLS reversible posterior leukoencephalopathy syndrome
SAE serious adverse event
I4T-MC-JVDF(b) Clinical Protocol Page [ADDRESS_953703] upper limit of normal
US [LOCATION_002]
VEGF vascular endothelial growth factor
VTE venous thromboembolic event
I4T-MC-JVDF(b) Clinical Protocol Page 122
LY3009806Attachment 9. Protocol JVDF A mendment(b )
Summary  An Open-Label, Multicenter, Phase [ADDRESS_953704] ion Adenocarcino ma, Non-Small Cell Lung Cancer, or Transit ional Cell 
Carcinoma of the Urothelium ,has been amended.  The new protocol is indicated by  
[CONTACT_61504](b) and will be used to conduct the study  in place of any preceding version o f the 
protocol.
The overall changes and rationale for the changes made to this protocolare as follows:
Addition of title, rationale, study  design, entry criteria, study procedures and statist ical 
elements for [ADDRESS_953705] -line Gastric-GEJ
(Schedule 1) , first-line NSCLCpatients(Schedule 2) , and second or third line BTC
patients(Schedule 1) .  At the time o f this amendment, Phase 1A Schedule 1 DLT 
observation is ongoing; Phase 1A Schedule [ADDRESS_953706] lineGastric/GEJ and first line NSCLC patients, more frequent tumor imaging 
schedule (every [ADDRESS_953707] 12 weeks) is required to monitor anti-tumor 
response to study  treatment and init iate alternative treatment as determined by [CONTACT_702403].  
Clarifications and refinements, as fo llows:
oThe final analysis o f safety and preliminary  efficacy will occur approximately 
2years after the first pati ent received first study  treatment.  Separate interim 
analyses will occur after all  patients in each cohort have completed 
approximately  24 weeks of study  treatment or di scontinued for any  reason.  
Safety and preliminary efficacy  will be analyzed separatel y for each cohort.  
Rationale: This change was implemented to harmonize the interim analysis and 
final analysis wit h the intent of the trial design.  There is no change to the study 
treatment durati on for each individual patient (35 cycles, approximately 2 years).
oIn Inclusio n Criterion [20], cl arified that baseline tumor tissue samples must be 
evaluable , andelaborated on guidance regarding the submissio n of tumor tissue 
samples in Sect ion 8.4.2. 
I4T-MC-JVDF(b) Clinical Protocol Page 123
LY3009806oThe timing of the required 1 -hour observat ion periods, to occur between 
ramucirumab and pembrolizumab administration *and* after pembrolizumab 
administration, for the first 2 cy cles. Rationale: this change was implemented to 
ensure the consistent implementation of the 1- hour observat ion periods for 
Schedule 1 and Schedule 2 patients.
oTwo additional categories of events are to be reported as SAEs: 1) new cancers 
(exception: metastases of cancer under study ),and 2) any  event associ ated with 
an overdose of either study  drug, as defined in Section [IP_ADDRESS].
oFor pembro lizumab, immune -related adverse events are no longer labeled as 
Events of Clinical Interest (ECIs).  Similarly, references in the protocol to the 
detailed Site Guidance Docum ent for Events of Clinical Interest were removed .  
Two (2) categories of ECIs remain: overdose and abnormal liver funct ion tests 
(as defined in Sect ion [IP_ADDRESS].3) . 
oPembrolizumab dose modificationtable “Note” was updated to specify that 
Grade 2 pneumonit is warrants permanent discont inuation of pembro lizumab (see 
“Note” in ta ble footnote) .
oPembrolizumab supportive care guidelines for Diarrhea/Co litis (Section 
[IP_ADDRESS].2) were updated to eliminate any  waiting period before beginning 
treatment for any Grade 2, 3, or 4 event. 
Other typographical , formatting errors or very  minor clarifications(key examples below) : 
oThe Introduction was updated to reflect current regulatory  approval status for 
ramucirumab and pembrolizumab.
oIn Inclusio n Criterion [7], to clarify  that the screening period is 28 days.  
oExclusion Criterion [20], to allow seasonal flu vaccines that do not contain live 
virus. 
oDose management for ramucirumab in case of Grade 2 toxi city, investigator 
“may” reduce ramucirumab dose or di scontinue ramucirumab.  See footnote b in 
Table JVDF.4.   
oIf radiologic imaging verifies init ial progressive disease, tumor assessment 
should be repeated approximately (not “at least” ) 4 weeks later to confirm PD. 
oThat “whole”blood sam ple is collected for pharmacogenetic analysis where 
local regulati ons and ERBs allow. 
oThat the overall response rates presented in the simulations represented by  [CONTACT_702404].[ADDRESS_953708] or MRI was added in the schedule o f events
(Attachm ent 1) to be consistent with inclusio n criteria for NSCLC and urothelial 
cancer patients. 
oCorrection of formatting error in baseline bio marker sam ples collection for 
Schedule 1 patients (Attachm ent 2).  Baseline sample should be collected pre -
dose.
I4T-MC-JVDF(b) Clinical Protocol Page 124
LY3009806Note: Changes that are applied globally to the document were described above .  Abrief section 
of text with strikethrough/underscore as an example of the type o f change that occurs throughout 
the amended protocol is providedbelow.
Leo Document ID = 69a09e1c-a512-4680-baeb-60d497185cde
Approver: 
Approval Date & Time: 11-Feb-2016 18:54:03 GMT
Signature [CONTACT_32869]: Approved
Approver: 
Approval Date & Time: 11-Feb-2016 20:23:25 GMT
Signature [CONTACT_32869]: Approved
[COMPANY_003]
[COMPANY_003]